Original Article
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
N Engl J Med 2008; 359:2195-2207November 20, 2008
- Abstract
Background
Increased levels of the inflammatory biomarker high-sensitivity C-reactive protein predict cardiovascular events. Since statins lower levels of high-sensitivity C-reactive protein as well as cholesterol, we hypothesized that people with elevated high-sensitivity C-reactive protein levels but without hyperlipidemia might benefit from statin treatment.
Methods
We randomly assigned 17,802 apparently healthy men and women with low-density lipoprotein (LDL) cholesterol levels of less than 130 mg per deciliter (3.4 mmol per liter) and high-sensitivity C-reactive protein levels of 2.0 mg per liter or higher to rosuvastatin, 20 mg daily, or placebo and followed them for the occurrence of the combined primary end point of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from cardiovascular causes.
Results
The trial was stopped after a median follow-up of 1.9 years (maximum, 5.0). Rosuvastatin reduced LDL cholesterol levels by 50% and high-sensitivity C-reactive protein levels by 37%. The rates of the primary end point were 0.77 and 1.36 per 100 person-years of follow-up in the rosuvastatin and placebo groups, respectively (hazard ratio for rosuvastatin, 0.56; 95% confidence interval [CI], 0.46 to 0.69; P<0.00001), with corresponding rates of 0.17 and 0.37 for myocardial infarction (hazard ratio, 0.46; 95% CI, 0.30 to 0.70; P=0.0002), 0.18 and 0.34 for stroke (hazard ratio, 0.52; 95% CI, 0.34 to 0.79; P=0.002), 0.41 and 0.77 for revascularization or unstable angina (hazard ratio, 0.53; 95% CI, 0.40 to 0.70; P<0.00001), 0.45 and 0.85 for the combined end point of myocardial infarction, stroke, or death from cardiovascular causes (hazard ratio, 0.53; 95% CI, 0.40 to 0.69; P<0.00001), and 1.00 and 1.25 for death from any cause (hazard ratio, 0.80; 95% CI, 0.67 to 0.97; P=0.02). Consistent effects were observed in all subgroups evaluated. The rosuvastatin group did not have a significant increase in myopathy or cancer but did have a higher incidence of physician-reported diabetes.
Conclusions
In this trial of apparently healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin significantly reduced the incidence of major cardiovascular events. (ClinicalTrials.gov number, NCT00239681.)
Media in This Article
Poll Results
Contributors
Figure 1
Cumulative Incidence of Cardiovascular Events According to Study Group.Figure 2
Effects of Rosuvastatin on the Primary End Point, According to Baseline Characteristics.Article Activity
- Article
Poll Results
Contributors
Current treatment algorithms for the prevention of myocardial infarction, stroke, and death from cardiovascular causes recommend statin therapy for patients with established vascular disease, diabetes, and overt hyperlipidemia.1,2 However, half of all myocardial infarctions and strokes occur among apparently healthy men and women with levels of low-density lipoprotein (LDL) cholesterol that are below currently recommended thresholds for treatment.
Measurement of high-sensitivity C-reactive protein, an inflammatory biomarker that independently predicts future vascular events, improves global classification of risk, regardless of the LDL cholesterol level.3-9 We have previously shown that statin therapy reduces high-sensitivity C-reactive protein levels10,11 and that among healthy persons,12 patients with stable coronary disease,13 and those with the acute coronary syndrome,14-16 the magnitude of the benefit associated with statin therapy correlates in part with the achieved high-sensitivity C-reactive protein level. To date, however, no prospective outcome trial has directly addressed the question of whether apparently healthy persons with levels of LDL cholesterol below current treatment thresholds but with elevated levels of high-sensitivity C-reactive protein might benefit from statin therapy. The primary objective of the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) was to investigate whether treatment with rosuvastatin, 20 mg daily, as compared with placebo, would decrease the rate of first major cardiovascular events.
Methods
Trial Design
JUPITER was a randomized, double-blind, placebo-controlled, multicenter trial conducted at 1315 sites in 26 countries (see the Supplementary Appendix, available with the full text of this article at www.nejm.org). The trial protocol was designed and written by the study chair and approved by the local institutional review board at each participating center. The trial data were analyzed by the academic study statistician and the academic programmer. The academic authors vouch for the accuracy and completeness of the data and the analyses.
The trial was financially supported by AstraZeneca. The sponsor collected the trial data and monitored the study sites but played no role in the conduct of the analyses or drafting of the manuscript and had no access to the unblinded trial data until after the manuscript was submitted for publication.
Study Population
As described in detail elsewhere,17,18 men 50 years of age or older and women 60 years of age or older were eligible for the trial if they did not have a history of cardiovascular disease and if, at the initial screening visit, they had an LDL cholesterol level of less than 130 mg per deciliter (3.4 mmol per liter) and a high-sensitivity C-reactive protein level of 2.0 mg per liter or more. Other requirements for inclusion were a willingness to participate for the duration of the trial, provision of written informed consent, and a triglyceride level of less than 500 mg per deciliter (5.6 mmol per liter).
Exclusion criteria were previous or current use of lipid-lowering therapy, current use of postmenopausal hormone-replacement therapy, evidence of hepatic dysfunction (an alanine aminotransferase level that was more than twice the upper limit of the normal range), a creatine kinase level that was more than three times the upper limit of the normal range, a creatinine level that was higher than 2.0 mg per deciliter (176.8 μmol per liter), diabetes, uncontrolled hypertension (systolic blood pressure >190 mm Hg or diastolic blood pressure >100 mm Hg), cancer within 5 years before enrollment (with the exception of basal-cell or squamous-cell carcinoma of the skin), uncontrolled hypothyroidism (a thyroid-stimulating hormone level that was more than 1.5 times the upper limit of the normal range), and a recent history of alcohol or drug abuse or another medical condition that might compromise safety or the successful completion of the study. Because a core scientific hypothesis of the trial concerned the role of underlying low-grade inflammation as evidenced by elevated high-sensitivity C-reactive protein levels, patients with inflammatory conditions such as severe arthritis, lupus, or inflammatory bowel disease were excluded, as were patients taking immunosuppressant agents such as cyclosporine, tacrolimus, azathioprine, or long-term oral glucocorticoids.
All potentially eligible subjects underwent a 4-week run-in phase during which they received placebo. The purpose of this phase was to identify a group of willing and eligible participants who demonstrated good compliance (defined as the taking of more than 80% of all study tablets) during that interval. Only subjects who successfully completed the run-in phase were enrolled.
Trial Protocol
Eligible subjects were randomly assigned in a 1:1 ratio to receive either rosuvastatin, 20 mg daily, or matching placebo. Randomization was performed with the use of an interactive voice-response system and was stratified according to center.
Follow-up visits were scheduled to occur at 13 weeks and then 6, 12, 18, 24, 30, 36, 42, 48, 54, and 60 months after randomization. A closeout visit occurred after study termination. Follow-up assessments included laboratory evaluations, pill counts, and structured interviews assessing outcomes and potential adverse events. Measurements of lipid levels, high-sensitivity C-reactive protein levels, hepatic and renal function, blood glucose levels, and glycated hemoglobin values were performed in a central laboratory. Personnel at each site also contacted their participants midway between scheduled visits to evaluate their well-being and to maintain study participation.
End Points
The primary outcome was the occurrence of a first major cardiovascular event, defined as nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina, an arterial revascularization procedure, or confirmed death from cardiovascular causes. Secondary end points included the components of the primary end point considered individually — arterial revascularization or hospitalization for unstable angina, myocardial infarction, stroke, or death from cardiovascular causes — and death from any cause.
All reported primary end points that occurred through March 30, 2008, were adjudicated on the basis of standardized criteria by an independent end-point committee unaware of the randomized treatment assignments. Only deaths classified as clearly due to cardiovascular or cerebrovascular causes by the end-point committee were included in the analysis of the primary end point. For the end point of death from any cause, all deaths were included, regardless of whether data were available to confirm the cause of death.
Statistical Analysis
JUPITER was an event-driven trial designed to continue until 520 confirmed primary end points had been documented, to provide a statistical power of 90% to detect a 25% reduction in the rate of the primary end point, with a two-sided significance level of 0.05. Pretrial estimates of the duration of follow-up and number of participants were based on event rates in earlier prevention trials19,20 and were modified to take into account plans to include low-risk groups, including women.
The trial's prespecified monitoring plan called for two interim efficacy analyses with O'Brien–Fleming stopping boundaries determined by means of the Lan–DeMets approach. The stopping boundary was crossed at the first prespecified efficacy evaluation, and on March 29, 2008, the independent data and safety monitoring board voted to recommend termination of the trial. This recommendation took into account the size and precision of the observed treatment benefit, as well as effects on the rates of death and other secondary end points being monitored and on major subgroups. Although the trial ended on March 30, 2008, when the steering committee formally accepted this recommendation, we continued the adverse-event reporting in a blinded manner for each study participant until the date he or she appeared for a formal closeout visit and discontinued therapy.
All primary analyses were performed on an intention-to-treat basis. Study participation was considered to be complete for any individual participant at the time he or she had an occurrence of the primary end point, had informed consent withdrawn, was unable to be followed further because the study site closed, or had been followed through at least March 30, 2008. The exposure time was calculated as the time between randomization and the first major cardiovascular event, the date of death, the date of the last study visit, the date of withdrawal or loss to follow-up, or March 30, 2008, whichever came first.
Cox proportional-hazards models were used to calculate hazard ratios and 95% confidence intervals for the comparison of event rates in the two study groups. Prespecified subgroup analyses were performed according to the presence or absence of major cardiovascular risk factors.
Results
Between February 4, 2003, and December 15, 2006, a total of 89,890 people were screened for enrollment. Of these, 72,088 were ineligible, including 37,611 (52.2%) with LDL cholesterol levels of 130 mg per deciliter or more and an additional 25,993 (36.1%) with high-sensitivity C-reactive protein levels of less than 2.0 mg per liter. Other reasons for exclusion are presented in Figure 1 in the Supplementary Appendix. A total of 17,802 people were randomly assigned to a study group.
Baseline Characteristics
By design, the study population was diverse; 6801 of the 17,802 participants were women (38.2%) and 4485 (25.2%) were black or Hispanic (Table 1Table 1
Baseline Characteristics of the Trial Participants, According to Study Group.). Aspirin was used by 16.6% of participants, and 41.4% had the metabolic syndrome.21 In both the rosuvastatin and placebo groups, the median LDL cholesterol level was 108 mg per deciliter (2.8 mmol per liter), the high-density lipoprotein (HDL) cholesterol level was 49 mg per deciliter (1.3 mmol per liter), and the triglyceride level was 118 mg per deciliter (1.3 mmol per liter); the high-sensitivity C-reactive protein level was 4.2 and 4.3 mg per liter in the rosuvastatin and placebo groups, respectively.Compliance and Effects of Rosuvastatin on Lipids and High-Sensitivity C-Reactive Protein
At the time the study was terminated, 75% of participants were taking their study pills. Among those assigned to rosuvastatin, the median LDL cholesterol level at 12 months was 55 mg per deciliter (1.4 mmol per liter) (interquartile range, 44 to 72 [1.1 to 1.9]), and the median high-sensitivity C-reactive protein level was 2.2 mg per liter (interquartile range, 1.2 to 4.4) (Table 2Table 2
Lipid and High-Sensitivity C-Reactive Protein Levels during the Follow-up Period, According to Study Group.). At the 12-month visit, the rosuvastatin group, as compared with the placebo group, had a 50% lower median LDL cholesterol level (mean difference, 47 mg per deciliter [1.2 mmol per liter]), a 37% lower median high-sensitivity C-reactive protein level, and a 17% lower median triglyceride level (P<0.001 for all three comparisons). These effects persisted throughout the study period. At 12 months, the median HDL cholesterol level was 4% higher in the rosuvastatin group than in the placebo group (P<0.001), but this effect was not present at the time of study completion (P=0.34).End Points
At the time of study termination (median follow-up, 1.9 years; maximal follow-up, 5.0 years), 142 first major cardiovascular events had occurred in the rosuvastatin group, as compared with 251 in the placebo group (Table 3Table 3
Outcomes According to Study Group.). The rates of the primary end point were 0.77 and 1.36 per 100 person-years of follow-up in the rosuvastatin and placebo groups, respectively (hazard ratio for rosuvastatin, 0.56; 95% confidence interval [CI], 0.46 to 0.69; P<0.00001) (Table 3 and Figure 1Figure 1Cumulative Incidence of Cardiovascular Events According to Study Group.). In a test for interaction between the study-group assignment and follow-up time, there was no significant violation of the proportional-hazards assumption.On the basis of Kaplan–Meier estimates (Figure 1), the number of patients who would need to be treated with rosuvastatin for 2 years to prevent the occurrence of one primary end point is 95, and the number needed to treat for 4 years is 31. If 4-year risks are projected over an average 5-year treatment period, as has been commonly done in previous statin trials according to the method of Altman and Andersen,22 the number needed to treat to prevent the occurrence of one primary end point is 25.
Rosuvastatin was also associated with significant reductions in rates of the individual components of the primary trial end point. For the end point of fatal or nonfatal myocardial infarction, event rates were 0.17 and 0.37 per 100 person-years of follow-up in the rosuvastatin and placebo groups, respectively (hazard ratio for rosuvastatin, 0.46; 95% CI, 0.30 to 0.70; P=0.0002). The corresponding rates were 0.18 and 0.34 for fatal or nonfatal stroke (hazard ratio, 0.52; 95% CI, 0.34 to 0.79; P=0.002), 0.41 and 0.77 for arterial revascularization or unstable angina (hazard ratio, 0.53; 95% CI, 0.40 to 0.70; P<0.00001), and 0.45 and 0.85 for the combined end point of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes (hazard ratio, 0.53; 95% CI, 0.40 to 0.69; P<0.00001).
In addition, the rates of death from any cause were 1.00 and 1.25 per 100 person-years of follow-up in the rosuvastatin and placebo groups, respectively (hazard ratio for the rosuvastatin group, 0.80; 95% CI, 0.67 to 0.97; P=0.02) (Table 3 and Figure 1). In analyses limited to deaths for which the date of death was known with certainty, there was a similar reduction in the hazard ratio associated with rosuvastatin (0.81; 95% CI, 0.67 to 0.98; P=0.03).
Subgroup Analyses
For the primary end point, there was no evidence of heterogeneity in the results for any subgroup evaluated. Relative hazard reductions in the rosuvastatin group were similar for women (46%) and men (42%) and were observed in every subgroup evaluated, including subgroups according to age, race or ethnic group, region of origin, status with regard to traditional risk factors, and Framingham risk score (Figure 2Figure 2
Effects of Rosuvastatin on the Primary End Point, According to Baseline Characteristics.). Groups typically assumed to be at very low risk also benefited. For participants who had elevated levels of high-sensitivity C-reactive protein but who were nonsmokers, were not overweight (had a body-mass index [the weight in kilograms divided by the square of the height in meters] ≤25), did not have the metabolic syndrome, had a calculated Framingham risk score of 10% or less, or had an LDL cholesterol level of 100 mg per deciliter (2.6 mmol per liter) or lower, the observed relative reductions in the hazard ratio associated with rosuvastatin for the primary end point were similar to those in higher-risk groups. For subjects with elevated high-sensitivity C-reactive protein levels but no other major risk factor other than increased age, the benefit of rosuvastatin was similar to that for higher-risk subjects (hazard ratio, 0.63; 95% CI, 0.44 to 0.92; P=0.01).Adverse Events
Total numbers of reported serious adverse events were similar in the rosuvastatin and placebo groups (1352 and 1377, respectively; P=0.60) (Table 4Table 4
Monitored Adverse Events, Measured Laboratory Values, and Other Reported Events of Interest during the Follow-up Period.). Nineteen myopathic events were reported (in 10 subjects receiving rosuvastatin and 9 receiving placebo, P=0.82). After closure of the trial, one nonfatal case of rhabdomyolysis was reported in a 90-year-old participant with febrile influenza, pneumonia, and trauma-induced myopathy who was in the rosuvastatin group (listed in Table 4).There were no significant differences between the two study groups with regard to muscle weakness, newly diagnosed cancer, or disorders of the hematologic, gastrointestinal, hepatic, or renal systems. With regard to direct measures of safety, rates of elevation of the alanine aminotransferase level to more than three times the upper limit of the normal range were similar in the two groups. Median glomerular filtration rates at 12 months were 66.8 and 66.6 ml per minute per 1.73 m2 of body-surface area in the rosuvastatin and placebo groups, respectively (P=0.02). Protocol-specified measurements showed no significant differences between the study groups during the follow-up period with respect to the fasting blood glucose level (98 mg per deciliter [5.4 mmol per liter] in both groups, P=0.12) or newly diagnosed glycosuria (in 36 subjects in the rosuvastatin group and 32 in the placebo group, P=0.64); there was a minimal difference in the median glycated hemoglobin value (5.9% and 5.8%, respectively; P=0.001). Nevertheless, physician-reported diabetes was more frequent in the rosuvastatin group (270 reports of diabetes, vs. 216 in the placebo group; P=0.01); these events were not adjudicated by the end-point committee. In contrast to the findings in a previous study of high-dose statin therapy,23 we found no significant between-group difference in the number of subjects with intracranial hemorrhage (six in the rosuvastatin group and nine in the placebo group, P=0.44).
Discussion
In this randomized trial of apparently healthy men and women with elevated levels of high-sensitivity C-reactive protein, rosuvastatin significantly reduced the incidence of major cardiovascular events, despite the fact that nearly all study participants had lipid levels at baseline that were well below the threshold for treatment according to current prevention guidelines. Rosuvastatin also significantly reduced the incidence of death from any cause. These effects were consistent in all subgroups evaluated, including subgroups customarily considered to be at low risk, such as people with Framingham risk scores of 10% or less, those with LDL cholesterol levels of 100 mg per deciliter or less, those without the metabolic syndrome, and those with elevated levels of high-sensitivity C-reactive protein but no other major risk factor. The trial also showed robust reductions in cardiovascular events with statin therapy in women and black and Hispanic populations for which data on primary prevention are limited.
Previous statin trials (most of which used LDL cholesterol level criteria for enrollment) have generally reported a 20% reduction in vascular risk for each 1 mmol per liter (38.7 mg per deciliter) of absolute reduction in the LDL cholesterol level,24,25 an effect that would have predicted a proportionate reduction in the number of events in our study of approximately 25%. However, the reduction in the hazard seen in our trial, in which enrollment was based on elevated high-sensitivity C-reactive protein levels rather than on elevated LDL cholesterol levels, was almost twice this magnitude and revealed a greater relative benefit than that found in most previous statin trials (see Figure 2 in the Supplementary Appendix).
In this trial, myopathy, hepatic injury, and cancer did not occur more frequently with rosuvastatin than with placebo, despite the fact that LDL cholesterol levels below 55 mg per deciliter were achieved in half the participants receiving rosuvastatin (and LDL cholesterol levels below 44 mg per deciliter in 25%). Since the median follow-up of subjects was 1.9 years, we cannot rule out the possibility that the rate of adverse events might increase in this population during longer courses of therapy. However, no such increase was detected in an analysis of participants who continued to receive treatment for 4 or more years.
We did detect a small but significant increase in the rate of physician-reported diabetes with rosuvastatin, as well as a small, though significant, increase in the median value of glycated hemoglobin. Increases in glucose and glycated hemoglobin levels, the incidence of newly diagnosed diabetes, and worsening glycemic control have been reported in previous trials of pravastatin, simvastatin, and atorvastatin.26,27 However, systematic protocol-specified measurements showed no significant difference between our two study groups in fasting blood glucose levels or glycosuria during the follow-up period. Therefore, although the increase in the rate of physician-reported diabetes in the rosuvastatin group could reflect the play of chance, further study is needed before any causative effect can be established or refuted. Physicians' reports of diabetes were not adjudicated by the end-point committee, and careful evaluation of participants' records will be needed to better understand this possible effect.
Potential limitations of our study merit consideration. First, we did not include people with low levels of high-sensitivity C-reactive protein in our trial, since our hypothesis-generating analysis of high-sensitivity C-reactive protein in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)12 showed extremely low event rates and no evidence that statin therapy lowered vascular risk among persons who had neither hyperlipidemia nor elevated high-sensitivity C-reactive protein levels. Thus, a trial of statin therapy involving people with both low cholesterol and low high-sensitivity C-reactive protein levels would have been not only infeasible in terms of statistical power and sample size but also highly unlikely to show a benefit.
Second, since the trial was stopped early by the independent data and safety monitoring board after a median follow-up of less than 2 years, the effect of longer-term therapy should be considered. We verified that the assumption of proportional hazards was not violated during the follow-up period, and we found a robust benefit of rosuvastatin in analyses restricted to events occurring more than 2 years after randomization. These findings, as well as the demonstration that rates of hospitalization and arterial revascularization were reduced by 47% within a 2-year period, suggest that the strategy tested could be cost-effective. The strategy also could reduce the demand for imaging tests in asymptomatic populations. On the other hand, our trial evaluated the use of rosuvastatin for the prevention of first cardiovascular events; therefore, the absolute event rates are lower than would be expected among patients with a history of vascular disease, a fact that should be taken into account in considering whether the use of statin therapy among those with low LDL cholesterol levels but elevated high-sensitivity C-reactive protein levels would be cost-effective if applied widely.
With regard to the inflammatory hypothesis of atherothrombosis, our trial involved an agent that is highly effective at reducing levels of both cholesterol and high-sensitivity C-reactive protein. In previous work, achieving low levels of both LDL cholesterol and high-sensitivity C-reactive protein appears to have contributed to the clinical benefit of statin therapy.12-16 Given the recognition that atherothrombosis is in some respects a disorder of innate immunity,28 we hope the data presented here spur the further development of targeted antiinflammatory drugs as potential vascular therapeutic agents and lead to innovative trials that can directly address whether the inhibition of inflammation by agents other than statins can reduce rates of vascular events.29
In conclusion, in this randomized trial of apparently healthy men and women who did not have hyperlipidemia but did have elevated levels of high-sensitivity C-reactive protein, the rates of a first major cardiovascular event and death from any cause were significantly reduced among the participants who received rosuvastatin as compared with those who received placebo.
Supported by AstraZeneca.
Dr. Ridker reports receiving grant support from AstraZeneca, Novartis, Merck, Abbott, Roche, and Sanofi-Aventis; consulting fees or lecture fees or both from AstraZeneca, Novartis, Merck, Merck–Schering-Plough, Sanofi-Aventis, Isis, Dade Behring, and Vascular Biogenics; and is listed as a coinventor on patents held by Brigham and Women's Hospital that relate to the use of inflammatory biomarkers in cardiovascular disease, including the use of high-sensitivity C-reactive protein in the evaluation of patients' risk of cardiovascular disease. These patents have been licensed to Dade Behring and AstraZeneca. Dr. Fonseca reports receiving research grants, lecture fees, and consulting fees from AstraZeneca, Pfizer, Schering-Plough, Sanofi-Aventis, and Merck; and Dr. Genest, lecture fees from AstraZeneca, Schering-Plough, Merck–Schering-Plough, Pfizer, Novartis, and Sanofi-Aventis and consulting fees from AstraZeneca, Merck, Merck Frosst, Schering-Plough, Pfizer, Novartis, Resverlogix, and Sanofi-Aventis. Dr. Gotto reports receiving consulting fees from Dupont, Novartis, Aegerion, Arisaph, Kowa, Merck, Merck–Schering-Plough, Pfizer, Genentech, Martek, and Reliant; serving as an expert witness; and receiving publication royalties. Dr. Kastelein reports receiving grant support from AstraZeneca, Pfizer, Roche, Novartis, Merck, Merck–Schering-Plough, Isis, Genzyme, and Sanofi-Aventis; lecture fees from AstraZeneca, GlaxoSmithKline, Pfizer, Novartis, Merck–Schering-Plough, Roche, Isis, and Boehringer Ingelheim; and consulting fees from AstraZeneca, Abbott, Pfizer, Isis, Genzyme, Roche, Novartis, Merck, Merck–Schering-Plough, and Sanofi-Aventis. Dr. Koenig reports receiving grant support from AstraZeneca, Roche, Anthera, Dade Behring and GlaxoSmithKline; lecture fees from AstraZeneca, Pfizer, Novartis, GlaxoSmithKline, DiaDexus, Roche, and Boehringer Ingelheim; and consulting fees from GlaxoSmithKline, Medlogix, Anthera, and Roche. Dr. Libby reports receiving lecture fees from Pfizer and lecture or consulting fees from AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Pfizer, Sanofi-Aventis, VIA Pharmaceuticals, Interleukin Genetics, Kowa Research Institute, Novartis, and Merck–Schering-Plough. Dr. Lorenzatti reports receiving grant support, lecture fees, and consulting fees from AstraZeneca, Takeda, and Novartis; Dr. Nordestgaard, lecture fees from AstraZeneca, Sanofi-Aventis, Pfizer, Boehringer Ingelheim, and Merck and consulting fees from AstraZeneca and BG Medicine; Dr. Shepherd, lecture fees from AstraZeneca, Pfizer, and Merck and consulting fees from AstraZeneca, Merck, Roche, GlaxoSmithKline, Pfizer, Nicox, and Oxford Biosciences; and Dr. Glynn, grant support from AstraZeneca and Bristol-Myers Squibb. No other potential conflict of interest relevant to this article was reported.
This article (10.1056/NEJMoa0807646) was published at www.nejm.org on November 9, 2008.
We thank the 17,802 study participants, their individual physicians, and the medical and clinical teams at AstraZeneca for their personal time and commitment to this project.
Source Information
From the Center for Cardiovascular Disease Prevention (P.M.R., E.D., J.G.M., R.J.G.) and Division of Cardiovascular Medicine (P.M.R., P.L.), Brigham and Women's Hospital, Harvard Medical School, Boston; Universidade Federal de São Paulo, São Paulo (F.A.H.F.); McGill University Health Center, Montreal (J.G.); Weill Cornell Medical College of Cornell University, New York (A.M.G.); Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam (J.J.P.K.); University of Ulm Medical Center, Ulm, Germany (W.K.); Hospital Cordoba, Cordoba, Argentina (A.J.L.); Herlev Hospital, Copenhagen University Hospital, Herlev, Denmark (B.G.N.); University of Glasgow, Glasgow, Scotland (J.S.); and St. Luke's Episcopal Hospital–Texas Heart Institute, Houston (J.T.W.).
Address reprint requests to Dr. Ridker at the Center for Cardiovascular Disease Prevention, Brigham and Women's Hospital, Boston, MA 02215, or at pridker@partners.org.
Members of the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) study group are listed in the Appendix and in the Supplementary Appendix, available with the full text of this article at www.nejm.org.
Appendix
Committee and board members for JUPITER were as follows: Steering Committee — P.M. Ridker (principal investigator and trial chair), F.A.H. Fonseca, J. Genest, A.M. Gotto, Jr., J.J.P. Kastelein, W. Koenig, P. Libby, A.J. Lorenzatti, B.G. Nordestgaard, J. Shepherd, J.T. Willerson; Clinical Coordinating Center — P.M. Ridker (chair), E. Danielson, R.J. Glynn, J.G. MacFadyen, S. Mora (Brigham and Women's Hospital, Boston); Study Statistician — R.J. Glynn; Independent Data and Safety Monitoring Board — R. Collins (chair), K. Bailey, B. Gersh, G. Lamas, S. Smith, D. Vaughan; Clinical End Point Committee — K. Mahaffey (chair), P. Brown, D. Montgomery, M. Wilson, F. Wood (Duke University, Durham NC). The site investigators are listed in the Supplementary Appendix.
- References
References
1
Grundy SM ,Cleeman JI ,Merz CN , et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-239[Erratum, Circulation 2004;110:763.]
CrossRef | Web of Science | Medline2
De Backer G ,Ambosioni E ,Borch-Johnson K , et al. European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2003;24:1601-1610
CrossRef | Web of Science | Medline3
Ridker PM ,Cushman M ,Stampfer MJ ,Tracy RP ,Hennekens CH . Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-979[Erratum, N Engl J Med 1997;337:356.]
Full Text | Web of Science | Medline4
Ridker PM ,Hennekens CH ,Buring JE ,Rifai N . C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-843
Full Text | Web of Science | Medline5
Ridker PM ,Rifai N ,Rose L ,Buring JE ,Cook NR . Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557-1565
Full Text | Web of Science | Medline6
Koenig W ,Lowel H ,Baumert J ,Meisinger C . C-reactive protein modulates risk prediction based on the Framingham score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation 2004;109:1349-1353
CrossRef | Web of Science | Medline7
Pai JK ,Pischon T ,Ma J , et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 2004;351:2599-2610
Full Text | Web of Science | Medline8
Boekholdt SM ,Hack CE ,Sandhu MS , et al. C-reactive protein levels and coronary artery disease incidence and mortality in apparently healthy men and women: the EPIC-Norfolk prospective population study 1993-2003. Atherosclerosis 2006;187:415-422
CrossRef | Web of Science | Medline9
Ballantyne CM ,Hoogeveen RC ,Bang H , et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2004;109:837-842
CrossRef | Web of Science | Medline10
Ridker PM ,Rifai N ,Pfeffer MA ,Sacks F ,Braunwald E . Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 1999;100:230-235
Web of Science | Medline11
Albert MA ,Danielson E ,Rifai N ,Ridker PM . Effect of statin therapy on C-reactive protein levels: the Pravastatin Inflammation/CRP Evaluation (PRINCE), a randomized trial and cohort study. JAMA 2001;286:64-70
CrossRef | Web of Science | Medline12
Ridker PM ,Rifai N ,Clearfield M , et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001;344:1959-1965
Full Text | Web of Science | Medline13
Ridker PM ,Rifai N ,Pfeffer MA , et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 1998;98:839-844
Web of Science | Medline14
Ridker PM ,Cannon CP ,Morrow D , et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005;352:20-28
Full Text | Web of Science | Medline15
Morrow DA ,de Lemos JA ,Sabatine MS , et al. Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial. Circulation 2006;114:281-288
CrossRef | Web of Science | Medline16
Ridker PM ,Morrow DA ,Rose LM ,Rifai N ,Cannon CP ,Braunwald E . Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial. J Am Coll Cardiol 2005;45:1644-1648
CrossRef | Web of Science | Medline17
Ridker PM . Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation 2003;108:2292-2297
CrossRef | Web of Science | Medline18
Ridker PM ,Fonseca FAH ,Genest J , et al. Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein. Am J Cardiol 2007;100:1659-1664
CrossRef | Web of Science | Medline19
Downs JR ,Clearfield M ,Weis S , et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS: Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-1622
CrossRef | Web of Science | Medline20
Shepherd J ,Cobbe SM ,Ford I , et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-1307
Full Text | Web of Science | Medline21
Grundy SM ,Cleeman JI ,Daniels SR , et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement: executive summary. Circulation 2005;112:2735-2752[Erratum, Circulation 2005;112(17):e297, e298.]
CrossRef | Web of Science | Medline22
Altman DG ,Andersen PK . Calculating the number needed to treat for trials where the outcome is time to an event. BMJ 1999;319:1492-1495
CrossRef | Web of Science | Medline23
The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators
Full Text | Web of Science | Medline24
Baigent C ,Keech A ,Kearney PM , et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-1278[Erratum, Lancet 2005;366:1358, 2008;371:2084.]
CrossRef | Web of Science | Medline25
Cannon CP ,Steinberg BA ,Murphy SA ,Mega JL ,Braunwald E . Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 2006;48:438-445
CrossRef | Web of Science | Medline26
Sabatine MS ,Wiviott SD ,Morrow DA ,McCabe CH ,Canon CP . High dose atorvastatin associated with worse glycemic control: a PROVE-IT TIMI 22 substudy. Circulation 2004;110:Suppl:S834-S834
Web of Science27
Sasaki J ,Iwashita M ,Kono S . Statins: beneficial or adverse for glucose metabolism. J Atheroscler Thromb 2006;13:123-129
CrossRef | Web of Science | Medline28
Hansson GK ,Libby P . The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 2006;6:508-519
CrossRef | Web of Science | Medline29
Ridker PM . The time for cardiovascular inflammation reduction trials has arrived: how low to go for hsCRP? Arterioscler Thromb Vasc Biol 2008;28:1222-1224
CrossRef | Web of Science | Medline
- Citing Articles (1011)
Citing Articles
1
Michael A. Sanchez, Christopher B. Thomas, Hollis R. O’Neal. (2012) Do aspirin and statins prevent severe sepsis?. Current Opinion in Infectious Diseases 25:3, 345-350
CrossRef2
Jerzy-Roch Nofer. (2012) Hyperlipidaemia and cardiovascular disease. Current Opinion in Lipidology 23:3, 260-262
CrossRef3
P. Y. Hsue, S. G. Deeks, P. W. Hunt. (2012) Immunologic Basis of Cardiovascular Disease in HIV-Infected Adults. Journal of Infectious Diseases 205:suppl 3, S375-S382
CrossRef4
Michael T. Koller, Heike Raatz, Ewout W. Steyerberg, Marcel Wolbers. (2012) Competing risks and the clinical community: irrelevance or ignorance?. Statistics in Medicine 31:11-12, 1089-1097
CrossRef5
Goldfine, Allison B., . (2012) Statins: Is It Really Time to Reassess Benefits and Risks?. New England Journal of Medicine 366:19, 1752-1755
Full Text6
Norihito Okina, Masanao Ohuchida, Tomohiro Takeuchi, Tomoki Fujiyama, Akira Satoh, Teruo Sakamoto, Hisashi Adachi, Tsutomu Imaizumi. (2012) Utility of measuring C-reactive protein for prediction of in-hospital events in patients with acute aortic dissection. Heart and Vessels
CrossRef7
Masahiro Natsuaki, Yoshihisa Nakagawa, Takeshi Morimoto, Koh Ono, Satoshi Shizuta, Yutaka Furukawa, Kazushige Kadota, Masashi Iwabuchi, Yoshihiro Kato, Satoru Suwa, Tsukasa Inada, Osamu Doi, Akinori Takizawa, Masakiyo Nobuyoshi, Toru Kita, Takeshi Kimura. (2012) Impact of Statin Therapy on Late Target Lesion Revascularization After Sirolimus-Eluting Stent Implantation (from the CREDO-Kyoto Registry Cohort-2). The American Journal of Cardiology 109:10, 1387-1396
CrossRef8
Chamindie Punyadeera. (2012) Human saliva as a tool to investigate intimate partner violence. Brain, Behavior, and Immunity 26:4, 541-542
CrossRef9
Gregory R. Pond, Andrew J. Armstrong, Brian A. Wood, Lance Leopold, Matthew D. Galsky, Guru Sonpavde. (2012) Ability of C-reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel-based chemotherapy. BJU Internationalno-no
CrossRef10
Allegra Battistoni, Speranza Rubattu, Massimo Volpe. (2012) Circulating biomarkers with preventive, diagnostic and prognostic implications in cardiovascular diseases. International Journal of Cardiology 157:2, 160-168
CrossRef11
Hae Chang Jeong, Youngkeun Ahn, Young Joon Hong, Ju Han Kim, Myung Ho Jeong, Young Jo Kim, Shung Chull Chae, Myeong Chan Cho. (2012) Statin therapy to reduce stent thrombosis in acute myocardial infarction patients with elevated high-sensitivity C-reactive protein. International Journal of Cardiology
CrossRef12
Alexander Bobik, Guido Grassi. (2012) Low-grade inflammation and arterial stiffness in the elderly. Journal of Hypertension 30:4, 679-681
CrossRef13
João Tomé-Carneiro, Manuel Gonzálvez, Mar Larrosa, María J. Yáñez-Gascón, Francisco J. García-Almagro, José A. Ruiz-Ros, María T. García-Conesa, Francisco A. Tomás-Barberán, Juan Carlos Espín. (2012) One-Year Consumption of a Grape Nutraceutical Containing Resveratrol Improves the Inflammatory and Fibrinolytic Status of Patients in Primary Prevention of Cardiovascular Disease. The American Journal of Cardiology
CrossRef14
Samia Mora, Robert J. Glynn, S. Matthijs Boekholdt, Børge G. Nordestgaard, John J.P. Kastelein, Paul M. Ridker. (2012) On-Treatment Non–High-Density Lipoprotein Cholesterol, Apolipoprotein B, Triglycerides, and Lipid Ratios in Relation to Residual Vascular Risk After Treatment With Potent Statin Therapy. Journal of the American College of Cardiology 59:17, 1521-1528
CrossRef15
Lisa M Younk, Stephen N Davis. (2012) Evaluation of colesevelam hydrochloride for the treatment of type 2 diabetes. Expert Opinion on Drug Metabolism & Toxicology 8:4, 515-525
CrossRef16
Jiri Frohlich, Ahmad Al-Sarraf. (2012) Cardiovascular risk and atherosclerosis prevention. Cardiovascular Pathology
CrossRef17
Lawrence de Koning, Cary Liptak, Aida Shkreta, Gary Bradwin, Frank B. Hu, Aruna Das Pradhan, Nader Rifai, Mark D. Kellogg. (2012) A multiplex immunoassay gives different results than singleplex immunoassays which may bias epidemiologic associations. Clinical Biochemistry
CrossRef18
Kevin C. Maki, Harold E. Bays, Mary R. Dicklin. (2012) Treatment options for the management of hypertriglyceridemia: Strategies based on the best-available evidence. Journal of Clinical Lipidology
CrossRef19
Menezes Arthur R, Lavie Carl J, V Milani Richard, Arena Ross A, S Church Timothy. (2012) Cardiac rehabilitation and exercise therapy in the elderly: Should we invest in the aged?. Journal of Geriatric Cardiology 9:1, 68-75
CrossRef20
E. Braunwald. (2012) The rise of cardiovascular medicine. European Heart Journal
CrossRef21
Marten A. Hoeksema, J. Lauran Stöger, Menno P. J. Winther. (2012) Molecular Pathways Regulating Macrophage Polarization: Implications for Atherosclerosis. Current Atherosclerosis Reports
CrossRef22
Chia-Hung Yen, Kun-Chen Lin, Steve Leu, Cheuk-Kwan Sun, Li-Teh Chang, Han-Tan Chai, Sheng-Ying Chung, Hsueh-Wen Chang, Sheung-Fat Ko, Yen-Ta Chen, Hon-Kan Yip. (2012) Chronic exposure to environmental contaminant nonylphenol exacerbates adenine-induced chronic renal insufficiency: Role of signaling pathways and therapeutic impact of rosuvastatin. European Journal of Pharmaceutical Sciences
CrossRef23
Ishak A. Mansi, Jennifer C. Thompson, Daniel E. Banks. (2012) Final Tips in Interpreting Evidence-Based Medicine. Southern Medical Journal 105:3, 173-180
CrossRef24
Stig Lyngbæk, Thomas Sehestedt, Jacob L. Marott, Tine W. Hansen, Michael H. Olsen, Ove Andersen, Allan Linneberg, Sten Madsbad, Steen B. Haugaard, Jesper Eugen-Olsen, Jørgen Jeppesen. (2012) CRP and suPAR are differently related to anthropometry and subclinical organ damage. International Journal of Cardiology
CrossRef25
Elizabeth P. Berbano, Nancy Baxi. (2012) Impact of Patient Selection in Various Study Designs. Southern Medical Journal 105:3, 149-155
CrossRef26
S Matthijs Boekholdt, Erik SG Stroes. (2012) The interleukin-6 pathway and atherosclerosis. The Lancet 379:9822, 1176-1178
CrossRef27
Marc Fisher, Majaz Moonis. (2012) Neuroprotective Effects of Statins: Evidence from Preclinical and Clinical Studies. Current Treatment Options in Cardiovascular Medicine
CrossRef28
Murray Epstein, Nosratola D. Vaziri. (2012) Statins in the management of dyslipidemia associated with chronic kidney disease. Nature Reviews Nephrology
CrossRef29
Nicole A Terpolilli, Michael A Moskowitz, Nikolaus Plesnila. (2012) Nitric oxide: considerations for the treatment of ischemic stroke. Journal of Cerebral Blood Flow & Metabolism
CrossRef30
Bernd Hewing, Edward A Fisher. (2012) Preclinical mouse models and methods for the discovery of the causes and treatments of atherosclerosis. Expert Opinion on Drug Discovery1-10
CrossRef31
K. Rahimi, W. Majoni, A. Merhi, J. Emberson. (2012) Effect of statins on ventricular tachyarrhythmia, cardiac arrest, and sudden cardiac death: a meta-analysis of published and unpublished evidence from randomized trials. European Heart Journal
CrossRef32
Veerle Bieghs, Patrick C.N. Rensen, Marten H. Hofker, Ronit Shiri-Sverdlov. (2012) NASH and atherosclerosis are two aspects of a shared disease: Central role for macrophages. Atherosclerosis 220:2, 287-293
CrossRef33
Ashish Upadhyay, Daniel E. Weiner. (2012) Lipid-Lowering Therapy in Individuals With CKD: Lessons Learned From SHARP. American Journal of Kidney Diseases 59:2, 170-173
CrossRef34
Uchechukwu K. Sampson, Sergio Fazio, MacRae F. Linton. (2012) Residual Cardiovascular Risk Despite Optimal LDL Cholesterol Reduction with Statins: The Evidence, Etiology, and Therapeutic Challenges. Current Atherosclerosis Reports 14:1, 1-10
CrossRef35
Cornelis J Roos, Paul HA Quax, J Wouter Jukema. (2012) Cardiovascular metabolic syndrome: mediators involved in the pathophysiology from obesity to coronary heart disease. Biomarkers in Medicine 6:1, 35-52
CrossRef36
Robert L. Ohsfeldt, Anders G. Olsson, Marie M. Jensen, Sanjay K. Gandhi, Thomas Paulsson. (2012) Cost-effectiveness of rosuvastatin 20 mg for the prevention of cardiovascular morbidity and mortality: a Swedish economic evaluation of the JUPITER trial. Journal of Medical Economics 15:1, 125-133
CrossRef37
Chary Lopez-Pedrera, Patricia Ruiz-Limon, M. Angeles Aguirre, Antonio Rodriguez-Ariza, Maria José Cuadrado. (2012) Potential Use of Statins in the Treatment of Antiphospholipid Syndrome. Current Rheumatology Reports 14:1, 87-94
CrossRef38
Dipan A. Desai, Sammy Zakaria, Pamela Ouyang. (2012) Initiation of Statin Therapy: Are There Age Limits?. Current Atherosclerosis Reports 14:1, 17-25
CrossRef39
Ernst Rietzschel, Marc De Buyzere. (2012) High-sensitive C-reactive protein: universal prognostic and causative biomarker in heart disease?. Biomarkers in Medicine 6:1, 19-34
CrossRef40
Christian Stratz, Michael Amann, David D. Berg, David A. Morrow, Franz-Josef Neumann, Willibald Hochholzer. (2012) Novel biomarkers in cardiovascular disease. Cardiology in Review1
CrossRef41
M. Alberton, P. Wu, E. Druyts, M. Briel, E. J. Mills. (2012) Adverse events associated with individual statin treatments for cardiovascular disease: an indirect comparison meta-analysis. QJM 105:2, 145-157
CrossRef42
William J. Kostis, Jerry Q. Cheng, Jeanne M. Dobrzynski, Javier Cabrera, John B. Kostis. (2012) Meta-Analysis of Statin Effects in Women Versus Men. Journal of the American College of Cardiology 59:6, 572-582
CrossRef43
B M Y Cheung, K L Ong, A W K Tso, R Y H Leung, A Xu, S S Cherny, P C Sham, T H Lam, K S L Lam. (2012) C-reactive protein as a predictor of hypertension in the Hong Kong Cardiovascular Risk Factor Prevalence Study (CRISPS) cohort. Journal of Human Hypertension 26:2, 108-116
CrossRef44
Kyoko Okada, Norihiro Furusyo, Masayuki Murata, Yasunori Sawayama, Mosaburo Kainuma, Jun Hayashi. (2012) A hypertriglyceridemic state increases high sensitivity C-reactive protein of Japanese men with normal glucose tolerance. Endocrine 41:1, 96-102
CrossRef45
Scott Kinlay. (2012) Role of C-Reactive Protein When Prescribing a Statin. Current Atherosclerosis Reports 14:1, 26-32
CrossRef46
Mark A. Moyad. (2012) The Optimal Male Health Diet and Dietary Supplement Program. Urologic Clinics of North America 39:1, 89-107
CrossRef47
Isabelle Plante, Patrick Vigneault, Benoît Drolet, Jacques Turgeon. (2012) Rosuvastatin blocks hERG current and prolongs cardiac repolarization. Journal of Pharmaceutical Sciences 101:2, 868-878
CrossRef48
Kousuke Hattori, Yukio Ozaki, Tevfik F. Ismail, Masanori Okumura, Hiroyuki Naruse, Shino Kan, Makoto Ishikawa, Tomoko Kawai, Masaya Ohta, Hideki Kawai, Tousei Hashimoto, Yasushi Takagi, Junichi Ishii, Patrick W. Serruys, Jagat Narula. (2012) Impact of Statin Therapy on Plaque Characteristics as Assessed by Serial OCT, Grayscale and Integrated Backscatter–IVUS. JACC: Cardiovascular Imaging 5:2, 169-177
CrossRef49
Todd C. Villines, Andrew S. Kim, Rosco S. Gore, Allen J. Taylor. (2012) Niacin: The Evidence, Clinical Use, and Future Directions. Current Atherosclerosis Reports 14:1, 49-59
CrossRef50
Rebecca Rudominer Ascunce, Jeffrey S. Berger, Howard S. Weintraub, Arthur Schwartzbard. (2012) The Role of Statin Therapy for Primary Prevention: What is the Evidence?. Current Atherosclerosis Reports
CrossRef51
G. Mendez-Lagares, A. Garcia-Perganeda, M. d. M. d. Pozo-Balado, M. Genebat, E. Ruiz-Mateos, M. Garcia Garcia, M. A. Munoz-Fernandez, Y. M. Pacheco, M. Leal. (2012) Differential alterations of the CD4 and CD8 T cell subsets in HIV-infected patients on highly active antiretroviral therapy with low CD4 T cell restoration. Journal of Antimicrobial Chemotherapy
CrossRef52
Sud Ramachandran, Ahmed Abbas, Sanjay Saraf, Jessie Raju, Christina Jewkes, Alan F Jones. (2012) Significant Increase in High-Density Lipoprotein Cholesterol with Fibrates Is Associated with Low Pretreatment High-Density Lipoprotein Cholesterol: Findings from An Outpatient Clinic Setting. Metabolic Syndrome and Related Disorders120127065325006
CrossRef53
Bodh I. Jugdutt. (2012) Prevention of heart failure in the elderly: when, where and how to begin?. Heart Failure Reviews
CrossRef54
Luciana Thiago, Selma Rumiko Tsuji, Álvaro N Atallah, Maria Eduarda dos Santos Puga, Aecio FT Gois, Orsine Valente, Luciana Thiago. 2012. Statins for aortic valve stenosis. .
CrossRef55
Warren J. Gasper, Sara J. Runge, Christopher D. Owens. (2012) Management of Infrapopliteal Peripheral Arterial Occlusive Disease. Current Treatment Options in Cardiovascular Medicine
CrossRef56
Andrea Lorenzo, Felipe Pittella, Antonio Rocha. (2012) Increased Preoperative C-Reactive Protein Levels Are Associated with Inhospital Death After Coronary Artery Bypass Surgery. Inflammation
CrossRef57
G. Danaei, M. Tavakkoli, M. A. Hernan. (2012) Bias in Observational Studies of Prevalent Users: Lessons for Comparative Effectiveness Research From a Meta-Analysis of Statins. American Journal of Epidemiology
CrossRef58
Roy L. Silverstein. (2012) Teaching an old dog new tricks: potential antiatherothrombotic use for statins. Journal of Clinical Investigation
CrossRef59
M. Rydén, P. Leanderson, K.-O. Kastbom, L. Jonasson. (2012) Effects of simvastatin on carotenoid status in plasma. Nutrition, Metabolism and Cardiovascular Diseases 22:1, 66-71
CrossRef60
Razvan T. Dadu, Vijay Nambi, Christie M. Ballantyne, Jessica L. Slocum, Michael Heung, Subramaniam Pennathur, Wenjun Ju, Shahaan Smith, Matthias Kretzler. (2012) Developing and assessing cardiovascular biomarkers. Translational Research 159:4, 265
CrossRef61
Nathaniel S. Rial, Kwan Choi, Tam Nguyen, Branden Snyder, Marvin J. Slepian. (2012) Nuclear factor kappa B (NF-κB): A novel cause for diabetes, coronary artery disease and cancer initiation and promotion?. Medical Hypotheses 78:1, 29-32
CrossRef62
Leslee J. Shaw, Y. Chandrashekhar, Jagat Narula. (2012) Progression of Coronary Calcium Scores. JACC: Cardiovascular Imaging 5:4, 465
CrossRef63
Takeharu Asano, Ikuo Nakamura, Mari Okajima, Kenichi Yamanaka, Shinichi Asabe, Hiroyuki Miyatani, Katsuhiko Matsuura, Yukio Yoshida, Michio Imawari. (2012) A case of pseudoaneurysm formed 10 years after segmental liver resection for hepatocellular carcinoma. Kanzo 53:1, 55-63
CrossRef64
Jian-Jun Li, Ping Yang, Jun Liu, Yan-Jun Jia, Zi-Cheng Li, Yuan-Lin Guo, Na-Qiong Wu, Yi-Da Tang, Li-Xin Jiang. (2012) Impact of 10mg rosuvastatin daily or alternate-day on lipid profile and inflammatory markers. Clinica Chimica Acta 413:1-2, 139-142
CrossRef65
M.C. Calle, M.L. Fernandez. (2012) Inflammation and type 2 diabetes. Diabetes & Metabolism
CrossRef66
L. Kristin Newby, Pamela S. Douglas. 2012. Cardiovascular Disease in Women. , 1757-1769.
CrossRef67
Paul M Ridker, Peter Libby. 2012. Risk Markers for Atherothrombotic Disease. , 914-934.
CrossRef68
Indira Tendolkar, Morteza Enajat, Marcel P. Zwiers, Guido van Wingen, Frank-Erik de Leeuw, Janet van Kuilenburg, Leon Bouwels, Gheorghe Pop, Monika Pop-Purceleanu. (2012) One-year cholesterol lowering treatment reduces medial temporal lobe atrophy and memory decline in stroke-free elderly with atrial fibrillation: evidence from a parallel group randomized trial. International Journal of Geriatric Psychiatry 27:1, 49-58
CrossRef69
David A. Morrow, William E. Boden. 2012. Stable Ischemic Heart Disease. , 1210-1269.
CrossRef70
Matthias Hermann, Dieter Fischer, Michael M. Hoffmann, Theo Gasser, Kurt Quitzau, Thomas Meinertz, Thomas Münzel, Thomas F. Lüscher. (2012) CRP and CD14 polymorphisms correlate with coronary plaque volume in patients with coronary artery disease – IVUS substudy of the ENCORE trials. Atherosclerosis 220:1, 172-176
CrossRef71
Tomas Kovarnik, Gary S. Mintz, Hana Skalicka, Ales Kral, Jan Horak, Roman Skulec, Jana Uhrova, Pavel Martasek, Richard W. Downe, Andreas Wahle, Milan Sonka, Vratislav Mrazek, Michael Aschermann, Ales Linhart. (2012) Virtual Histology Evaluation of Atherosclerosis Regression During Atorvastatin and Ezetimibe Administration. Circulation Journal 76:1, 176-183
CrossRef72
Faiez Zannad, Guy De Backer, Ian Graham, Matthias Lorenz, Giuseppe Mancia, David A. Morrow, Željko Reiner, Wolfgang Koenig, Jean Dallongeville, Robert J. Macfadyen, Luis M. Ruilope, Lars Wilhelmsen, . (2012) Risk stratification in cardiovascular disease primary prevention - scoring systems, novel markers, and imaging techniques. Fundamental & Clinical Pharmacologyno-no
CrossRef73
Ren Kawaguchi. (2012) Low-Density Lipoprotein Cholesterol Lowering Therapy and Established Atherosclerosis. Circulation Journal 76:1, 49-50
CrossRef74
Tsochiang Ma, Mu-Hsin Chang, Liyun Tien, Yi-Sheng Liou, Gwo-Ping Jong. (2012) The Long-Term Effect of Statins on the Risk of New-Onset Diabetes Mellitus in Elderly Taiwanese Patients with Hypertension and Dyslipidaemia. Drugs & Aging 29:1, 45-51
CrossRef75
Larry B. Goldstein. 2012. Prevention and Management of Stroke. , 1359-1367.
CrossRef76
Mark Houston. (2012) The Role of Nutraceutical Supplements in the Treatment of Dyslipidemia. The Journal of Clinical Hypertensionno-no
CrossRef77
Masaharu Ishihara. (2012) Intensive Lipid-Lowering Therapy With Statins for Primary Prevention. Circulation Journal 76:1, 55-56
CrossRef78
Erik Ingelsson, Li Yin, Magnus Bäck. (2012) Nationwide cohort study of the leukotriene receptor antagonist montelukast and incident or recurrent cardiovascular disease. Journal of Allergy and Clinical Immunology
CrossRef79
Rishi Puri, MyNgan Duong, Kiyoko Uno, Yu Kataoka, Stephen J Nicholls. (2012) The emerging role of plasma lipidomics in cardiovascular drug discovery. Expert Opinion on Drug Discovery 7:1, 63-72
CrossRef80
Milan Gupta, Narendra Singh, Michelle Tsigoulis, Mahesh Kajil, Sheriar Hirjikaka, Adrian Quan, Hwee Teoh, Subodh Verma. (2012) Perceptions of Canadian Primary Care Physicians Towards Cardiovascular Risk Assessment and Lipid Management. Canadian Journal of Cardiology 28:1, 14-19
CrossRef81
Evan A. Stein, Donald G. Vidt, James Shepherd, Valerie A. Cain, Deborah Anzalone, Michael Cressman. (2012) Renal Safety of Intensive Cholesterol-Lowering Treatment with Rosuvastatin: A Retrospective Analysis of Renal Adverse Events among 40,600 Participants in the Rosuvastatin Clinical Development Program. Atherosclerosis
CrossRef82
John T. Wilkins, Donald M. Lloyd-Jones. (2012) Are Novel Serum Biomarkers Informative?. Medical Clinics of North America 96:1, 1-11
CrossRef83
Mayer Bassan. (2012) A case for immediate-release niacin. Heart & Lung: The Journal of Acute and Critical Care 41:1, 95-98
CrossRef84
Kuo-Ho Yeh, Tzu-Hsien Tsai, Han-Tan Chai, Steve Leu, Sheng-Ying Chung, Sarah Chua, Yung-Lung Chen, Hung-Sheng Lin, Chun-Man Yuen, Hon-Kan Yip. (2012) Comparison of Acute versus Convalescent Stage High-Sensitivity C-Reactive Protein Level in Predicting Clinical Outcome after Acute Ischemic Stroke and Impact of Erythropoietin. Journal of Translational Medicine 10:1, 6
CrossRef85
Jacques Genest, Peter Libby. 2012. Lipoprotein Disorders and Cardiovascular Disease. , 975-995.
CrossRef86
Hussain Isma'eel, Zeina Mohanna, Ghassan Hamadeh, Elie Alam, Kamal Badr, Samir Alam, Abdallah Rebeiz. (2012) The public cost of 3 statins for primary prevention of cardiovascular events in 7 Middle East countries: Not all of them can afford it. International Journal of Cardiology
CrossRef87
Peter P. Toth, Nicolas W. Shammas, Eric J. Dippel, Blair Foreman. 2012. Cardiovascular Disease. , 478-549.
CrossRef88
Luca Mascitelli, Mark R. Goldstein. (2012) Long-Standing Statin Therapy and the Risk of New-Onset Diabetes in the Elderly. Drugs & Aging 29:1, 9-13
CrossRef89
Khurram Nasir, Leslee J. Shaw, Matthew J. Budoff, Paul M. Ridker, Jessica M. Peña. (2012) Coronary Artery Calcium Scanning Should be Used for Primary Prevention. JACC: Cardiovascular Imaging 5:1, 111-118
CrossRef90
Nina C. Raju, Qilong Yi, Mark Nidorf, Nick D. Fagel, Rajesh Hiralal, John W. Eikelboom. (2012) Effect of colchicine compared with placebo on high sensitivity C-reactive protein in patients with acute coronary syndrome or acute stroke: a pilot randomized controlled trial. Journal of Thrombosis and Thrombolysis 33:1, 88-94
CrossRef91
Hong Seog Seo. (2012) The Role and Clinical Significance of High-Sensitivity C-Reactive Protein in Cardiovascular Disease. Korean Circulation Journal 42:3, 151
CrossRef92
Nikolaos G. Frangogiannis, Maneesh Bhargava, Chris H. Wendt, Rekha Vij, Imre Noth. (2012) Biomarkers: hopes and challenges in the path from discovery to clinical practice. Translational Research 159:4, 197
CrossRef93
Elizabeth Gorevski, Boyang Bian, Christina M.L. Kelton, Jill E. Martin Boone, Jeff J. Guo. (2012) Evidence-Based Prediction of Statin Use with Lipid-Panel Data from the National Health and Nutrition Examination Survey. Value in Health 15:1, 32-38
CrossRef94
Michael R. Bristow. (2012) Pharmacogenetic targeting of drugs for heart failure. Pharmacology & Therapeutics
CrossRef95
Per Torger Skretteberg, Irene Grundvold, Sverre E. Kjeldsen, Jan E. Erikssen, Leiv Sandvik, Knut Liestøl, Gunnar Erikssen, Terje R. Pedersen, Johan Bodegard. (2012) HDL-cholesterol and prediction of coronary heart disease: Modified by physical fitness?. Atherosclerosis 220:1, 250-256
CrossRef96
Akil A. Merchant, Cindy N. Roy. (2012) Not so benign haematology: anaemia of the elderly. British Journal of Haematology 156:2, 173-185
CrossRef97
Seth S. Martin, Roger S. Blumenthal, Michael Miller. (2012) LDL Cholesterol: The Lower the Better. Medical Clinics of North America 96:1, 13-26
CrossRef98
Ryuji Nohara, Hiroyuki Daida, Mitsumasa Hata, Kohei Kaku, Ryuzo Kawamori, Junji Kishimoto, Masahiko Kurabayashi, Izuru Masuda, Ichiro Sakuma, Tsutomu Yamazaki, Hiroyoshi Yokoi, Masayuki Yoshida, the Justification for Atheroscleros. (2012) Effect of Intensive Lipid-Lowering Therapy With Rosuvastatin on Progression of Carotid Intima-Media Thickness in Japanese Patients. Circulation Journal 76:1, 221-229
CrossRef99
Smita Pattanaika, Samir Malhotraa, Yash Paul Sharma, Promila Pandhi. (2012) Comparison of alternate day atorvastatin treatment to daily treatment in maintaining LDL-Cholesterol targets in patients with variable coronary risk profile. Journal of Cardiovascular Pharmacology1
CrossRef100
Clay F. Semenkovich. 2012. Disorders of Lipid Metabolism. , 1346-1354.
CrossRef101
Michael J. Klag. 2012. Epidemiology of Cardiovascular Disease. , 256-260.
CrossRef102
J. M. Pena, J. MacFadyen, R. J. Glynn, P. M. Ridker. (2011) High-sensitivity C-reactive protein, statin therapy, and risks of atrial fibrillation: an exploratory analysis of the JUPITER trial. European Heart Journal
CrossRef103
2011. Complications Associated with Diabetes. , 201-249.
CrossRef104
Lun Li, TianTian Sun, Peizhen Zhang, Jinhui Tian, KeHu Yang, Jinhui Tian. 2011. Statins for primary prevention of venous thromboembolism. .
CrossRef105
Nicholls, Stephen J., Ballantyne, Christie M., Barter, Philip J., Chapman, M. John, Erbel, Raimund M., Libby, Peter, Raichlen, Joel S., Uno, Kiyoko, Borgman, Marilyn, Wolski, Kathy, Nissen, Steven E., . (2011) Effect of Two Intensive Statin Regimens on Progression of Coronary Disease. New England Journal of Medicine 365:22, 2078-2087
Full Text106
Behnood Bikdeli. (2011) C-Reactive Protein, Statins and the Risk of Vascular Events: A Better Understanding. Cardiovascular Drugs and Therapy 25:6, 545-549
CrossRef107
Beatriz G. Talayero, Frank M. Sacks. (2011) The Role of Triglycerides in Atherosclerosis. Current Cardiology Reports 13:6, 544-552
CrossRef108
Ángel Díaz Rodríguez, Adalberto Serrano Cumplido, David Fierro González, Luis Alberto Rodríguez Arroyo, Francisco-Javier García-Norro Herreros, Serafín de Abajo Olea, Isidro López Rodríguez, Josefa María Panisello Royo, Jose Carlos Minguez Villar, Jesús Palomo del Arco, Rafael Colás Chacartegui, Vicente Pascual Fuster, Juan Carlos Verdes-Montenegro Atalaya. (2011) Pitavastatina: una nueva alternativa en el tratamiento de la dislipemia. Clínica e Investigación en Arteriosclerosis
CrossRef109
Kwang Kon Koh, Michael J. Quon, Ichiro Sakuma, Seung Hwan Han, Hanul Choi, Kyounghoon Lee, Eak Kyun Shin. (2011) Differential metabolic effects of rosuvastatin and pravastatin in hypercholesterolemic patients. International Journal of Cardiology
CrossRef110
M. Madjid, J. T. Willerson. (2011) Inflammatory markers in coronary heart disease. British Medical Bulletin 100:1, 23-38
CrossRef111
Duk-Woo Park, Seung-Whan Lee, Sung-Cheol Yun, Hae-Geun Song, Jung-Min Ahn, Jong-Young Lee, Won-Jang Kim, Soo-Jin Kang, Young-Hak Kim, Cheol Whan Lee, Seong-Wook Park, Seung-Jung Park. (2011) A Point-of-Care Platelet Function Assay and C-Reactive Protein for Prediction of Major Cardiovascular Events After Drug-Eluting Stent Implantation. Journal of the American College of Cardiology 58:25, 2630-2639
CrossRef112
Romesh Khardori, Nancy Misri Khardori. (2011) Biologic Response Modifiers: Relevance & Repercussions. Infectious Disease Clinics of North America 25:4, 719-722
CrossRef113
Mario Di Napoli, Mitchell SV Elkind, Daniel Agustin Godoy, Puneetpal Singh, Francesca Papa, Aurel Popa-Wagner. (2011) Role of C-reactive protein in cerebrovascular disease: a critical review. Expert Review of Cardiovascular Therapy 9:12, 1565-1584
CrossRef114
J.-J. Perrenoud. (2011) Ethical considerations in geriatric cardiology. European Geriatric Medicine 2:6, 363-370
CrossRef115
Rodrigo Antonini Ribeiro, Patricia Klarmann Ziegelmann, Bruce Bartholow Duncan, Steffan Frosi Stella, José Luiz da Costa Vieira, Luciane Maria Fabian Restelatto, Emílio Hideyuki Moriguchi, Carisi Anne Polanczyk. (2011) Impact of statin dose on major cardiovascular events: A mixed treatment comparison meta-analysis involving more than 175,000 patients. International Journal of Cardiology
CrossRef116
Katrin Schäfer, Stavros Konstantinides. (2011) Adipokines and thrombosis. Clinical and Experimental Pharmacology and Physiology 38:12, 864-871
CrossRef117
Alexander Mauskop, William B. Borden. (2011) Predictors of Statin Adherence. Current Cardiology Reports 13:6, 553-558
CrossRef118
Nicole Cristell, Domenico Cianflone, Alessandro Durante, Enrico Ammirati, Diego Vanuzzo, Michela Banfi, Giliola Calori, Azeem Latib, Filippo Crea, Giancarlo Marenzi, Monica De Metrio, Luciano Moretti, Hui Li, Neal G. Uren, Dayi Hu, Attilio Maseri. (2011) High-Sensitivity C-Reactive Protein Is Within Normal Levels at the Very Onset of First ST-Segment Elevation Acute Myocardial Infarction in 41% of Cases. Journal of the American College of Cardiology 58:25, 2654-2661
CrossRef119
Veena Rajanna, Kristen B. Campbell, Jeffrey Leimberger, Bibhu D. Mohanty, John R. Guyton. (2011) Elevation of fasting morning glucose relative to hemoglobin A1c in normoglycemic patients treated with niacin and with statins. Journal of Clinical Lipidology
CrossRef120
Harvey S. Hecht. (2011) Coronary Artery Calcium: Utilization for Primary Prevention of CHD. Current Cardiology Reports 13:6, 465-474
CrossRef121
Kwok Leung Ong, Ben J. Wu, Bernard M.Y. Cheung, Philip J. Barter, Kerry-Anne Rye. (2011) Association of lower total bilirubin level with statin usage: The United States National Health and Nutrition Examination Survey 1999–2008. Atherosclerosis 219:2, 728-733
CrossRef122
Esam Abulhul, Kenneth McDonald, Ramon Martos, Dermot Phelan, J. Paul Spiers, Martina Hennessy, John Baugh, Chris Watson, Christina O'Loughlin, Mark Ledwidge. (2011) Long-Term Statin Therapy in Patients With Systolic Heart Failure and Normal Cholesterol: Effects on Elevated Serum Markers of Collagen Turnover, Inflammation, and B-Type Natriuretic Peptide. Clinical Therapeutics
CrossRef123
David Preiss, Naveed Sattar. (2011) Statins and the risk of new-onset diabetes. Current Opinion in Lipidology 22:6, 460-466
CrossRef124
Travis J. Bench, Allen Jeremias, David L. Brown. (2011) Matrix metalloproteinase inhibition with tetracyclines for the treatment of coronary artery disease. Pharmacological Research 64:6, 561-566
CrossRef125
B. K. MAHMOODI, A. B. MULDER, F. WAANDERS, H. M. H. SPRONK, R. MULDER, M. C. J. SLAGMAN, L. VOGT, G. NAVIS, H. TEN CATE, H. C. KLUIN-NELEMANS, G. D. LAVERMAN. (2011) The impact of antiproteinuric therapy on the prothrombotic state in patients with overt proteinuria. Journal of Thrombosis and Haemostasis 9:12, 2416-2423
CrossRef126
W. Nseir, A. Shalata, A. Marmor, N. Assy. (2011) Mechanisms Linking Nonalcoholic Fatty Liver Disease with Coronary Artery Disease. Digestive Diseases and Sciences 56:12, 3439-3449
CrossRef127
Leslee J. Shaw. (2011) The challenge of imaging-guided therapeutic management. Journal of Nuclear Cardiology 18:6, 995-996
CrossRef128
Kamran I Muhammad, Thomas Morledge, Ravish Sachar, Annette Zeldin, Kathy Wolski, Deepak L Bhatt. (2011) Treatment with ω-3 fatty acids reduces serum C-reactive protein concentration. Clinical Lipidology 6:6, 723-729
CrossRef129
S Schneeweiss, J J Gagne, R J Glynn, M Ruhl, J A Rassen. (2011) Assessing the Comparative Effectiveness of Newly Marketed Medications: Methodological Challenges and Implications for Drug Development. Clinical Pharmacology & Therapeutics 90:6, 777-790
CrossRef130
Richard Kones. (2011) Inflammation, C-reactive protein and cardiometabolic risk: how compelling is the potential therapeutic role of n-3 PUFAs in cardiovascular disease?. Clinical Lipidology 6:6, 627-630
CrossRef131
Emil M. deGoma, Joshua W. Knowles, Fabio Angeli, Matthew J. Budoff, Daniel J. Rader. (2011) The Evolution and Refinement of Traditional Risk Factors for Cardiovascular Disease. Cardiology in Review1
CrossRef132
Jonathan P. Piccini, Thomas W. Wallace, Manesh R. Patel, Richard C. Becker. (2011) Stroke Prevention in Atrial Fibrillation. Cardiovascular Drugs and Therapy 25:6, 561-570
CrossRef133
Claudia Stefanutti, Antonio Vivenzio, Pietro Manuel Ferraro, Claudia Morozzi, Dany Belotherkovsky. (2011) Apheresis-inducible cytokine pattern change in severe, genetic dyslipidemias. Cytokine 56:3, 835-841
CrossRef134
J F Marcinak, P Viswanathan, V Arora, L E Roebel, T R Strack, E Leifke. (2011) Shift From Surrogate End Point to Outcome Trials: Implications for Cardiovascular Safety Assessment in Development Programs for Antidiabetic Drugs. Clinical Pharmacology & Therapeutics
CrossRef135
Pál Maurovich-Horvat, Kimberly Kallianos, Leif-Christopher Engel, Jackie Szymonifka, Caroline S. Fox, Udo Hoffmann, Quynh A. Truong. (2011) Influence of pericoronary adipose tissue on local coronary atherosclerosis as assessed by a novel MDCT volumetric method. Atherosclerosis 219:1, 151-157
CrossRef136
Michael Domanski, Donald Lloyd-Jones, Valentin Fuster, Scott Grundy. (2011) Can we dramatically reduce the incidence of coronary heart disease?. Nature Reviews Cardiology 8:12, 721-725
CrossRef137
G. Tibolla, G.D. Norata, R. Artali, F. Meneghetti, A.L. Catapano. (2011) Proprotein convertase subtilisin/kexin type 9 (PCSK9): From structure–function relation to therapeutic inhibition. Nutrition, Metabolism and Cardiovascular Diseases 21:11, 835-843
CrossRef138
Philipp M. Lepper, Marcus E. Kleber, Tanja B. Grammer, Kristina Hoffmann, Simone Dietz, Bernhard R. Winkelmann, Bernhard O. Boehm, Winfried März. (2011) Lipopolysaccharide-binding protein (LBP) is associated with total and cardiovascular mortality in individuals with or without stable coronary artery disease – Results from the Ludwigshafen Risk and Cardiovascular Health Study (LURIC). Atherosclerosis 219:1, 291-297
CrossRef139
B. W. J. Hellebrekers, T. Kooistra. (2011) Pathogenesis of postoperative adhesion formation. British Journal of Surgery 98:11, 1503-1516
CrossRef140
Vincent E. Friedewald, William E. Boden, Gregg W. Stone, Clyde W. Yancy, William C. Roberts. (2011) The Editor's Roundtable: Role of Percutaneous Coronary Intervention and Drug-Eluting Stents in Patients With Stable Coronary Heart Disease. The American Journal of Cardiology 108:10, 1417-1425
CrossRef141
M. Seguí Díaz, J.J. Mediavilla Bravo, J.M. Comas Samper, A. Barquilla García, F. Carramiñana Barrera. (2011) Prevención de la diabetes mellitus 2. SEMERGEN - Medicina de Familia 37:9, 496-503
CrossRef142
Peter P Toth, Thomas D Dayspring. (2011) Drug safety evaluation of rosuvastatin. Expert Opinion on Drug Safety 10:6, 969-986
CrossRef143
Timothy R. McGuire, Susan K. Brusnahan, Laura D. Bilek, John D. Jackson, M. Anne Kessinger, Anne M. Berger, Kevin L. Garvin, Barbara J. O'Kane, Sonal R. Tuljapurkar, John G. Sharp. (2011) Inflammation Associated With Obesity: Relationship With Blood and Bone Marrow Endothelial Cells. Obesity 19:11, 2130-2136
CrossRef144
E. Moutzouri, E. Liberopoulos, D. P. Mikhailidis, M. S. Kostapanos, A. A. Kei, H. Milionis, M. Elisaf. (2011) Comparison of the effects of simvastatin vs. rosuvastatin vs. simvastatin/ezetimibe on parameters of insulin resistance. International Journal of Clinical Practice 65:11, 1141-1148
CrossRef145
Stephen J Nicholls, Kiyoko Uno, Yu Kataoka. (2011) Clinical experience with rosuvastatin in the management of hyperlipidemia and the reduction of cardiovascular risk. Expert Review of Cardiovascular Therapy 9:11, 1383-1390
CrossRef146
Jia-Yi Dong, Peiyu Wang, Ka He, Li-Qiang Qin. (2011) Effect of soy isoflavones on circulating C-reactive protein in postmenopausal women. Menopause 18:11, 1256-1262
CrossRef147
Chris T. Longenecker, Brian D. Hoit. (2011) Imaging atherosclerosis in HIV: carotid intima-media thickness and beyond. Translational Research
CrossRef148
Hiroki Mizukami, Wataru Inaba, Kazunori Takahashi, Keisuke Inoue, Kimio Sawanobori, Soroku Yagihashi. (2011) Augmented reduction of islet β-cell mass in Goto-Kakizaki rats fed high-fat diet and its suppression by pitavastatin treatment. Journal of Diabetes Investigationno-no
CrossRef149
Boris N. Mankovsky. (2011) 4 th Annual Symposium on Self Monitoring of Blood Glucose (SMBG) Applications and Beyond, May 12–14, 2011, Budapest, Hungary. Diabetes Technology & Therapeutics 13:11, 1161-1176
CrossRef150
B. Molins, E. Pena, R. de la Torre, L. Badimon. (2011) Monomeric C-reactive protein is prothrombotic and dissociates from circulating pentameric C-reactive protein on adhered activated platelets under flow. Cardiovascular Research 92:2, 328-337
CrossRef151
Jan Bucerius, Raphaël Duivenvoorden, Venkatesh Mani, Colin Moncrieff, James H.F. Rudd, Claudia Calcagno, Josef Machac, Valentin Fuster, Michael E. Farkouh, Zahi A. Fayad. (2011) Prevalence and Risk Factors of Carotid Vessel Wall Inflammation in Coronary Artery Disease Patients. JACC: Cardiovascular Imaging 4:11, 1195-1205
CrossRef152
L-S Tam, EK Li, Q Shang, B Tomlinson, VW Lee, KK Lee, M Li, W Pang Kuan, TK Li, L Tseung, GWK Yip, B Freedman, C-M Yu. (2011) Effects of rosuvastatin on subclinical atherosclerosis and arterial stiffness in rheumatoid arthritis: a randomized controlled pilot trial. Scandinavian Journal of Rheumatology 40:6, 411-421
CrossRef153
Alberto Ortiz, Ziad A. Massy, Danilo Fliser, Bengt Lindholm, Andrzej Wiecek, Alberto Martínez-Castelao, Adrian Covic, David Goldsmith, Gültekin Süleymanlar, Gérard M. London, Carmine Zoccali. (2011) Clinical usefulness of novel prognostic biomarkers in patients on hemodialysis. Nature Reviews Nephrology
CrossRef154
Damian O. McCall, Michelle C. McKinley, Rebecca Noad, Pascal P. McKeown, David R. McCance, Ian S. Young, Jayne V. Woodside. (2011) The assessment of vascular function during dietary intervention trials in human subjects. British Journal of Nutrition 106:07, 981-994
CrossRef155
Paul M Ridker, Tom Thuren, Andrew Zalewski, Peter Libby. (2011) Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: Rationale and Design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). American Heart Journal 162:4, 597-605
CrossRef156
Kanako Shimizu, Kana Shimomura, Yoshiaki Tokuyama, Kenzo Sakurai, Kenji Isahaya, Satoshi Takaishi, Bunta Kato, Noriko Usuki, Takahiro Shimizu, Koji Yamada, Yasuhiro Hasegawa. (2011) Association between Inflammatory Biomarkers and Progression of Intracranial Large Artery Stenosis after Ischemic Stroke. Journal of Stroke and Cerebrovascular Diseases
CrossRef157
Qing Zhao, Zhi-hong Liu, Zhi-hui Zhao, Qin Luo, R. Doug McEvoy, Hong-liang Zhang, Yong Wang. (2011) Effects of obstructive sleep apnea and its treatment on cardiovascular risk in CAD patients. Respiratory Medicine 105:10, 1557-1564
CrossRef158
Cecilia Grundtman, Georg Wick. (2011) The autoimmune concept of atherosclerosis. Current Opinion in Lipidology 22:5, 327-334
CrossRef159
Luca Mascitelli, Mark R. Goldstein. (2011) Statins, cholesterol depletion and risk of incident diabetes. International Journal of Cardiology 152:2, 275-276
CrossRef160
Ronen Gurfinkel, Tisha R. Joy. (2011) Anacetrapib: Hope for CETP Inhibitors?. Cardiovascular Therapeutics 29:5, 327-339
CrossRef161
Sandeep S. Mangalmurti, Michael H. Davidson. (2011) The Incremental Value of Lipids and Inflammatory Biomarkers in Determining Residual Cardiovascular Risk. Current Atherosclerosis Reports 13:5, 373-380
CrossRef162
Dimitris Tousoulis, Nikolaos Papageorgiou, George Latsios, Gerasimos Siasos, Charalambos Antoniades, Christodoulos Stefanadis. (2011) C-reactive protein and endothelial dysfunction: Gazing at the coronaries. International Journal of Cardiology 152:1, 1-3
CrossRef163
W. Koenig. (2011) Recent developments in cardiovascular risk assessment: relevance to the nephrologist. Nephrology Dialysis Transplantation 26:10, 3080-3083
CrossRef164
Luis Palomo, Galo Sánchez-Robles. (2011) La extrapolación del número de pacientes que es necesario tratar atenta contra la bioestadística y conduce a la inmortalidad. Atención Primaria
CrossRef165
Ki Hong Lee, Myung Ho Jeong, Ha Mi Kim, Youngkeun Ahn, Jong Hyun Kim, Shung Chull Chae, Young Jo Kim, Seung Ho Hur, In Whan Seong, Taek Jong Hong, Dong Hoon Choi, Myeong Chan Cho, Chong Jin Kim, Ki Bae Seung, Wook Sung Chung, Yang Soo Jang, Seung Woon Rha, Jang Ho Bae, Jeong Gwan Cho, Seung Jung Park. (2011) Benefit of Early Statin Therapy in Patients With Acute Myocardial Infarction Who Have Extremely Low Low-Density Lipoprotein Cholesterol. Journal of the American College of Cardiology 58:16, 1664-1671
CrossRef166
Benjamin I. Goldstein, Katelyn A. Collinger, Francis Lotrich, Anna L. Marsland, Mary-Kay Gill, David A. Axelson, Boris Birmaher. (2011) Preliminary Findings Regarding Proinflammatory Markers and Brain-Derived Neurotrophic Factor Among Adolescents with Bipolar Spectrum Disorders. Journal of Child and Adolescent Psychopharmacology 21:5, 479-484
CrossRef167
R. Molino-Lova, C. Macchi, A.M. Gori, R. Marcucci, P. Polcaro, F. Cecchi, F. Lauretani, S. Bandinelli, R. Abbate, E. Beghi, J.M. Guralnik, L. Ferrucci. (2011) High sensitivity C-reactive protein predicts the development of new carotid artery plaques in older persons. Nutrition, Metabolism and Cardiovascular Diseases 21:10, 776-782
CrossRef168
Ho Il Yoon, Don D. Sin. (2011) Biomarkers of Therapeutic Response in Patients with Chronic Obstructive Pulmonary Disease. Drugs 71:14, 1821-1837
CrossRef169
Ulf G. Bronas, Diane Treat-Jacobson. (2011) Peripheral Artery Disease in the Elderly: Prevalence, Clinical Implications, and Therapy. Current Cardiovascular Risk Reports 5:5, 457-466
CrossRef170
Ryo Yoshimoto, Yoshiko Fujita, Akemi Kakino, Shin Iwamoto, Tomohide Takaya, Tatsuya Sawamura. (2011) The Discovery of LOX-1, its Ligands and Clinical Significance. Cardiovascular Drugs and Therapy 25:5, 379-391
CrossRef171
F. Liu, H. Y. Chen, X. R. Huang, A. C. K. Chung, L. Zhou, P. Fu, A. J. Szalai, H. Y. Lan. (2011) C-reactive protein promotes diabetic kidney disease in a mouse model of type 1 diabetes. Diabetologia 54:10, 2713-2723
CrossRef172
Fernando Rodríguez-Artalejo, Auxiliadora Graciani, Pilar Guallar-Castillón, Luz M. León-Muñoz, M. Clemencia Zuluaga, Esther López-García, Juan Luis Gutiérrez-Fisac, José M. Taboada, M. Teresa Aguilera, Enrique Regidor, Fernando Villar-Álvarez, José R. Banegas. (2011) Rationale and Methods of the Study on Nutrition and Cardiovascular Risk in Spain (ENRICA). Revista Española de Cardiología (English Edition) 64:10, 876-882
CrossRef173
Fernando Rodríguez-Artalejo, Auxiliadora Graciani, Pilar Guallar-Castillón, Luz M. León-Muñoz, M. Clemencia Zuluaga, Esther López-García, Juan Luis Gutiérrez-Fisac, José M. Taboada, M. Teresa Aguilera, Enrique Regidor, Fernando Villar-Álvarez, José R. Banegas. (2011) Justificación y métodos del estudio sobre nutrición y riesgo cardiovascular en España (ENRICA). Revista Española de Cardiología 64:10, 876-882
CrossRef174
Diego Vanuzzo. (2011) The epidemiological concept of residual risk. Internal and Emergency Medicine 6:S1, 45-51
CrossRef175
Salim S. Virani, LeChauncy D. Woodard, Supicha S. Chitwood, Cassie R. Landrum, Tracy H. Urech, Degang Wang, Jeffrey Murawsky, Christie M. Ballantyne, Laura A. Petersen. (2011) Frequency and correlates of treatment intensification for elevated cholesterol levels in patients with cardiovascular disease. American Heart Journal 162:4, 725-732.e1
CrossRef176
John C. LaRosa. (2011) How Much Statin Intervention Is Enough?. Journal of the American College of Cardiology 58:16, 1672-1673
CrossRef177
Ryan P. Morrissey, George A. Diamond, Sanjay Kaul. (2011) The JUPITER Trial: Myth or Reality?. Current Atherosclerosis Reports 13:5, 413-421
CrossRef178
Seth Uretsky, Alan Rozanski, Azhar Supariwala, Gargi Thotakura, Sirisha Kanneganti, Niriksha Satyanarayana, Pranitha Mantrala, Supraja Reddy Yeturi, M. Robert Peters, Edward Fisher, Steven D. Wolff. (2011) Clinical outcomes following a strategy of optimized medical management and selective “downstream” procedures following coronary computed tomography angiography. International Journal of Cardiology
CrossRef179
Chamindie Punyadeera, Goce Dimeski, Karam Kostner, Peter Beyerlein, Justin Cooper-White. (2011) One-step homogeneous C-reactive protein assay for saliva. Journal of Immunological Methods 373:1-2, 19-25
CrossRef180
Karen E. Porter, Neil A. Turner. (2011) Statins and myocardial remodelling: cell and molecular pathways. Expert Reviews in Molecular Medicine 13,
CrossRef181
Harvey S. Hecht. (2011) The Role of Atherosclerosis Imaging in Redefining Normal and Abnormal Cholesterol Values, and Risk Reduction in Primary Prevention Statin Trials. Current Atherosclerosis Reports 13:5, 422-430
CrossRef182
Andre Pascal Kengne, Eugene Sobngwi, John Chalmers. (2011) Multiple risk factor interventions and inflammatory biomarkers in high risk individuals with type 2 diabetes. Diabetes Research and Clinical Practice
CrossRef183
Nikolaos Alexopoulos, Paolo Raggi. (2011) Biomarkers: Coronary artery calcium is a better risk marker than hsCRP. Nature Reviews Cardiology 8:11, 616-618
CrossRef184
Ruslan Medzhitov, Ethan M. Shevach, Giorgio Trinchieri, Andrew L. Mellor, David H. Munn, Siamon Gordon, Peter Libby, Göran K. Hansson, Ken Shortman, Chen Dong, Dmitry Gabrilovich, Leona Gabryšová, Ashleigh Howes, Anne O'Garra. (2011) Highlights of 10 years of immunology in Nature Reviews Immunology. Nature Reviews Immunology 11:10, 693-702
CrossRef185
E. Braunwald. (2011) Creating controversy where none exists: the important role of C-reactive protein in the CARE, AFCAPS/TexCAPS, PROVE IT, REVERSAL, A to Z, JUPITER, HEART PROTECTION, and ASCOT trials. European Heart Journal
CrossRef186
Markus P. Schneider, Bernhard M. Schmidt, Stefan John, Roland E. Schmieder. (2011) Effects of statin treatment on endothelial function, oxidative stress and inflammation in patients with arterial hypertension and normal cholesterol levels. Journal of Hypertension 29:9, 1757-1764
CrossRef187
Robert Kleemann, Lars Verschuren, Martine Morrison, Susanne Zadelaar, Marjan J. van Erk, Peter Y. Wielinga, Teake Kooistra. (2011) Anti-inflammatory, anti-proliferative and anti-atherosclerotic effects of quercetin in human in vitro and in vivo models. Atherosclerosis 218:1, 44-52
CrossRef188
Russell H. Samson, Deepak G. Nair. (2011) Influence and Critique of the JUPITER Trial (Statins v No Statins for Primary Prevention of Cardiovascular Events in Patients with Normal Lipids and Elevated C-Reactive Protein). Seminars in Vascular Surgery 24:3, 172-179
CrossRef189
D.O. McCall, C.P. McGartland, M.C. McKinley, P. Sharpe, D.R. McCance, I.S. Young, J.V. Woodside. (2011) The effect of increased dietary fruit and vegetable consumption on endothelial activation, inflammation and oxidative stress in hypertensive volunteers. Nutrition, Metabolism and Cardiovascular Diseases 21:9, 658-664
CrossRef190
Christie M. Ballantyne, Michael H. Davidson, Carolyn M. Setze, Maureen T. Kelly. (2011) Effects of combination therapy with rosuvastatin and fenofibric acid in patients with mixed dyslipidemia and high-sensitivity C-reactive protein (≥2 mg/L). Journal of Clinical Lipidology 5:5, 401-407
CrossRef191
Icilio Cavero. (2011) Promises and partnership: FDA's Critical Path Initiative and its intersection with pharmacology: an ASPET 2011 annual meeting symposium. Expert Opinion on Drug Safety 10:5, 827-837
CrossRef192
Michael H. Davidson, Christie M. Ballantyne, Terry A. Jacobson, Vera A. Bittner, Lynne T. Braun, Alan S. Brown, W.Virgil Brown, William C. Cromwell, Ronald B. Goldberg, James M. McKenney, Alan T. Remaley, Allan D. Sniderman, Peter P. Toth, Sotirios Tsimikas, Paul E. Ziajka, Kevin C. Maki, Mary R. Dicklin. (2011) Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel of lipid specialists. Journal of Clinical Lipidology 5:5, 338-367
CrossRef193
Josep Franch Nadal. (2011) Efectos hipoglucemiantes de las resinas de intercambio. Del secuestro de los ácidos biliares a la activación del metabolismo de la glucosa. Clínica e Investigación en Arteriosclerosis 23, 3-8
CrossRef194
Danai Khemasuwan, Young Kwang Chae, Shikha Gupta, Alejandra Carpio, Jeong Hyun Yun, Stefan Neagu, Anabella B. Lucca, Matias E. Valsecchi, Jorge I. Mora. (2011) Dose-related Effect of Statins in Venous Thrombosis Risk Reduction. The American Journal of Medicine 124:9, 852-859
CrossRef195
D. Sander, H. Poppert, K. Sander, T. Etgen. (2011) The role of intima-media-thickness, ankle-brachial-index and inflammatory biochemical parameters for stroke risk prediction: a systematic review. European Journal of Neurologyno-no
CrossRef196
D. K. Y. Chan, F. O’Rourke, Q. Shen, J. C. S. Mak, W. T. Hung. (2011) Meta-analysis of the cardiovascular benefits of intensive lipid lowering with statins. Acta Neurologica Scandinavica 124:3, 188-195
CrossRef197
Teresa Padró, Maisa García-Arguinzonis, Lina Badimon. (2011) Effects of rosuvastatin on the coordinated proteomic response of human coronary smooth muscle cells to low density lipoproteins. Clínica e Investigación en Arteriosclerosis 23:5, 191-200
CrossRef198
Klaus F Rabe, Jadwiga A Wedzicha. (2011) Controversies in treatment of chronic obstructive pulmonary disease. The Lancet 378:9795, 1038-1047
CrossRef199
Prashant D. Bhave, L. Elizabeth Goldman, Eric Vittinghoff, Judith H. Maselli, Andrew Auerbach. (2011) Statin use and postoperative atrial fibrillation after major noncardiac surgery. Heart Rhythm
CrossRef200
G.B. John Mancini, Steven Baker, Jean Bergeron, David Fitchett, Jiri Frohlich, Jacques Genest, Milan Gupta, Robert A. Hegele, Dominic Ng, Janet Pope. (2011) Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Proceedings of a Canadian Working Group Consensus Conference. Canadian Journal of Cardiology 27:5, 635-662
CrossRef201
Pitchai Balakumar, Sonam Kathuria, Gaurav Taneja, Sanjeev Kalra, Nanjaian Mahadevan. (2011) Is targeting eNOS a key mechanistic insight of cardiovascular defensive potentials of statins?. Journal of Molecular and Cellular Cardiology
CrossRef202
Woo Jung Park, Sang-Ho Jo, Sung-Ai Kim, Hyun-Sook Kim, Sang-Jin Han, Young Jin Choi, Chong-Yun Rhim. (2011) Rationale and design of STOP DVT study: Rosuvastatin for the prevention of deep vein thrombosis in patients undergoing total knee replacement arthroplasty — A prospective randomized open-label controlled trial. Contemporary Clinical Trials 32:5, 779-782
CrossRef203
Scott O. Grebe, Uwe Kuhlmann, Dominik Fogl, Valerie A. Luyckx, Thomas F. Mueller. (2011) Macrophage activation is associated with poorer long-term outcomes in renal transplant patients. Clinical Transplantation 25:5, 744-754
CrossRef204
Mayurkumar D Bhakta, Farouk Mookadam, Susan Wilansky. (2011) Cardiovascular disease in women. Future Cardiology 7:5, 613-627
CrossRef205
Abhimanyu Garg. (2011) What is the role of alternative biomarkers for coronary heart disease?. Clinical Endocrinology 75:3, 289-293
CrossRef206
Steven Snapinn, Qi Jiang. (2011) On the clinical meaningfulness of a treatment's effect on a time-to-event variable. Statistics in Medicine 30:19, 2341-2348
CrossRef207
Jiangqin Sun, Dingguo Liu, Zhimin Wang. 2011. Representative Chiral Drugs. , 401-448.
CrossRef208
Markolf Hanefeld, Ulrike Schatz, Frank Schaper. 2011. Treatments for the Metabolic Syndrome. , 327-346.
CrossRef209
Michael H. Davidson. (2011) Pharmacotherapy: Implications of high-dose statin link with incident diabetes. Nature Reviews Cardiology 8:10, 543-544
CrossRef210
Axel Schmermund, Thomas Voigtländer. (2011) Predictive ability of coronary artery calcium and CRP. The Lancet 378:9792, 641-643
CrossRef211
Caroline Drake, Hervé Boutin, Matthew S. Jones, Adam Denes, Barry W. McColl, Johann R. Selvarajah, Sharon Hulme, Rachel F. Georgiou, Rainer Hinz, Alexander Gerhard, Andy Vail, Christian Prenant, Peter Julyan, Renaud Maroy, Gavin Brown, Alison Smigova, Karl Herholz, Michael Kassiou, David Crossman, Sheila Francis, Spencer D. Proctor, James C. Russell, Stephen J. Hopkins, Pippa J. Tyrrell, Nancy J. Rothwell, Stuart M. Allan. (2011) Brain inflammation is induced by co-morbidities and risk factors for stroke. Brain, Behavior, and Immunity 25:6, 1113-1122
CrossRef212
Charles F. Jackson, Nanette K. Wenger. (2011) Enfermedad cardiovascular en el anciano. Revista Española de Cardiología 64:8, 697-712
CrossRef213
Ralph A. DeFronzo, Muhammad Abdul-Ghani. (2011) Assessment and Treatment of Cardiovascular Risk in Prediabetes: Impaired Glucose Tolerance and Impaired Fasting Glucose. The American Journal of Cardiology 108:3, 3B-24B
CrossRef214
Ilaria Spoletini, Cristiana Vitale, Giuseppe MC Rosano. (2011) Biomarkers for predicting postmenopausal coronary heart disease. Biomarkers in Medicine 5:4, 485-495
CrossRef215
Hourfil-Gabin Ntougou Assoumou, Jean Claude Barthelemy, Martin Garet, Virginie Dauphinot, Sébastien Celle, Vincent Pichot, Michel Kossovsky, Jean-Michel Gaspoz, Frédéric Roche. (2011) Increased Waist Circumference Is the Component of Metabolic Syndrome the Most Strongly Associated with Elevated C-Reactive Protein in Elderly. Metabolic Syndrome and Related Disorders 9:4, 281-285
CrossRef216
Domenico Scrutinio, Andrea Passantino, Francesca Di Serio, Domenico Angiletta, Daniela Santoro, Guido Regina. (2011) High-sensitivity C-reactive protein predicts cardiovascular events and myocardial damage after vascular surgery. Journal of Vascular Surgery 54:2, 474-479
CrossRef217
Murray Flaster, Sarkis Morales-Vidal, Michael J Schneck, José Biller. (2011) Statins in hemorrhagic stroke. Expert Review of Neurotherapeutics 11:8, 1141-1149
CrossRef218
Luis C.L. Correia, Anis Rassi. (2011) Is Reclassification of Intermediate-Risk Subjects by Coronary Artery Calcium Scoring Clinically Useful?. Journal of the American College of Cardiology 58:10, 1081
CrossRef219
Philip Joseph, Koon Teo. (2011) Optimal Medical Therapy, Lifestyle Intervention, and Secondary Prevention Strategies for Cardiovascular Event Reduction in Ischemic Heart Disease. Current Cardiology Reports 13:4, 287-295
CrossRef220
András Szabó. (2011) A D-vitamin-hiány csontrendszeri és csontrendszeren kívüli következményei. Orvosi Hetilap 152:33, 1312-1319
CrossRef221
Carlos D Malvestutto, Judith A Aberg. (2011) Management of dyslipidemia in HIV-infected patients. Clinical Lipidology 6:4, 447-462
CrossRef222
Francesca Perego, Elio Renesto, Massimo Arquati, Luciana Scandiani, Chiara Cogliati, Daniela Torzillo, Luca Zocchi, Giovanni Casazza, Piergiorgio Duca, Saverio Chirchiglia, Gemma Lacaita, Mauro Panteghini, Michele Cortellaro. (2011) Target organ damage in a population at intermediate cardiovascular risk, with adjunctive major risk factors: CArdiovascular PREvention Sacco Study (CAPRESS). Internal and Emergency Medicine 6:4, 337-347
CrossRef223
S. Yamamoto, Y. Zuo, J. Ma, P. G. Yancey, T. E. Hunley, M. Motojima, A. B. Fogo, M. F. Linton, S. Fazio, I. Ichikawa, V. Kon. (2011) Oral activated charcoal adsorbent (AST-120) ameliorates extent and instability of atherosclerosis accelerated by kidney disease in apolipoprotein E-deficient mice. Nephrology Dialysis Transplantation 26:8, 2491-2497
CrossRef224
Michael J Blaha, Matthew J Budoff, Andrew P DeFilippis, Ron Blankstein, Juan J Rivera, Arthur Agatston, Daniel H O'Leary, Joao Lima, Roger S Blumenthal, Khurram Nasir. (2011) Associations between C-reactive protein, coronary artery calcium, and cardiovascular events: implications for the JUPITER population from MESA, a population-based cohort study. The Lancet 378:9792, 684-692
CrossRef225
Elena M. Massarotti, Peter H. Schur. (2011) To What Extent Can Preventive Treatments Prevent Damage From Systemic Lupus Erythematosus?. Current Rheumatology Reports 13:4, 317-323
CrossRef226
Kristine H. Allin, Børge G. Nordestgaard. (2011) Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer. Critical Reviews in Clinical Laboratory Sciences 48:4, 155-170
CrossRef227
Jack Challem. (2011) Current Controversies in Nutrition: The Blind Leading the Blind: Common Problems with the Nature of Clinical Trials. Alternative and Complementary Therapies 17:5, 279-283
CrossRef228
Laurie L. Yee, Eric A. Wright. (2011) Pitavastatin Calcium: Clinical Review of a New Antihyperlipidemic Medication. Clinical Therapeutics 33:8, 1023-1042
CrossRef229
Terry A. Jacobson. (2011) Opening a New Lipid “Apo-thecary”: Incorporating Apolipoproteins as Potential Risk Factors and Treatment Targets to Reduce Cardiovascular Risk. Mayo Clinic Proceedings 86:8, 762-780
CrossRef230
Fabio Fabbian, Alfredo Giorgi, Marco Pala, Ruana Tiseo, Roberto Manfredini, Francesco Portaluppi. (2011) Evidence-based statin prescription for cardiovascular protection in renal impairment. Clinical and Experimental Nephrology 15:4, 456-463
CrossRef231
Bradley W. Blaser, Haesook T. Kim, Edwin P. Alyea, Vincent T. Ho, Corey Cutler, Philippe Armand, John Koreth, Joseph H. Antin, Jorge Plutzky, Robert J. Soiffer. (2011) Hyperlipidemia and Statin Use after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation
CrossRef232
Louise E. Full, Claudia Monaco. (2011) Targeting Inflammation as a Therapeutic Strategy in Accelerated Atherosclerosis in Rheumatoid Arthritis. Cardiovascular Therapeutics 29:4, 231-242
CrossRef233
Altan Onat. (2011) Metabolic syndrome: nature, therapeutic solutions and options. Expert Opinion on Pharmacotherapy 12:12, 1887-1900
CrossRef234
S. H. Stein, I. N. Dean, S. Y. Rawal, D. A. Tipton. (2011) Statins regulate interleukin-1β-induced RANKL and osteoprotegerin production by human gingival fibroblasts. Journal of Periodontal Research 46:4, 483-490
CrossRef235
Charles F. Jackson, Nanette K. Wenger. (2011) Cardiovascular Disease in the Elderly. Revista Española de Cardiología (English Edition) 64:8, 697-712
CrossRef236
Serena Tonstad, Jean-Pierre Després. (2011) Treatment of lipid disorders in obesity. Expert Review of Cardiovascular Therapy 9:8, 1069-1080
CrossRef237
Naveed Adoni, Ghassan Abusaid, Ken Fujise. 2011. Inflammation and Heart Diseases. .
CrossRef238
Seth S. Martin, Atif N. Qasim, Dan J. Rader, Muredach P. Reilly. (2011) C-Reactive Protein Modifies the Association of Plasma Leptin With Coronary Calcium in Asymptomatic Overweight Individuals. Obesity
CrossRef239
, , Z. Reiner, A. L. Catapano, G. De Backer, I. Graham, M.-R. Taskinen, O. Wiklund, S. Agewall, E. Alegria, M. J. Chapman, P. Durrington, S. Erdine, J. Halcox, R. Hobbs, J. Kjekshus, P. P. Filardi, G. Riccardi, R. F. Storey, D. Wood, , J. Bax, A. Vahanian, A. Auricchio, H. Baumgartner, C. Ceconi, V. Dean, C. Deaton, R. Fagard, G. Filippatos, C. Funck-Brentano, D. Hasdai, R. Hobbs, A. Hoes, P. Kearney, J. Knuuti, P. Kolh, T. McDonagh, C. Moulin, D. Poldermans, B. A. Popescu, Z. Reiner, U. Sechtem, P. A. Sirnes, M. Tendera, A. Torbicki, P. Vardas, P. Widimsky, S. Windecker, D. Reviewers:, C. Funck-Brentano, D. Poldermans, G. Berkenboom, J. De Graaf, O. Descamps, N. Gotcheva, K. Griffith, G. F. Guida, S. Gulec, Y. Henkin, K. Huber, Y. A. Kesaniemi, J. Lekakis, A. J. Manolis, P. Marques-Vidal, L. Masana, J. McMurray, M. Mendes, Z. Pagava, T. Pedersen, E. Prescott, Q. Rato, G. Rosano, S. Sans, A. Stalenhoef, L. Tokgozoglu, M. Viigimaa, M. E. Wittekoek, J. L. Zamorano. (2011) ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). European Heart Journal 32:14, 1769-1818
CrossRef240
Claudio Marelli, Candace Gunnarsson, Susan Ross, Sara Haas, Donna F. Stroup, Paul Cload, Paul Clopton, Anthony N. DeMaria. (2011) Statins and Risk of Cancer. Journal of the American College of Cardiology 58:5, 530-537
CrossRef241
R Teles, C-Y Wang. (2011) Mechanisms involved in the association between peridontal diseases and cardiovascular disease. Oral Diseases 17:5, 450-461
CrossRef242
Uchechukwu K Sampson, MacRae F Linton, Sergio Fazio. (2011) Are statins diabetogenic?. Current Opinion in Cardiology 26:4, 342-347
CrossRef243
Alain Li-Wan-Po, Bart Loeys, Peter Farndon, David Latham, Caroline Bradley. (2011) Preventing the aortic complications of Marfan syndrome: a case-example of translational genomic medicine. British Journal of Clinical Pharmacology 72:1, 6-17
CrossRef244
Mariano A Giorgi, Christian Caroli, Hernán Cohen Arazi, Guillermo Di Girolamo. (2011) Pharmacogenomics and adverse drug reactions: the case of statins. Expert Opinion on Pharmacotherapy 12:10, 1499-1509
CrossRef245
Toshiro Kitagawa, Hideya Yamamoto, Jun Horiguchi, Norihiko Ohashi, Eiji Kunita, Hiroto Utsunomiya, Yasuki Kihara. (2011) Effects of statin therapy on non-calcified coronary plaque assessed by 64-slice computed tomography. International Journal of Cardiology 150:2, 146-150
CrossRef246
Jonathan W Waks, Benjamin M Scirica. (2011) Established and novel biomarkers in ST-elevation myocardial infarction. Future Cardiology 7:4, 523-546
CrossRef247
Xuguang Li, Guangtian Yang, Gang Zhao, Bin Wu, Matthew L Edin, Darryl C Zeldin, Dao Wen Wang. (2011) Rosuvastatin attenuates the elevation in blood pressure induced by overexpression of human C-reactive protein. Hypertension Research 34:7, 869-875
CrossRef248
Paloma Muñoz-Pacheco, Adriana Ortega-Hernández, Arturo Fernández-Cruz, Dulcenombre Gómez-Garre. (2011) Ezetimibe inhibe la adhesión y la migración de monocitos a través de la ruta de las proteincinasas activadas extracelularmente (p44/p42ERK1/2. Clínica e Investigación en Arteriosclerosis 23:4, 160-167
CrossRef249
S. Agewall. (2011) The large clinical statin trials. International Journal of Cardiology 150:1, 108-111
CrossRef250
Michelle A. Albert, Robert J. Glynn, Francisco A.H. Fonseca, Alberto J. Lorenzatti, Keith C. Ferdinand, Jean G. MacFadyen, Paul M Ridker. (2011) Race, ethnicity, and the efficacy of rosuvastatin in primary prevention: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. American Heart Journal 162:1, 106-114.e2
CrossRef251
Junya Aoki, Ken Uchino. (2011) Treatment of Risk Factors to Prevent Stroke. Neurotherapeutics 8:3, 463-474
CrossRef252
Melinda B Davis, Claire S Duvernoy. (2011) How to stay heart healthy in 2011: considerations for the primary prevention of cardiovascular disease in women. Women's Health 7:4, 433-451
CrossRef253
Wilbert S. Aronow, Jerome L. Fleg, Carl J. Pepine, Nancy T. Artinian, George Bakris, Alan S. Brown, Keith C. Ferdinand, Mary Ann Forciea, William H. Frishman, Cheryl Jaigobin, John B. Kostis, Giuseppi Mancia, Suzanne Oparil, Eduardo Ortiz, Efrain Reisin, Michael W. Rich, Douglas D. Schocken, Michael A. Weber, Deborah J. Wesley, Robert A. Harrington, Eric R. Bates, Deepak L. Bhatt, Charles R. Bridges, Mark J. Eisenberg, Victor A. Ferrari, John D. Fisher, Timothy J. Gardner, Federico Gentile, Michael F. Gilson, Mark A. Hlatky, Alice K. Jacobs, Sanjay Kaul, David J. Moliterno, Debabrata Mukherjee, Robert S. Rosenson, James H. Stein, Howard H. Weitz, Deborah J. Wesley. (2011) ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly. Journal of the American Society of Hypertension 5:4, 259-352
CrossRef254
I. Ramasamy. (2011) Biochemical markers in acute coronary syndrome. Clinica Chimica Acta 412:15-16, 1279-1296
CrossRef255
Ahmed A. Khattab, Gjin Ndrepepa, Stefanie Schulz, Franz-Josef Neumann, Julinda Mehilli, Heinz Joachim Büttner, Jürgen Pache, Melchior Seyfarth, Josef Dirschinger, Adnan Kastrati, Peter B. Berger, Albert Schömig, Gert Richardt. (2011) Statin effect on thrombin inhibitor effectiveness during percutaneous coronary intervention: a post-hoc analysis from the ISAR-REACT 3 trial. Clinical Research in Cardiology 100:7, 579-585
CrossRef256
Alberico L. Catapano, Željko Reiner, Guy De Backer, Ian Graham, Marja-Riitta Taskinen, Olov Wiklund, Stefan Agewall, Eduardo Alegria, M. John Chapman, Paul Durrington, Serap Erdine, Julian Halcox, Richard Hobbs, John Kjekshus, Pasquale Perrone Filardi, Gabriele Riccardi, Robert F. Storey, David Wood. (2011) ESC/EAS Guidelines for the management of dyslipidaemias. Atherosclerosis 217:1, 3-46
CrossRef257
Alberico L. Catapano, Željko Reiner, Guy De Backer, Ian Graham, Marja-Riitta Taskinen, Olov Wiklund, Stefan Agewall, Eduardo Alegria, M. John Chapman, Paul Durrington, Serap Erdine, Julian Halcox, Richard Hobbs, John Kjekshus, Pasquale Perrone Filardi, Gabriele Riccardi, Robert F. Storey, David Wood. (2011) ESC/EAS Guidelines for the management of dyslipidaemias. Atherosclerosis 217, 1-44
CrossRef258
Jonathan Bullman, Andrew Nicholls, Kevan Van Landingham, Richard Fleck, Alain Vuong, James Miller, Sarah Alexander, John Messenheimer. (2011) Effects of lamotrigine and phenytoin on the pharmacokinetics of atorvastatin in healthy volunteers. Epilepsia 52:7, 1351-1358
CrossRef259
Kerstin Wustmann, Marco Klaey, Annika Burow, Sidney G. Shaw, Otto M. Hess, Yves Allemann. (2011) Additive Effect of Homocysteine- and Cholesterol-Lowering Therapy on Endothelium-Dependent Vasodilation in Patients with Cardiovascular Disease. Cardiovascular Therapeuticsno-no
CrossRef260
J. A. Hanley. (2011) Measuring Mortality Reductions in Cancer Screening Trials. Epidemiologic Reviews 33:1, 36-45
CrossRef261
K.-C. Sung, E.-J. Rhee, H. Kim, J.-B. Park, Y.-K. Kim, R.S. Rosenson. (2011) Prevalence of low LDL-cholesterol levels and elevated high-sensitivity C-reactive protein levels in apparently healthy Korean adults. Nutrition, Metabolism and Cardiovascular Diseases
CrossRef262
De-xiu Bu, Gabriel Griffin, Andrew H Lichtman. (2011) Mechanisms for the anti-inflammatory effects of statins. Current Opinion in Lipidology 22:3, 165-170
CrossRef263
Therese M Heinonen, Donald M Black. (2011) New considerations in the design of clinical trials for anti-atherosclerotic drugs. Clinical Investigation 1:6, 795-803
CrossRef264
Paul M Ridker, Wolfgang Koenig, John JP Kastelein. (2011) C-reactive protein in the Heart Protection Study. The Lancet 377:9781, 1918
CrossRef265
R A Wilke. (2011) High-density lipoprotein (HDL) cholesterol: leveraging practice-based biobank cohorts to characterize clinical and genetic predictors of treatment outcome. The Pharmacogenomics Journal 11:3, 162-173
CrossRef266
Per Lytsy, Gunilla Burell, Ragnar Westerling. (2011) How do prescribing doctors anticipate the effect of statins?. Journal of Evaluation in Clinical Practice 17:3, 420-428
CrossRef267
Bernhard Föger. (2011) Lipid lowering therapy in type 2 diabetes. Wiener Medizinische Wochenschrift 161:11-12, 289-296
CrossRef268
Danilo Fliser, Andrzej Wiecek, Gultekin Suleymanlar, Alberto Ortiz, Ziad Massy, Bengt Lindholm, Alberto Martinez-Castelao, Rajiv Agarwal, Kitty J Jager, Friedo W Dekker, Peter J Blankestijn, David Goldsmith, Adrian Covic, Gerard London, Carmine Zoccali. (2011) The dysfunctional endothelium in CKD and in cardiovascular disease: mapping the origin(s) of cardiovascular problems in CKD and of kidney disease in cardiovascular conditions for a research agenda. Kidney International Supplements 1:1, 6-9
CrossRef269
Tommaso Gori, Thomas Münzel. (2011) Oxidative stress and endothelial dysfunction: Therapeutic implications. Annals of Medicine 43:4, 259-272
CrossRef270
P. Anagnostis, D. Selalmatzidou, S. A. Polyzos, A. Panagiotou, A. Slavakis, A. Panagiotidou, V. G. Athyros, A. Karagiannis, D. P. Mikhailidis, M. Kita. (2011) Comparative effects of rosuvastatin and atorvastatin on glucose metabolism and adipokine levels in non-diabetic patients with dyslipidaemia: a prospective randomised open-label study. International Journal of Clinical Practice 65:6, 679-683
CrossRef271
Robert S. Rosenson. (2011) Systemic Inflammation and the Dynamics of HDL Cholesterol–Associated Residual Cardiovascular Risk. Current Atherosclerosis Reports 13:3, 187-189
CrossRef272
R. S. Minocher Homji, S. Lakhoo, J. G. Ray. (2011) Recruitment of immigrant and ethnic minorities in primary prevention trials of cardiovascular disease. QJM 104:6, 469-476
CrossRef273
A. P. Agouridis, V. Tsimihodimos, T. D. Filippatos, A. D. Tselepis, M. S. Elisaf. (2011) High Doses of Rosuvastatin are Superior to Low Doses of Rosuvastatin Plus Fenofibrate or n-3 Fatty Acids in Mixed Dyslipidemia. Lipids 46:6, 521-528
CrossRef274
Mirella Coppo, Manuela Bandinelli, Andrea Berni, Sara Galastri, Rosanna Abbate, Loredana Poggesi, Fabio Marra, Gian Franco Gensini, Maria Boddi. (2011) Ang II Upregulation of the T-Lymphocyte Renin–Angiotensin System Is Amplified by Low-Grade Inflammation in Human Hypertension. American Journal of Hypertension 24:6, 716-723
CrossRef275
D. Schmidt, A. Kwetkat, M. Gogol. (2011) Chronische Inflammation und Biomarker. Zeitschrift für Gerontologie und Geriatrie 44:3, 153-157
CrossRef276
Antonio Ruiz García, Francisco Javier Gordillo López, Ezequiel Arranz Martínez, Juan Carlos Hermosa Hernán. (2011) Optimización fármaco-económica del tratamiento de la hipercolesterolemia con estatinas. Medicina Clínica 137:3, 119-125
CrossRef277
Harold E. Bays. (2011) Adiposopathy. Journal of the American College of Cardiology 57:25, 2461-2473
CrossRef278
Chi Chiu Mok, Chun Kwok Wong, Chi Hung To, Judy Po Shan Lai, Cheuk Sum Lam. (2011) Effects of rosuvastatin on vascular biomarkers and carotid atherosclerosis in lupus: A randomized, double-blind, placebo-controlled trial. Arthritis Care & Research 63:6, 875-883
CrossRef279
Tarek AN Ahmed, Ioannis Karalis, J Wouter Jukema. (2011) Emerging drugs for coronary artery disease. From past achievements and current needs to clinical promises. Expert Opinion on Emerging Drugs 16:2, 203-233
CrossRef280
Karen R. Sando, Jose Barboza, Crystal Willis, James Taylor. (2011) Recent Diabetes Issues Affecting the Primary Care Clinician. Southern Medical Journal 104:6, 456-461
CrossRef281
João L. Cavalcante, Balajii Tamarappoo, Rory Hachamovitch. (2011) Assessing Risk and Predicting Outcomes in Coronary Artery Disease: Physiology, Anatomy, or Biology?. Current Cardiovascular Imaging Reports 4:3, 180-189
CrossRef282
R. Krysiak, B. Okopien. (2011) Haemostatic effects of simvastatin in subjects with impaired glucose tolerance. Internal Medicine Journal 41:6, 473-481
CrossRef283
Mikkel Malby Schoos, Henning Kelbæk, Klaus F. Kofoed, Lars Køber, Lene Kløvgaard, Steffen Helqvist, Thomas Engstrøm, Kari Saunamäki, Erik Jørgensen, Lene Holmvang, Peter Clemmensen. (2011) Usefulness of Preprocedure High-Sensitivity C-Reactive Protein to Predict Death, Recurrent Myocardial Infarction, and Stent Thrombosis According to Stent Type in Patients With ST-Segment Elevation Myocardial Infarction Randomized to Bare Metal or Drug-Eluting Stenting During Primary Percutaneous Coronary Intervention. The American Journal of Cardiology 107:11, 1597-1603
CrossRef284
Jean-Pierre Déry. (2011) Controlling lipids after acute coronary syndromes: what is the best strategy?. Clinical Lipidology 6:3, 253-255
CrossRef285
Giovanni Battista Vigna, Giovanni Zuliani, Renato Fellin. (2011) Dyslipidemias in the older subject: features, significance and treatment dilemmas. Clinical Lipidology 6:3, 339-350
CrossRef286
Elvin Tyrone Price, Michael A. Pacanowski, Michael A. Martin, Rhonda M. Cooper-DeHoff, Carl J. Pepine, Issam Zineh, Julie A. Johnson. (2011) Liver X receptor α gene polymorphisms and variable cardiovascular outcomes in patients treated with antihypertensive therapy. Pharmacogenetics and Genomics 21:6, 333-340
CrossRef287
Russell Heath, T. Brett Reece, Simon Shakar, JoAnn Lindenfeld. (2011) Post-pericardial injury syndrome after continuous-flow ventricular assistance. The Journal of Heart and Lung Transplantation 30:6, 726-729
CrossRef288
Kwan Leung Chan, Jean G. Dumesnil, James Tam, Andy Ni, Koon Teo. (2011) Effect of rosuvastatin on C-reactive protein and progression of aortic stenosis. American Heart Journal 161:6, 1133-1139
CrossRef289
Gen-Min Lin, Yi-Hwei Li, Kai-Min Chu, Chih-Lu Han. (2011) What else does the JUPITER trial add regarding C-reactive protein and cardiovascular disease?. International Journal of Cardiology 149:3, 387
CrossRef290
Donald G. Vidt, Paul M. Ridker, John T. Monyak, Martin J. Schreiber, Michael D. Cressman. (2011) Longitudinal Assessment of Estimated Glomerular Filtration Rate in Apparently Healthy Adults: A Post hoc Analysis from the JUPITER Study (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin). Clinical Therapeutics 33:6, 717-725
CrossRef291
Stephen J. Nicholls, Marilyn Borgman, Steven E. Nissen, Joel S. Raichlen, Christie Ballantyne, Philip Barter, M. John Chapman, Raimund Erbel, Peter Libby. (2011) Impact of statins on progression of atherosclerosis: rationale and design of SATURN (Study of Coronary Atheroma by InTravascular Ultrasound: Effect of Rosuvastatin versus AtorvastatiN). Current Medical Research and Opinion 27:6, 1119-1129
CrossRef292
Gissette Reyes-Soffer, Carlos Rondon-Clavo, Henry N Ginsberg. (2011) Combination therapy with statin and fibrate in patients with dyslipidemia associated with insulin resistance, metabolic syndrome and type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy 12:9, 1429-1438
CrossRef293
George S. Abela, Ameeth Vedre, Abed Janoudi, Ruiping Huang, Sridevi Durga, Umesh Tamhane. (2011) Effect of Statins on Cholesterol Crystallization and Atherosclerotic Plaque Stabilization. The American Journal of Cardiology 107:12, 1710-1717
CrossRef294
Yu-gang YIN, Bin WANG. (2011) Effects of rosuvastatin on instent restenosis, plasma lipid level and inflammatory factors after coronary stenting. Academic Journal of Second Military Medical University 31:2, 227-228
CrossRef295
Vera Krane, Christoph Wanner. (2011) Statins, inflammation and kidney disease. Nature Reviews Nephrology 7:7, 385-397
CrossRef296
Cristiano Fava, Martina Montagnana, Gian Cesare Guidi, Olle Melander. (2011) From circulating biomarkers to genomics and imaging in the prediction of cardiovascular events in the general population. Annals of Medicine1-15
CrossRef297
Peter Libby, Paul M Ridker, Göran K. Hansson. (2011) Progress and challenges in translating the biology of atherosclerosis. Nature 473:7347, 317-325
CrossRef298
Vasilios G. Athyros, Konstantinos Tziomalos, Georgios N. Daskalopoulos, Asterios Karagiannis, Dimitri P. Mikhailidis. (2011) Statin-based treatment for cardiovascular risk and non-alcoholic fatty liver disease. Killing two birds with one stone?. Annals of Medicine 43:3, 167-171
CrossRef299
Gregory G. Schwartz, Bernard R. Chaitman, Jeffrey J. Goldberger, Michael Messig. (2011) High-dose atorvastatin and risk of atrial fibrillation in patients with prior stroke or transient ischemic attack: Analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. American Heart Journal 161:5, 993-999
CrossRef300
Richard Safeer, Meg M. Rothenstein. (2011) Creating a Physically Active Society: The Next Great Challenge. American Journal of Health Promotion 25:5, 291-293
CrossRef301
Thura T Abd, Terry A Jacobson. (2011) Statin-induced myopathy: a review and update. Expert Opinion on Drug Safety 10:3, 373-387
CrossRef302
Mark D. Huffman, Deepak Bhatnagar. (2011) Novel Treatments for Cardiovascular Disease Prevention. Cardiovascular Therapeuticsno-no
CrossRef303
Vincent E. Friedewald, Christie M. Ballantyne, Michael H. Davidson, Antonio M. Gotto, Paul M. Ridker, William C. Roberts. (2011) The Editor's Roundtable: JUPITER Follow-Up. The American Journal of Cardiology 107:10, 1549-1557
CrossRef304
Israel F. Charo, Rebecca Taub. (2011) Anti-inflammatory therapeutics for the treatment of atherosclerosis. Nature Reviews Drug Discovery 10:5, 365-376
CrossRef305
Raul D. Santos, Alberto J. Lorenzatti, Carlos Fernandez Barros, Edgardo Escobar. (2011) Clinical perspective: Have the results of recent clinical trials of lipid-lowering therapies influenced the way we should practice? A Latin American perspective of current issues in clinical lipidology. Journal of Clinical Lipidology 5:3, 124-132
CrossRef306
Syed M. Mohiuddin, Kamlesh M. Thakker, Carolyn M. Setze, Maureen T. Kelly. (2011) Evaluating optimal lipid levels in patients with mixed dyslipidemia following short- and long-term treatment with fenofibric acid and statin combination therapy: a post hoc analysis. Current Medical Research and Opinion 27:5, 1067-1078
CrossRef307
Elisabeth Aslangul, Soraya Fellahi, Lambert K Assoumou, Jean-Philippe Bastard, Jacqueline Capeau, Dominique Costagliola. (2011) High-sensitivity C-reactive protein levels fall during statin therapy in HIV-infected patients receiving ritonavir-boosted protease inhibitors. AIDS 25:8, 1128-1131
CrossRef308
Christie M. Bartels, Amy J. H. Kind, Christine Everett, Matthew Mell, Patrick McBride, Maureen Smith. (2011) Low frequency of primary lipid screening among Medicare patients with rheumatoid arthritis. Arthritis & Rheumatism 63:5, 1221-1230
CrossRef309
Semon Wu, Lung-An Hsu, Ching-Feng Cheng, Ming-Sheng Teng, Hsin-Hua Chou, Heng Lin, Pi-Yueh Chang, Yu-Lin Ko. (2011) Effect of obesity on the association between ATF3 gene haplotypes and C-reactive protein level in Taiwanese. Clinica Chimica Acta 412:11-12, 1026-1031
CrossRef310
C M Khoo, M Tan, Y Wu, C H Wai, T Subramaniam, J Lee, E S Tai. (2011) Central obesity and smoking are key modifiable risk factors for elevated C-reactive protein in Asian individuals who are not eligible for statin therapy. Nutrition and Diabetes 1:5, e8
CrossRef311
Flavio Ribichini, Fabrizio Tomai, Giuseppe De Luca, Giacomo Boccuzzi, Patrizia Presbitero, Gabriele Pesarini, Valeria Ferrero, Anna S. Ghini, Ramadan Abukaresh, Cristina Aurigemma, Leonardo De Luca, Dennis Zavalloni, Daniela Soregaroli, Paolo Marino, Roberto Garbo, Luisa Zanolla, Corrado Vassanelli. (2011) Immunosuppressive Therapy with Oral Prednisone to Prevent Restenosis after PCI. A Multicenter Randomized Trial. The American Journal of Medicine 124:5, 434-443
CrossRef312
Wilbert S. Aronow, Jerome L. Fleg, Carl J. Pepine, Nancy T. Artinian, George Bakris, Alan S. Brown, Keith C. Ferdinand, Mary Ann Forciea, William H. Frishman, Cheryl Jaigobin, John B. Kostis, Giuseppi Mancia, Suzanne Oparil, Eduardo Ortiz, Efrain Reisin, Michael W. Rich, Douglas D. Schocken, Michael A. Weber, Deborah J. Wesley. (2011) ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly. Journal of the American College of Cardiology 57:20, 2037-2114
CrossRef313
Maren S. Mayhew. (2011) Statins for Cardiovascular Disease Prevention. The Journal for Nurse Practitioners 7:5, 419-420
CrossRef314
Samir B. Damani, Eric J. Topol. (2011) Emerging Genomic Applications in Coronary Artery Disease. JACC: Cardiovascular Interventions 4:5, 473-482
CrossRef315
Piyush Jain, Jaspal S. Kooner, Usha Raval, Avijit Lahiri. (2011) Prevalence of coronary artery calcium scores and silent myocardial ischaemia was similar in Indian Asians and European whites in a cross-sectional study of asymptomatic subjects from a UK population (LOLIPOP-IPC). Journal of Nuclear Cardiology 18:3, 435-442
CrossRef316
J. V. Baker, J. D. Lundgren. (2011) Cardiovascular implications from untreated human immunodeficiency virus infection. European Heart Journal 32:8, 945-951
CrossRef317
Judith Hsia, Jean G. MacFadyen, John Monyak, Paul M. Ridker. (2011) Cardiovascular Event Reduction and Adverse Events Among Subjects Attaining Low-Density Lipoprotein Cholesterol <50 mg/dl With Rosuvastatin. Journal of the American College of Cardiology 57:16, 1666-1675
CrossRef318
Charlotte E. Bolton, Wiebke Schumacher, John R. Cockcroft, Nicholas J. Timpson, George Davey Smith, John Gallacher, Anne Rumley, Gordon D. Lowe, Shah Ebrahim, Dennis J. Shale, Yoav Ben
Shlomo. (2011) The CRP genotype, serum levels and lung function in men: the Caerphilly Prospective Study. Clinical Science 120:8, 347-355
CrossRef319
Vimal Ramjee, Terry A Jacobson. (2011) Intensifying statin therapy to maximize cardiovascular risk reduction: is 50 the new 70? Goals are getting old. Clinical Lipidology 6:2, 131-136
CrossRef320
Robert Krysiak, Anna Gdula-Dymek, Bogusław Okopien. (2011) Effect of Simvastatin and Fenofibrate on Cytokine Release and Systemic Inflammation in Type 2 Diabetes Mellitus With Mixed Dyslipidemia. The American Journal of Cardiology 107:7, 1010-1018.e1
CrossRef321
Andrea Feher, Gabriella Pusch, Katalin Koltai, Antal Tibold, Beata Gasztonyi, Laszlo Szapary, Gergely Feher. (2011) Statintherapy in the primary and the secondary prevention of ischaemic cerebrovascular diseases. International Journal of Cardiology 148:2, 131-138
CrossRef322
Robert Krysiak, Boguslaw Okopien. (2011) The Effect of Ezetimibe and Simvastatin on Monocyte Cytokine Release in Patients With Isolated Hypercholesterolemia. Journal of Cardiovascular Pharmacology 57:4, 505-512
CrossRef323
Thura T. Abd, Danny J. Eapen, Ambareesh Bajpai, Abhinav Goyal, Allen Dollar, Laurence Sperling. (2011) The Role of C-Reactive Protein as a Risk Predictor of Coronary Atherosclerosis: Implications from the JUPITER Trial. Current Atherosclerosis Reports 13:2, 154-161
CrossRef324
Subinay Datta, Zahidul Iqbal, K. R. Prasad. (2011) Comparison Between Serum hsCRP and LDL Cholesterol for Search of a Better Predictor for Ischemic Heart Disease. Indian Journal of Clinical Biochemistry 26:2, 210-213
CrossRef325
Jean-Louis Vincent, Katia Donadello, Xavier Schmit. (2011) Biomarkers in the Critically Ill Patient: C-reactive Protein. Critical Care Clinics 27:2, 241-251
CrossRef326
Alan J. Garber. (2011) Hypertension and Lipid Management in Prediabetic States. The Journal of Clinical Hypertension 13:4, 270-274
CrossRef327
C. Hernández, G. Francisco, A. Ciudin, P. Chacón, B. Montoro, G. Llaverias, F. Blanco-Vaca, R. Simó. (2011) Effect of atorvastatin on lipoprotein (a) and interleukin-10: A randomized placebo-controlled trial. Diabetes & Metabolism 37:2, 124-130
CrossRef328
Maria Hughes, Frank Kee, Veikko Salomaa. (2011) Clinical Utility of Multiple Biomarker Panels for Cardiovascular Disease Risk Prediction. Current Cardiovascular Risk Reports 5:2, 165-173
CrossRef329
Nour-Eddine Rhaleb, Xiao-Ping Yang, Oscar A. Carretero. 2011. The Kallikrein-Kinin System as a Regulator of Cardiovascular and Renal Function. .
CrossRef330
Tanja B. Grammer, Michael M. Hoffmann, Wilfried Renner, Marcus E. Kleber, Bernhard R. Winkelmann, Bernhard O. Böhm, Winfried März. (2011) Apolipoprotein E genotypes, circulating C-reactive protein and angiographic coronary artery disease: The Ludwigshafen Risk and Cardiovascular Health Study. Atherosclerosis 215:2, 487-493
CrossRef331
Amanda N. Long, Samuel Dagogo-Jack. (2011) Comorbidities of Diabetes and Hypertension: Mechanisms and Approach to Target Organ Protection. The Journal of Clinical Hypertension 13:4, 244-251
CrossRef332
Benoit J. Arsenault, S. Matthijs Boekholdt, John J. P. Kastelein. (2011) Lipid parameters for measuring risk of cardiovascular disease. Nature Reviews Cardiology 8:4, 197-206
CrossRef333
D. S. H. Bell, F. Al Badarin, J. H. O’Keefe. (2011) Therapies for diabetic dyslipidaemia. Diabetes, Obesity and Metabolism 13:4, 313-325
CrossRef334
Altan Onat, Gülay Hergenç. (2011) Low-grade inflammation, and dysfunction of high-density lipoprotein and its apolipoproteins as a major driver of cardiometabolic risk. Metabolism 60:4, 499-512
CrossRef335
Henry R. Kramer, Jon T. Giles. (2011) Cardiovascular disease risk in rheumatoid arthritis: Progress, debate, and opportunity. Arthritis Care & Research 63:4, 484-499
CrossRef336
Deepika S. Reddy, Vivian Fonseca. 2011. Screening Patients with Prediabetes and Diabetes for Cardiovascular Disease. , 34-40.
CrossRef337
A. Ganesan, N. Crum-Cianflone, J. Higgins, J. Qin, C. Rehm, J. Metcalf, C. Brandt, J. Vita, C. F. Decker, P. Sklar, M. Bavaro, S. Tasker, D. Follmann, F. Maldarelli. (2011) High Dose Atorvastatin Decreases Cellular Markers of Immune Activation Without Affecting HIV-1 RNA Levels: Results of a Double-blind Randomized Placebo Controlled Clinical Trial. Journal of Infectious Diseases 203:6, 756-764
CrossRef338
D. A. Fryburg, M. T. Vassileva. (2011) Atherosclerosis Drug Development in Jeopardy: The Need for Predictive Biomarkers of Treatment Response. Science Translational Medicine 3:72, 72cm6-72cm6
CrossRef339
Kwang Kon Koh, Ichiro Sakuma, Michael J. Quon. (2011) Differential metabolic effects of distinct statins. Atherosclerosis 215:1, 1-8
CrossRef340
James A. Stone. (2011) Framing Cardiovascular Disease Event Risk Prediction. Canadian Journal of Cardiology 27:2, 171-173
CrossRef341
Lionel S. Lim, Nowreen Haq, Shamail Mahmood, Laura Hoeksema. (2011) Atherosclerotic Cardiovascular Disease Screening in Adults. American Journal of Preventive Medicine 40:3, 381.e1-381.e10
CrossRef342
Lawrence A. Leiter, David H. Fitchett, Richard E. Gilbert, Milan Gupta, G.B. John Mancini, Philip A. McFarlane, Robert Ross, Hwee Teoh, Subodh Verma, Sonia Anand, Kathryn Camelon, Chi-Ming Chow, Jafna L. Cox, Jean-Pierre Després, Jacques Genest, Stewart B. Harris, David C.W. Lau, Richard Lewanczuk, Peter P. Liu, Eva M. Lonn, Ruth McPherson, Paul Poirier, Shafiq Qaadri, Rémi Rabasa-Lhoret, Simon W. Rabkin, Arya M. Sharma, Andrew W. Steele, James A. Stone, Jean-Claude Tardif, Sheldon Tobe, Ehud Ur. (2011) Cardiometabolic Risk in Canada: A Detailed Analysis and Position Paper by the Cardiometabolic Risk Working Group. Canadian Journal of Cardiology 27:2, e1-e33
CrossRef343
Bertrand Cariou. (2011) Que choisir en association aux statines chez les patients à haut risque cardiovasculaire : la niacine ou l’ezetimibe ?. Médecine des Maladies Métaboliques 5:1, H7-H8
CrossRef344
M. Endres, P. U. Heuschmann, U. Laufs, A. M. Hakim. (2011) Primary prevention of stroke: blood pressure, lipids, and heart failure. European Heart Journal 32:5, 545-552
CrossRef345
Christian W. Hamm, Holger M. Nef, Andreas Rolf, Helge Möllmann. (2011) Calcium and C-Reactive Protein. Journal of the American College of Cardiology 57:13, 1465-1467
CrossRef346
Lori Mosca, Emelia J. Benjamin, Kathy Berra, Judy L. Bezanson, Rowena J. Dolor, Donald M. Lloyd-Jones, L. Kristin Newby, Ileana L. Piña, Véronique L. Roger, Leslee J. Shaw, Dong Zhao, Theresa M. Beckie, Cheryl Bushnell, Jeanine D'Armiento, Penny M. Kris-Etherton, Jing Fang, Theodore G. Ganiats, Antoinette S. Gomes, Clarisa R. Gracia, Constance K. Haan, Elizabeth A. Jackson, Debra R. Judelson, Ellie Kelepouris, Carl J. Lavie, Anne Moore, Nancy A. Nussmeier, Elizabeth Ofili, Suzanne Oparil, Pamela Ouyang, Vivian W. Pinn, Katherine Sherif, Sidney C. Smith, George Sopko, Nisha Chandra-Strobos, Elaine M. Urbina, Viola Vaccarino, Nanette K. Wenger. (2011) Effectiveness-Based Guidelines for the Prevention of Cardiovascular Disease in Women—2011 Update. Journal of the American College of Cardiology 57:12, 1404-1423
CrossRef347
Idan Roifman, Paul L. Beck, Todd J. Anderson, Mark J. Eisenberg, Jacques Genest. (2011) Chronic Inflammatory Diseases and Cardiovascular Risk: A Systematic Review. Canadian Journal of Cardiology 27:2, 174-182
CrossRef348
Stefan Möhlenkamp, Nils Lehmann, Susanne Moebus, Axel Schmermund, Nico Dragano, Andreas Stang, Johannes Siegrist, Klaus Mann, Karl-Heinz Jöckel, Raimund Erbel. (2011) Quantification of Coronary Atherosclerosis and Inflammation to Predict Coronary Events and All-Cause Mortality. Journal of the American College of Cardiology 57:13, 1455-1464
CrossRef349
Eswar Krishnan, Jeremy Sokolove. (2011) Uric acid in heart disease: a new C-reactive protein?. Current Opinion in Rheumatology 23:2, 174-177
CrossRef350
Yue Wu, Weiping Zhang, Weimin Liu, Xiaozhen Zhuo, Zhao Zhao, Zuyi Yuan. (2011) The double-faced metabolic and inflammatory effects of standard drug therapy in patients after percutaneous treatment with drug-eluting stent. Atherosclerosis 215:1, 170-175
CrossRef351
Hans J. Avis, Ian P. Hargreaves, Jos P.N. Ruiter, John M. Land, Ronald J. Wanders, Frits A. Wijburg. (2011) Rosuvastatin Lowers Coenzyme Q10 Levels, but not Mitochondrial Adenosine Triphosphate Synthesis, in Children with Familial Hypercholesterolemia. The Journal of Pediatrics 158:3, 458-462
CrossRef352
Ariel Brautbar, Christie M. Ballantyne. (2011) Pharmacological strategies for lowering LDL cholesterol: statins and beyond. Nature Reviews Cardiology
CrossRef353
Minghan Wang. 2011. Current Antidiabetic Therapies and Mechanisms. , 253-278.
CrossRef354
Mark Hlatky. (2011) The Cost-Effectiveness of Rosuvastatin Therapy. Journal of the American College of Cardiology 57:7, 792-793
CrossRef355
E. J. Mills, P. WU, G. Chong, I. Ghement, S. Singh, E. A. Akl, O. Eyawo, G. Guyatt, O. Berwanger, M. Briel. (2011) Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170 255 patients from 76 randomized trials. QJM 104:2, 109-124
CrossRef356
K. L. Billups, M. M. Miner, A. S. Wierzbicki, G. Jackson. (2011) Gender-based cardiometabolic risk evaluation in minority and non-minority men grading the evidence of non-traditional determinants of cardiovascular risk. International Journal of Clinical Practice 65:2, 134-147
CrossRef357
Tieraona Low Dog. (2011) The Medicalization of Life: Are We First Doing Harm?. Alternative and Complementary Therapies 17:1, 6-8
CrossRef358
Sang-Hwan Kim, Ji-Won Lee, Jee-Aee Im, Hee-Jin Hwang. (2011) Monocyte chemoattractant protein-1 is related to metabolic syndrome and homocysteine in subjects without clinically significant atherosclerotic cardiovascular disease. Scandinavian Journal of Clinical & Laboratory Investigation 71:1, 1-6
CrossRef359
M. R. Goldstein, L. Mascitelli. (2011) Statin-induced diabetes: perhaps, it's the tip of the iceberg. QJM 104:2, 174-178
CrossRef360
Keith C. Ferdinand. (2011) Are Cardiovascular Benefits in Statin Lipid Effects Dependent on Baseline Lipid Levels?. Current Atherosclerosis Reports 13:1, 64-72
CrossRef361
Vincent Prinz, Matthias Endres. (2011) Statins and stroke: prevention and beyond. Current Opinion in Neurology 24:1, 75-80
CrossRef362
Robert Krysiak, Anna Gdula-Dymek, Joanna Ścieszka, Bogusław Okopień. (2011) Anti-Inflammatory and Monocyte-Suppressing Effects of Simvastatin in Patients with Impaired Fasting Glucose. Basic & Clinical Pharmacology & Toxicology 108:2, 131-137
CrossRef363
Kristopher S. Lyons, Gary E. McVeigh, Mark T. Harbinson. (2011) Statins in Heart Failure—Where Do We Stand?. Cardiovascular Drugs and Therapy 25:1, 99-104
CrossRef364
J. S. Rana, B. J. Arsenault, J.-P. Despres, M. Cote, P. J. Talmud, E. Ninio, J. Wouter Jukema, N. J. Wareham, J. J. P. Kastelein, K.-T. Khaw, S. Matthijs Boekholdt. (2011) Inflammatory biomarkers, physical activity, waist circumference, and risk of future coronary heart disease in healthy men and women. European Heart Journal 32:3, 336-344
CrossRef365
David Nanchen, Mark J. Pletcher, Jacques Cornuz, Pedro-Manuel Marques-Vidal, Fred Paccaud, Gérard Waeber, Peter Vollenweider, Nicolas Rodondi. (2011) Public health impact of statin prescribing strategies based on JUPITER. Preventive Medicine 52:2, 159-163
CrossRef366
Niteesh K. Choudhry, Amanda R. Patrick, Robert J. Glynn, Jerry Avorn. (2011) The Cost-Effectiveness of C-Reactive Protein Testing and Rosuvastatin Treatment for Patients With Normal Cholesterol Levels. Journal of the American College of Cardiology 57:7, 784-791
CrossRef367
Jennifer M. Belavic. (2011) Annual Drug Update. The Nurse Practitioner 36:2, 10-22
CrossRef368
Arnold von Eckardstein, Rahel A Sibler. (2011) Possible contributions of lipoproteins and cholesterol to the pathogenesis of diabetes mellitus type 2. Current Opinion in Lipidology 22:1, 26-32
CrossRef369
Denise H Rhoney. (2011) Contemporary Management of Transient Ischemic Attack: Role of the Pharmacist. Pharmacotherapy 31:2, 193-213
CrossRef370
K. Amann, K. Benz. (2011) Statins--beyond lipids in CKD. Nephrology Dialysis Transplantation 26:2, 407-410
CrossRef371
Jean-Pierre Després. (2011) CRP: star trekking the galaxy of risk markers. The Lancet 377:9764, 441-442
CrossRef372
Nkechinyere Ijioma, Jennifer G Robinson. (2011) Lipid-lowering effects of ezetimibe and simvastatin in combination. Expert Review of Cardiovascular Therapy 9:2, 131-145
CrossRef373
Nuntakorn Thongtang, Masumi Ai, Seiko Otokozawa, Thomas V. Himbergen, Bela F. Asztalos, Katsuyuki Nakajima, Evan Stein, Peter H. Jones, Ernst J. Schaefer. (2011) Effects of Maximal Atorvastatin and Rosuvastatin Treatment on Markers of Glucose Homeostasis and Inflammation. The American Journal of Cardiology 107:3, 387-392
CrossRef374
N J Timpson, B G Nordestgaard, R M Harbord, J Zacho, T M Frayling, A Tybjærg-Hansen, G Davey Smith. (2011) C-reactive protein levels and body mass index: elucidating direction of causation through reciprocal Mendelian randomization. International Journal of Obesity 35:2, 300-308
CrossRef375
Sridevi Devaraj, David Siegel, Ishwarlal Jialal. (2011) Statin Therapy in Metabolic Syndrome and Hypertension Post-JUPITER: What is the Value of CRP?. Current Atherosclerosis Reports 13:1, 31-42
CrossRef376
Fiona Taylor, Kirsten Ward, Theresa HM Moore, Margaret Burke, George Davey Smith, Juan-Pablo Casas, Shah Ebrahim, Fiona Taylor. 2011. Statins for the primary prevention of cardiovascular disease. .
CrossRef377
Fabian Bamberg, Quynh A. Truong, Wolfgang Koenig, Christopher L. Schlett, Khurram Nasir, Javed Butler, Emily Kurtz, Konstantin Nikolaou, Udo Hoffmann, James L. Januzzi. (2011) Differential associations between blood biomarkers of inflammation, oxidation, and lipid metabolism with varying forms of coronary atherosclerotic plaque as quantified by coronary CT angiography. The International Journal of Cardiovascular Imaging
CrossRef378
Mark S. Nash, Kevin L. Dalal, Jasmine Martinez-Barrizonte, Diana D. Cardenas. (2011) Suppression of Proatherogenic Inflammatory Cytokines as a Therapeutic Countermeasure to CVD Risks Accompanying SCI. Topics in Spinal Cord Injury Rehabilitation 16:3, 14-32
CrossRef379
S. Ylä-Herttuala, J. F. Bentzon, M. Daemen, E. Falk, H. M. Garcia-Garcia, J. Herrmann, I. Hoefer, J. W. Jukema, R. Krams, B. R. Kwak, N. Marx, M. Naruszewicz, A. Newby, G. Pasterkamp, P. W. J. C. Serruys, J. Waltenberger, C. Weber, L. Tokgözoglu. (2011) Stabilisation of atherosclerotic plaques. Thrombosis and Haemostasis 106:1, 1-19
CrossRef380
Kana Shimomura, Kanako Shimizu, Yoshiaki Tokuyama, Kenzo Sakurai, Kenji Isahaya, Satoshi Takaishi, Bunta Kato, Yasuhiro Hasegawa. (2011) Circulating levels of inflammatory biomarkers associated withischemic stroke subtype. Nosotchu 33:6, 564-571
CrossRef381
Agneta Simionescu, Jason B. Schulte, George Fercana, Dan T. Simionescu. (2011) Inflammation in Cardiovascular Tissue Engineering: The Challenge to a Promise: A Minireview. International Journal of Inflammation 2011, 1-11
CrossRef382
Barry Sears, Camillo Ricordi. (2011) Anti-Inflammatory Nutrition as a Pharmacological Approach to Treat Obesity. Journal of Obesity 2011, 1-14
CrossRef383
Oh Young Bang. (2011) Biomarkers of Stroke. Korean Journal of Stroke 13:2, 57
CrossRef384
Clay F. Semenkovich, Anne C. Goldberg, Ira J. Goldberg. 2011. Disorders of Lipid Metabolism. , 1633-1674.
CrossRef385
Cynthia A. Stuenkel. (2011) Hold, raise, or fold. Menopause 18:1, 8-10
CrossRef386
William C. Roberts, Antonio M. Gotto, John Guyton, John LaRosa, Ronald Viggiani. (2011) The Editor's Roundtable: Closing the Clinical Practice Gap—Using Evidence-Based Treatments for Managing Lipids. The American Journal of Cardiology 107:2, 230-242
CrossRef387
Kenzo Sakurai, Kenji Isahaya, Satoshi Takaishi, Bunta Kato, Kanako Shimizu, Kana Shimomura, Yoshiaki Tokuyama, Yasuhiro Hasegawa. (2011) Effects of early statin treatment on inflammatory biomarkers and clinical deterioration in patients with acute ischemic stroke. Rinsho Shinkeigaku 51:1, 6-13
CrossRef388
Masanori Abe, Noriaki Maruyama, Yoshinori Yoshida, Midori Ito, Kazuyoshi Okada, Masayoshi Soma. (2011) Efficacy analysis of the lipid-lowering and renoprotective effects of rosuvastatin in patients with chronic kidney disease. Endocrine Journal 58:8, 663-674
CrossRef389
Juan José Badimón, Carlos G. Santos-Gallego, Francisco Torres, Jesús Castillo, Juan Carlos Kaski. (2011) Nuevas herramientas en la estratificación del riesgo cardiovascular. Revista Española de Cardiología Suplementos 11, 21-28
CrossRef390
Victor L. Serebruany. (2011) Extreme All-Cause Mortality in JUPITER Requires Reexamination of Vital Records. Cardiology 120:2, 84-88
CrossRef391
Tsunenari Soeda, Shiro Uemura, Satoshi Okayama, Rika Kawakami, Yu Sugawara, Hitoshi Nakagawa, Takaki Matsumoto, Ji-Hee Sung, Taku Nishida, Ayako Senoo, Satoshi Somekawa, Yukiji Takeda, Kenichi Ishigami, Hiroyuki Kawata, Manabu Horii, Yoshihiko Saito. (2011) Intensive Lipid-Lowering Therapy With Rosuvastatin Stabilizes Lipid-Rich Coronary Plaques. Circulation Journal 75:11, 2621-2627
CrossRef392
Shaista Malik, Nathan D. Wong. 2011. Metabolic Syndrome and Cardiovascular Disease. , 371-387.
CrossRef393
M. K. Rutter, H. R. Prais, V. Charlton-Menys, M. Gittins, C. Roberts, R. R. Davies, A. Moorhouse, P. Jinadev, M. France, P. G. Wiles, J. M. Gibson, J. Dean, P. A. Kalra, J. K. Cruickshank, P. N. Durrington. (2011) Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): a randomized double-blind placebo-controlled trial of high- vs. low-dose atorvastatin1. Diabetic Medicine 28:1, 100-108
CrossRef394
Larry B. Goldstein, Ralph L. Sacco. 2011. Primary Prevention of Stroke. , 242-251.
CrossRef395
Julio Núñez, Juan Sanchis, Eduardo Núñez, Gregg C. Fonarow, Vicent Bodí, Vicente Bertomeu-González, Gema Miñana, Patricia Palau, Lorenzo Fácila, Francisco J. Chorro. (2011) Beneficios del tratamiento con estatinas según los valores plasmáticos del antígeno carbohidrato 125 tras un ingreso por insuficiencia cardiaca aguda. Revista Española de Cardiología 64:12, 1100
CrossRef396
Michael H Schiff, Joel M Kremer, Angelika Jahreis, Emma Vernon, John D Isaacs, Ronald F van Vollenhoven. (2011) Integrated safety in tocilizumab clinical trials. Arthritis Research & Therapy 13:5, R141
CrossRef397
Soo Lim, Jean-Pierre Despres, Kwang Kon Koh. (2011) Prevention of Atherosclerosis in Overweight/Obese Patients. Circulation Journal 75:5, 1019-1027
CrossRef398
Mori J Krantz, Carlin S Long, Patrick Hosokawa, Elhum Karimkahani, Miriam Dickinson, Raymond O Estacio, Frederick A Masoudi, Edward P Havranek. (2011) Pulse wave velocity and carotid atherosclerosis in White and Latino patients with hypertension. BMC Cardiovascular Disorders 11:1, 15
CrossRef399
Viviane Zorzanelli Rocha, Eduardo J. Folco. (2011) Inflammatory Concepts of Obesity. International Journal of Inflammation 2011, 1-14
CrossRef400
N. Gerdes, A. Zirlik. (2011) Co-stimulatory molecules in and beyond co-stimulation – tipping the balance in atherosclerosis?. Thrombosis and Haemostasis 106:5, 804-813
CrossRef401
Finn Akerström, Luis Rodríguez-Padial. (2011) The IMPROVE-IT trial: current status and potential clinical implications of ezetimibe. Clinical Investigation 1:1, 137-144
CrossRef402
Kiran Musunuru, Sekar Kathiresan. 2011. Genetics of Cardiovascular Disease and Its Role in Risk Prediction. , 46-53.
CrossRef403
G.L. Moneta. (2011) Contemporary Results of Carotid Endarterectomy for Asymptomatic Carotid Stenosis. Yearbook of Vascular Surgery 2011, 230-231
CrossRef404
Koutaro Yokote. (2011) Dyslipidemia. Nippon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics 48:3, 250-252
CrossRef405
Justin Szawlewicz, Steven M. Hollenberg. 2011. Biochemical or Electrocardiographic Evidence of Acute Myocardial Injury. , 120-122.
CrossRef406
Min Seok Oh, Yun Joo Min, Jee Eun Kwon, Eun Jeong Cho, Jung Eun Kim, Wang-Soo Lee, Kwang Je Lee, Sang-Wook Kim, Tae Ho Kim, Chee Jeong Kim, Wang Seong Ryu. (2011) Effects of Ezetimibe Added to Ongoing Statin Therapy on C-Reactive Protein Levels in Hypercholesterolemic Patients. Korean Circulation Journal 41:5, 253
CrossRef407
Luigina Guasti, Franca Marino, Marco Cosentino, Lorenzo Maroni, Andrea M. Maresca, Fausto Colombo, Ramona C. Maio, Luana Castiglioni, Federica Saporiti, Anna Loraschi, Giovanni Gaudio, Antonella Bernasconi, Emanuela Laurita, Anna M. Grandi, Achille Venco. (2011) Cytokine production from peripheral blood mononuclear cells and polymorphonuclear leukocytes in patients studied for suspected obstructive sleep apnea. Sleep and Breathing 15:1, 3-11
CrossRef408
Victor L. Serebruany. (2011) Reply. Cardiology 120:4, 236-236
CrossRef409
Vijay Nambi, Ariel Brautbar, Christie M. Ballantyne. 2011. Novel Biomarkers and the Assessment of Cardiovascular Risk. , 54-63.
CrossRef410
Paul M. Ridker. (2011) Increased Mortality Rates in the JUPITER Trial. Cardiology 120:4, 235-235
CrossRef411
Markolf Hanefeld, Andreas Pfützner, Thomas Forst, Iris Kleine, Winfried Fuchs. (2011) Double-blind, randomized, multicentre, and active comparator controlled investigation of the effect of Pioglitazone, Metformin, and the combination of both on cardiovascular risk in patients with type 2 diabetes receiving stable basal insulin therapy: the PIOCOMB study. Cardiovascular Diabetology 10:1, 65
CrossRef412
Yoshiko Mizuno, Robert Francis Jacob, R Preston Mason. (2011) Inflammation and the Development of Atherosclerosis. Journal of Atherosclerosis and Thrombosis 18:5, 351-358
CrossRef413
Soner Dogan, Johannes Jacob Pieter Kastelein, Diederick Egbertus Grobbee, Michiel Leonardus Bots. (2011) Mean Common or Mean Maximum Carotid Intima-Media Thickness as Primary Outcome in Lipid-Modifying Intervention Studies. Journal of Atherosclerosis and Thrombosis 18:11, 946-957
CrossRef414
Jay L. Bock. 2011. Cardiac Injury, Atherosclerosis, and Thrombotic Disease. , 249-258.
CrossRef415
P.P. Toth. (2011) Effects of Maximal Atorvastatin and Rosuvastatin Treatment on Markers of Glucose Homeostasis and Inflammation. Yearbook of Endocrinology 2011, 57-60
CrossRef416
Paul Nestel. 2011. Drugs that affect lipid metabolism. , 921-934.
CrossRef417
Yannick Le Manach, Cristina Ibanez Esteves, Michelle Bertrand, Jean Pierre Goarin, Marie-Hélène Fléron, Pierre Coriat, Fabien Koskas, Bruno Riou, Paul Landais. (2011) Impact of Preoperative Statin Therapy on Adverse Postoperative Outcomes in Patients Undergoing Vascular Surgery. Anesthesiology 114:1, 98-104
CrossRef418
E. Hevia Álvarez, C. Barreda Velásquez, R. Fernández Urrusuno. (2011) Prevención primaria cardiovascular con estatinas: beneficio clínico real aún por confirmar. Farmacéuticos de Atención Primaria 9:1, 24-25
CrossRef419
Peter Libby. 2011. Molecular Mechanisms of the Acute Coronary Syndromes. , 53-60.
CrossRef420
Robert Berent, Johann Auer, Peter Schmid, Gerald Krennmair, Stephen F. Crouse, John S. Green, Helmut Sinzinger, Serge P. von Duvillard. (2011) Periodontal and coronary heart disease in patients undergoing coronary angiography. Metabolism 60:1, 127-133
CrossRef421
Benoit J. Arsenault, Philip Barter, David A. DeMicco, Weihang Bao, Gregory M. Preston, John C. LaRosa, Scott M. Grundy, Prakash Deedwania, Heiner Greten, Nanette K. Wenger, James Shepherd, David D. Waters, John J.P. Kastelein. (2011) Prediction of Cardiovascular Events in Statin-Treated Stable Coronary Patients by Lipid and Nonlipid Biomarkers. Journal of the American College of Cardiology 57:1, 63-69
CrossRef422
G. Piazza, S. Z. Goldhaber, D. M. Lessard, R. J. Goldberg, C. Emery, F. A. Spencer. (2011) Venous thromboembolism in patients with symptomatic atherosclerosis. Thrombosis and Haemostasis 106:6, 1095-1102
CrossRef423
Joseph Shalhoub, Mika A Falck-Hansen, Alun H Davies, Claudia Monaco. (2011) Innate Immunity and Monocyte-Macrophage Activation in Atherosclerosis. Journal of Inflammation 8:1, 9
CrossRef424
Hiroaki Sakamoto, Yasunori Watanabe, Masataka Satou. (2011) Do Preoperative Statins Reduce Atrial Fibrillation after Coronary Artery Bypass Grafting?. Annals of Thoracic and Cardiovascular Surgery 17:4, 376-382
CrossRef425
Louis F. Amorosa, Esther J. Lee, David E. Swee. 2011. Diabetes Mellitus. , 731-755.
CrossRef426
Željko Reiner, Alberico L. Catapano, Guy De Backer, Ian Graham, Marja-Riitta Taskinen, Olov Wiklund, Stefan Agewall, Eduardo Alegría, M. John Chapman, Paul Durrington. (2011) Guía de la ESC/EAS sobre el manejo de las dislipemias. Revista Española de Cardiología 64:12, 1168.e1
CrossRef427
Giovanni Corso, Edo Bottacchi, Adriana Brusa, Chiara Lia, Susanna Cordera, Guido Giardini, Massimo Pesenti Campagnoni, Massimo Veronese Morosini. (2011) Blood C-Reactive Protein Concentration with ABCD<sup>2</sup> Is a Better Prognostic Tool than ABCD<sup>2</sup> Alone. Cerebrovascular Diseases 32:2, 97-105
CrossRef428
Han-Tan Chai, Yung-Lung Chen, Sheng-Ying Chung, Tzu-Hsien Tsai, Cheng-Hsu Yang, Huang-Chung Chen, Pei-Hsun Sung, Cheuk-Kwan Sun, Li-Teh Chang, Chang-Qing Fan, Hon-Kan Yip. (2011) Value and Level of Plasma Homocysteine in Patients With Angina Pectoris Undergoing Coronary Angiographic Study. International Heart Journal 52:5, 280-285
CrossRef429
Michael J. Blaha, Ty J. Gluckman, Roger S. Blumenthal. 2011. Preventive Cardiology. , 1-13.
CrossRef430
Tomohiro Katsuya. (2011) Interventions for life style related disease in the elderly: dyslipidemia. Nippon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics 48:1, 29-32
CrossRef431
Corissa L. Lamphear, Elaina A. Zverina, James L. Hougland, Carol A. Fierke. 2011. Global Identification of Protein Prenyltransferase Substrates. , 207-234.
CrossRef432
Pierre Théroux. 2011. The Past, the Present, the Future. , 1-13.
CrossRef433
Raza H. Orakzai, Chrisandra L. Shufelt, Leslee J. Shaw, C. Noel Bairey Merz. 2011. Prevention of Ischemic Heart Disease in Women. , 398-414.
CrossRef434
Rushika Conroy, Eun-Ju Lee, Amy Jean, Sharon E. Oberfield, Aviva Sopher, Krystina Kiefer, Courtney Raker, Donald J. McMahon, Jeffrey L. Zitsman, Ilene Fennoy. (2011) Effect of Laparoscopic Adjustable Gastric Banding on Metabolic Syndrome and Its Risk Factors in Morbidly Obese Adolescents. Journal of Obesity 2011, 1-8
CrossRef435
A. Viljoen. (2011) A practical approach to lipid management in the elderly. The journal of nutrition, health & aging 15:1, 65-70
CrossRef436
B. García Robredo, V. Arroyo Pineda, C. Barreda Velázquez. (2011) Los beneficios cardiovasculares del tratamiento con estatinas contrarrestan el ligero incremento del riesgo de desarrollar diabetes. Farmacéuticos de Atención Primaria 9:1, 27-28
CrossRef437
Aimé Bonny, Joelci Tonet, Manlio F. Márquez, Antonio De Sisti, Abdou Temfemo, Caroline Himbert, Fatima Gueffaf, Fabrice Larrazet, Ivo Ditah, Robert Frank, Françoise Hidden-Lucet, Guy Fontaine. (2011) C-Reactive Protein Levels in the Brugada Syndrome. Cardiology Research and Practice 2011, 1-6
CrossRef438
Christoph Gensch, Uta Hoppe, Michael Böhm, Ulrich Laufs. (2011) Late-breaking clinical trials presented at the American Heart Association Congress in Chicago 2010. Clinical Research in Cardiology 100:1, 1-9
CrossRef439
Julio Núñez, Juan Sanchis, Eduardo Núñez, Gregg C. Fonarow, Vicent Bodí, Vicente Bertomeu-González, Gema Miñana, Patricia Palau, Lorenzo Fácila, Francisco J. Chorro. (2011) Benefits of Statin Therapy Based on Plasma Carbohydrate Antigen 125 Values Following an Admission for Acute Heart Failure. Revista Española de Cardiología (English Edition) 64:12, 1100
CrossRef440
Yoshio Fujioka, Akira Fukuda, Tatsuro Ishida, Shinji Kagimoto, Yoshio Nakamura, Akane Iwakura, Kyoko Hara, Taizo Yamamoto, Akira Kuroe, Michihiro Ohya, Shinpei Fujimoto, Yoshiyuki Hamamoto, Sachiko Honjo, Hiroki Ikeda, Koichiro Nabe, Kinsuke Tsuda, Ataru Taniguchi, Kiyoshi Tanaka, Hiroyuki Koshiyama, Noriaki Kume, Ken-ichi Hirata. (2011) Pitavastatin Reduces Elevated IL-18 Levels in Japanese Subjects with Hypercholesterolemia: Sub-analysis of Kansai Investigation of Statin for Hyperlipidemic Intervention in Metabolism and Endocrinology (KISHIMEN). Journal of Atherosclerosis and Thrombosis 18:1, 8-15
CrossRef441
Jerome L. Fleg, Wilbert S. Aronow, William H. Frishman. (2011) Cardiovascular drug therapy in the elderly: benefits and challenges. Nature Reviews Cardiology 8:1, 13-28
CrossRef442
H. Pieringer, M. Pichler. (2011) Cardiovascular morbidity and mortality in patients with rheumatoid arthritis: vascular alterations and possible clinical implications. QJM 104:1, 13-26
CrossRef443
Masanori Abe, Noriaki Maruyama, Kazuyoshi Okada, Shiro Matsumoto, Koichi Matsumoto, Masayoshi Soma. (2011) Effects of Lipid-Lowering Therapy with Rosuvastatin on Kidney Function and Oxidative Stress in Patients with Diabetic Nephropathy. Journal of Atherosclerosis and Thrombosis 18:11, 1018-1028
CrossRef444
Johan Frostegård. (2011) Cardiovascular co-morbidity in patients with rheumatic diseases. Arthritis Research & Therapy 13:3, 225
CrossRef445
C.L. Martyn-Simmons, R.R. Ranawaka, P. Chowienczyk, M.A. Crook, M.S. Marber, C.H. Smith, J.N.W.N. Barker. (2011) A prospective case-controlled cohort study of endothelial function in patients with moderate to severe psoriasis. British Journal of Dermatology 164:1, 26-32
CrossRef446
W. Koenig, P. M. Ridker. (2011) Rosuvastatin for primary prevention in patients with European systematic coronary risk evaluation risk >=5% or Framingham risk >20%: post hoc analyses of the JUPITER trial requested by European health authorities. European Heart Journal 32:1, 75-83
CrossRef447
Enrique C. Morales-Villegas, Germano Di Sciascio, Carlo Briguori. (2011) Statins: Cardiovascular Risk Reduction in Percutaneous Coronary Intervention—Basic and Clinical Evidence of Hyperacute Use of Statins. International Journal of Hypertension 2011, 1-12
CrossRef448
Luca Puccetti, Francesca Santilli, Anna Laura Pasqui, Stefano Lattanzio, Rossella Liani, Federica Ciani, Elisabetta Ferrante, Giovanni Ciabattoni, Francesca Scarpini, Anna Ghezzi, Alberto Auteri, Giovanni Davì. (2011) Effects of atorvastatin and rosuvastatin on thromboxane-dependent platelet activation and oxidative stress in hypercholesterolemia. Atherosclerosis 214:1, 122-128
CrossRef449
Andrei C. Sposito, Bruno Farah Alvarenga, Alison S. Alexandre, Ana Laura Ribeiro Araújo, Simone N. Santos, Joalbo M. Andrade, Jose A.F. Ramires, Jose C. Quinaglia e Silva, Otavio Rizzi Coelho. (2011) Most of the patients presenting myocardial infarction would not be eligible for intensive lipid-lowering based on clinical algorithms or plasma C-reactive protein. Atherosclerosis 214:1, 148-150
CrossRef450
Keijiro Saku, Bo Zhang, Keita Noda, The PATROL Trial Investigators. (2011) Randomized Head-to-Head Comparison of Pitavastatin, Atorvastatin, and Rosuvastatin for Safety and Efficacy (Quantity and Quality of LDL). Circulation Journal 75:6, 1493-1505
CrossRef451
B. García Robredo, V. Arroyo Pineda, C. Barreda Velázquez. (2011) Los beneficios cardiovasculares del tratamiento con estatinas contrarrestan el ligero incremento del riesgo de desarrollar diabetes. Farmacéuticos de Atención Primaria 9:2, 68-69
CrossRef452
F. Montecucco, F. Mach. (2011) Should we focus on “venous vulnerability” instead of “plaque vulnerability” in symptomatic atherosclerotic patients?. Thrombosis and Haemostasis 106:6, 995-996
CrossRef453
Raymond Q Migrino, Mark Bowers, Leanne Harmann, Robert Prost, John F LaDisa. (2011) Carotid plaque regression following 6-month statin therapy assessed by 3T cardiovascular magnetic resonance: comparison with ultrasound intima media thickness. Journal of Cardiovascular Magnetic Resonance 13:1, 37
CrossRef454
Nai-Wen Tsai, Tsu-Kung Lin, Wen-Neng Chang, Chung-Ren Jan, Chi-Ren Huang, Shang-Der Chen, Kuei-Yueh Cheng, Yi-Fang Chiang, Hung-Chen Wang, Tzu-Ming Yang, Yu-Jun Lin, Wei-Che Lin, Hsueh-Wen Chang, Lian-Hui Lee, Cheng-Hsien Lu. (2011) Statin pre-treatment is associated with lower platelet activity and favorable outcome in patients with acute non-cardio-embolic ischemic stroke. Critical Care 15:4, R163
CrossRef455
Natalie J. Carter. (2010) Rosuvastatin. American Journal Cardiovascular Drugs 10:6, 383-400
CrossRef456
Mark R. Goldstein, Luca Mascitelli, Francesca Pezzetta. (2010) Rosuvastatin and vitamin D: Might there be hypovitaminosis D on JUPITER?. International Journal of Cardiology 145:3, 556-557
CrossRef457
J Woodcock. (2010) Assessing the Clinical Utility of Diagnostics Used in Drug Therapy. Clinical Pharmacology & Therapeutics 88:6, 765-773
CrossRef458
Eli M. Roth, Robert S. Rosenson, Dawn M. Carlson, Sandra M. Fukumoto, Carolyn M. Setze, James W. Blasetto, Nardev S. Khurmi, James C. Stolzenbach, Laura A. Williams. (2010) Efficacy and Safety of Rosuvastatin 5 mg in Combination with Fenofibric Acid 135 mg in Patients with Mixed Dyslipidemia – A Phase 3 Study. Cardiovascular Drugs and Therapy 24:5-6, 421-428
CrossRef459
Terje R. Pedersen. (2010) Pleiotropic Effects of Statins. American Journal Cardiovascular Drugs 10, 10-17
CrossRef460
Ross L. Prentice. (2010) Chronic Disease Prevention Research Methods and Their Reliability, With Illustrations From the Women’s Health Initiative. Journal of the American Statistical Association 105:492, 1431-1443
CrossRef461
T. Wethal, H.S. Haugnes, J. Kjekshus, M.C. Småstuen, T. Ueland, P. Aukrust, S.D. Fosså. (2010) C-reactive protein; a potential marker of second cancer and cardiovascular disease in testicular cancer survivors?. European Journal of Cancer 46:18, 3425-3433
CrossRef462
Alfonso Perez, Randal Jacks, Vipin Arora, Robert Spanheimer. (2010) Effects of Pioglitazone and Metformin Fixed-Dose Combination Therapy on Cardiovascular Risk Markers of Inflammation and Lipid Profile Compared With Pioglitazone and Metformin Monotherapy in Patients With Type 2 Diabetes. The Journal of Clinical Hypertension 12:12, 973-982
CrossRef463
Michel P Hermans, Jean-Charles Fruchart. (2010) Reducing residual vascular risk in patients with atherogenic dyslipidemia: where do we go from here?. Clinical Lipidology 5:6, 811-826
CrossRef464
Allan Sniderman, Ken Williams, Jacqueline de Graaf. (2010) Non-HDL C equals apolipoprotein B: except when it does not!. Current Opinion in Lipidology 21:6, 518-524
CrossRef465
M. Malach, W. J. Baumol. (2010) Further Opportunities for Cost Reduction of Medical Care. Journal of Community Health 35:6, 561-571
CrossRef466
Luigi Marzio Biasucci, Gina Biasillo, Antonella Stefanelli. (2010) Inflammatory markers, cholesterol and statins: pathophysiological role and clinical importance. Clinical Chemistry and Laboratory Medicine 48:12, 1685-1691
CrossRef467
William Nseir, Julnar Khateeb, Imad Tatour, Samah Haiek, Mousa Samara, Nimer Assy. (2010) Long-Term Statin Therapy Affects the Severity of Chronic Gastritis. Helicobacter 15:6, 510-515
CrossRef468
Ronald G. Schwartz. (2010) Early insights of cardiac risk and treatment response with quantitative PET monitoring of coronary-specific endothelial dysfunction and myocardial perfusion reserve. Journal of Nuclear Cardiology 17:6, 985-989
CrossRef469
David Niederseer, Josef Niebauer. (2010) Die Bedeutung von körperlicher Aktivität und körperlichem Training in der Prävention der koronaren Herzkrankheit. Wiener klinische Wochenschrift Education 5:3-4, 165-179
CrossRef470
Joakim Alfredsson, Eva Swahn. (2010) Management of acute coronary syndromes from a gender perspective. Fundamental & Clinical Pharmacology 24:6, 719-728
CrossRef471
Philip Greenland, Joseph S. Alpert, George A. Beller, Emelia J. Benjamin, Matthew J. Budoff, Zahi A. Fayad, Elyse Foster, Mark A. Hlatky, John McB. Hodgson, Frederick G. Kushner, Michael S. Lauer, Leslee J. Shaw, Sidney C. Smith, Allen J. Taylor, William S. Weintraub, Nanette K. Wenger. (2010) 2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults. Journal of the American College of Cardiology 56:25, e50-e103
CrossRef472
M. M. Miner, A. D. Seftel. (2010) Erectile dysfunction and testosterone screening with prostate specific antigen screening at age 40: are these three gender specific determinants additive for overall men’s heath and do they improve traditional non-gender specific determinants to lessen ca. International Journal of Clinical Practice 64:13, 1754-1762
CrossRef473
Mariaelena Lombardi, Giuseppe Mercuro, Massimo Fini, Giuseppe M.C. Rosano. (2010) Gender-specific aspects of treatment of cardiovascular risk factors in primary and secondary prevention. Fundamental & Clinical Pharmacology 24:6, 699-705
CrossRef474
Phillip L. Kalarickal, Charles J. Fox, Jeffrey Y. Tsai, Henry Liu, Alan D. Kaye. (2010) Perioperative Statin Use: An Update. Anesthesiology Clinics 28:4, 739-751
CrossRef475
Philip Greenland, Joseph S. Alpert, George A. Beller, Emelia J. Benjamin, Matthew J. Budoff, Zahi A. Fayad, Elyse Foster, Mark A. Hlatky, John McB. Hodgson, Frederick G. Kushner, Michael S. Lauer, Leslee J. Shaw, Sidney C. Smith, Allen J. Taylor, William S. Weintraub, Nanette K. Wenger. (2010) 2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults: Executive Summary. Journal of the American College of Cardiology 56:25, 2182-2199
CrossRef476
Joseph E. Thomas, Andrew M. Tershakovec, Charlotte Jones-Burton, Reza A. Sayeed, JoAnne M. Foody. (2010) Lipid Lowering for Secondary Prevention of Cardiovascular Disease in Older Adults. Drugs & Aging 27:12, 959-972
CrossRef477
Michael J. Pencina, Ralph B. D'Agostino, Ramachandran S. Vasan. (2010) Statistical methods for assessment of added usefulness of new biomarkers. Clinical Chemistry and Laboratory Medicine 48:12, 1703-1711
CrossRef478
R Temple. (2010) Enrichment of Clinical Study Populations. Clinical Pharmacology & Therapeutics 88:6, 774-778
CrossRef479
Om P. Ganda. (2010) The Role of Bile Acid Sequestrants in the Management of Type 2 Diabetes Mellitus. Metabolic Syndrome and Related Disorders 8:S1, S-15-S-21
CrossRef480
Gregory A Sgueglia, Filippo Crea. (2010) The risks of a new hypothesis: why did JUPITER patients have almost twice the predicted event rate of reduction?. Journal of Cardiovascular Medicine1
CrossRef481
Mario Marzilli. (2010) Pleiotropic Effects of Statins. American Journal Cardiovascular Drugs 10, 3-9
CrossRef482
Paul M. Ridker, Nina P. Paynter, Jacqueline S. Danik, Robert J. Glynn. (2010) Interpretation of Mendelian Randomization Studies and the Search for Causal Pathways in Atherothrombosis: The Need for Caution. Metabolic Syndrome and Related Disorders 8:6, 465-469
CrossRef483
Daniel E. Forman, J. Michael Gaziano. (2010) Assessment of the JUPITER Trial. Current Cardiovascular Risk Reports 4:6, 399-401
CrossRef484
Andrew L Mammen, Anthony A Amato. (2010) Statin myopathy: a review of recent progress. Current Opinion in Rheumatology 22:6, 644-650
CrossRef485
A. Calderón, C. Escobar, V. Barrios. (2010) ¿Debemos modificar nuestra conducta terapéutica como consecuencia de la revisión de 2009 de la guía para el manejo de la hipertensión arterial de la ESH/ESC?. Revista Clínica Española 210:10, 511-516
CrossRef486
Colleen Harrington, Aaron Horne, Rani K. Hasan, Roger S. Blumenthal. (2010) Statin Therapy in Primary Prevention: New Insights Regarding Women and the Elderly. The American Journal of Cardiology 106:9, 1357-1359
CrossRef487
C. Richard Conti. (2010) Is Calcium Scoring of the Coronary Arteries Necessary for Proper Management of Asymptomatic Subjects With Classic Risk Factors?. Clinical Cardiology 33:11, 658-659
CrossRef488
Daniel E Nixon, Alan L Landay. (2010) Biomarkers of immune dysfunction in HIV. Current Opinion in HIV and AIDS 5:6, 498-503
CrossRef489
Jennifer G. Robinson, Benjamin Booth. (2010) Statin use and lipid levels in older adults: National Health and Nutrition Examination Survey, 2001 to 2006. Journal of Clinical Lipidology 4:6, 483-490
CrossRef490
Robert Krysiak, Boguslaw Okopien. (2010) The Effect of Simvastatin on Lymphocyte Secretory Function in Patients With Impaired Fasting Glucose. Journal of Cardiovascular Pharmacology 56:5, 491-497
CrossRef491
Karin Müller, Simon Aichele, Mario Herkommer, Boris Bigalke, Konstantinos Stellos, Patrik Htun, Suzanne Fateh-Moghadam, Andreas E. May, Marcus Flather, Meinrad Gawaz, Tobias Geisler. (2010) Impact of inflammatory markers on platelet inhibition and cardiovascular outcome including stent thrombosis in patients with symptomatic coronary artery disease. Atherosclerosis 213:1, 256-262
CrossRef492
Muthiah Vaduganathan, Neil J. Stone, Richard Lee, Edwin C. McGee, S. Chris Malaisrie, Robert A. Silverberg, Patrick M. McCarthy. (2010) Perioperative statin therapy reduces mortality in normolipidemic patients undergoing cardiac surgery. The Journal of Thoracic and Cardiovascular Surgery 140:5, 1018-1027
CrossRef493
A.H.E.M. Maas, Y.E.A. Appelman. (2010) Gender differences in coronary heart disease. Netherlands Heart Journal 18:12, 598-603
CrossRef494
Gaietà Permanyer Miralda. (2010) ¿Son valores antagónicos la prevención y la compasión?. Medicina Clínica 135:14, 650-652
CrossRef495
P. Stenvinkel. (2010) Chronic kidney disease: a public health priority and harbinger of premature cardiovascular disease. Journal of Internal Medicine 268:5, 456-467
CrossRef496
Paul M. Ridker, Robert J. Glynn. (2010) The JUPITER Trial: Responding to the Critics. The American Journal of Cardiology 106:9, 1351-1356
CrossRef497
Lars H. Breimer, D.P. Mikhailidis. (2010) Primary prevention using statins: to be or not to be?. Current Medical Research and Opinion 26:11, 2701-2706
CrossRef498
Arthur E. Fass. (2010) Chronic Coronary Disease in the Post-COURAGE Era. Cardiology in Review 18:6, 292-297
CrossRef499
M. T. Keddis, V. D. Garovic, K. R. Bailey, C. M. Wood, Y. Raissian, J. P. Grande. (2010) Ischaemic nephropathy secondary to atherosclerotic renal artery stenosis: clinical and histopathological correlates. Nephrology Dialysis Transplantation 25:11, 3615-3622
CrossRef500
John W. McEvoy, Michael J. Blaha, Andrew P. DeFilippis, Matthew J. Budoff, Khurram Nasir, Roger S. Blumenthal, Steven R. Jones. (2010) Coronary Artery Calcium Progression: An Important Clinical Measurement?. Journal of the American College of Cardiology 56:20, 1613-1622
CrossRef501
Carl E. Orringer. (2010) The absence of coronary calcium: Clinical and therapeutic implications for the clinical lipidologist. Journal of Clinical Lipidology 4:6, 472-477
CrossRef502
L. M. Biasucci, I. Porto. (2010) Has atorvastatin more than a DUAAL face?. European Heart Journal 31:21, 2567-2568
CrossRef503
T. Nozaki, S. Sugiyama, K. Sugamura, K. Ohba, Y. Matsuzawa, M. Konishi, J. Matsubara, E. Akiyama, H. Sumida, K. Matsui, H. Jinnouchi, H. Ogawa. (2010) Prognostic value of endothelial microparticles in patients with heart failure. European Journal of Heart Failure 12:11, 1223-1228
CrossRef504
Jennifer L. Butcher, Renea L. Beckstrand. (2010) Fiber's impact on high-sensitivity C-reactive protein levels in cardiovascular disease. Journal of the American Academy of Nurse Practitioners 22:11, 566-572
CrossRef505
S. Fazio, J. R. Guyton, J. Lin, J. E. Tomassini, A. Shah, A. M. Tershakovec. (2010) Long-term efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome. Diabetes, Obesity and Metabolism 12:11, 983-993
CrossRef506
Adie Viljoen. (2010) A practical approach to lipid management in the elderly. The journal of nutrition, health & aging
CrossRef507
Melvyn Rubenfire, Robert D. Brook, Robert S. Rosenson. (2010) Treating Mixed Hyperlipidemia and the Atherogenic Lipid Phenotype for Prevention of Cardiovascular Events. The American Journal of Medicine 123:10, 892-898
CrossRef508
Tsann Lin, Juhn-Cherng Liu, Li-Ya Chang, Chien-Wei Shen. (2010) Association of C-reactive protein and homocysteine with subclinical coronary plaque subtype and stenosis using low-dose MDCT coronary angiography. Atherosclerosis 212:2, 501-506
CrossRef509
S. Vordenbäumen, S. Schinner, M. Halle, R. Fischer-Betz, M. Schneider. (2010) Therapie der Dyslipidämie bei entzündlich-rheumatischen Erkrankungen. Zeitschrift für Rheumatologie 69:8, 689-695
CrossRef510
A. Poli, A. Corsini. (2010) Reversible and non-reversible cardiovascular risk in patients treated with lipid-lowering therapy: Analysis of SEAS and JUPITER trials. European Journal of Internal Medicine 21:5, 372-373
CrossRef511
Julia F. Slejko, Robert L. Page, Patrick W. Sullivan. (2010) Cost-effectiveness of statin therapy for vascular event prevention in adults with elevated C-reactive protein: implications of JUPITER. Current Medical Research and Opinion 26:10, 2485-2497
CrossRef512
Massimo Volpe, John Camm, Antonio Coca, Thomas Unger. (2010) The cardiovascular continuum refined: A hypothesis. Blood Pressure 19:5, 273-277
CrossRef513
C.H. Saely, H. Drexel, K. Huber. (2010) Hochdosierte Statintherapie für kardiovaskuläre Risikopatienten. Herz 35:7, 497-502
CrossRef514
Toshio Imanishi, Hideyuki Ikejima, Hiroto Tsujioka, Akio Kuroi, Kohei Ishibashi, Kenichi Komukai, Takashi Tanimoto, Yasushi Ino, Tatsuya Takeshita, Takashi Akasaka. (2010) Association of monocyte subset counts with coronary fibrous cap thickness in patients with unstable angina pectoris. Atherosclerosis 212:2, 628-635
CrossRef515
Christoph H. Saely, Philipp Rein, Alexander Vonbank, Heinz Drexel. (2010) Serum levels of C-reactive protein in patients with stable coronary artery disease: JUPITER in perspective. International Journal of Cardiology 144:3, 448-450
CrossRef516
Michel R Hoenig, Philip J Walker, Christine Gurnsey, Karen Beadle, Leslie Johnson. (2010) Markers of Cholesterol Absorption and Synthesis Predict the Low-density Lipoprotein Cholesterol Response to Atorvastatin. Journal of Cardiovascular Pharmacology 56:4, 396-401
CrossRef517
Andrea Corsonello, Sabrina Garasto, Angela Marie Abbatecola, Giuseppina Rose, Giuseppe Passarino, Bruno Mazzei, Luigi Pranno, Enrico Eugenio Guffanti, Silvia Bustacchini, Fabrizia Lattanzio. (2010) Targeting inflammation to slow or delay functional decline: where are we?. Biogerontology 11:5, 603-614
CrossRef518
Bas J.M. Peters, Andrei S. Rodin, Olaf H. Klungel, Bruno H.Ch. Stricker, Anthonius de Boer, Anke-Hilse Maitland-van der Zee. (2010) Variants of ADAMTS1 modify the effectiveness of statins in reducing the risk of myocardial infarction. Pharmacogenetics and Genomics1
CrossRef519
Ulrich Laufs, Uta C. Hoppe, Stephan Rosenkranz, Paulus Kirchhof, Michael Böhm, Hans-Christoph Diener, Matthias Endres, Martin Grond, Werner Hacke, Thomas Meinertz, E. Bernd Ringelstein, Joachim Röther, Martin Dichgans. (2010) Cardiological evaluation after cerebral ischaemia. Clinical Research in Cardiology 99:10, 609-625
CrossRef520
L. Tomasoni, S. Sitia, C. Borghi, A.F.G. Cicero, C. Ceconi, F. Cecaro, A. Morganti, V. De Gennaro Colonna, M. Guazzi, L. Morricone, A.E. Malavazos, P. Marino, C. Cavallino, Y. Shoenfeld, M. Turiel. (2010) Effects of treatment strategy on endothelial function. Autoimmunity Reviews 9:12, 840-844
CrossRef521
Giuseppe Boriani, Igor Diemberger, Cinzia Valzania, Mauro Biffi, Cristian Martignani, Emanuel Raschi, Valentina Mantovani, Matteo Ziacchi, Matteo Bertini, Fabrizio De Ponti, Angelo Branzi. (2010) Role of drugs and devices in patients at risk of sudden cardiac death. Fundamental & Clinical Pharmacology 24:5, 575-594
CrossRef522
Terry A Jacobson, Peter H Jones, Eli M Roth. (2010) Combination therapy with rosuvastatin and fenofibric acid for mixed dyslipidemia: overview of efficacy and safety. Clinical Lipidology 5:5, 627-649
CrossRef523
Eleanor Brindle, Masako Fujita, Jane Shofer, Kathleen A. O'Connor. (2010) Serum, plasma, and dried blood spot high-sensitivity C-reactive protein enzyme immunoassay for population research. Journal of Immunological Methods 362:1-2, 112-120
CrossRef524
Masamichi Yoshika, Yutaka Komiyama, Midori Masuda, Toyohiko Yokoi, Hiroya Masaki, Hiroe Ohkura, Hakuo Takahashi. (2010) Pitavastatin Further Decreases Serum High-Sensitive C-Reactive Protein Levels in Hypertensive Patients with Hypercholesterolemia Treated with Angiotensin II, Type-1 Receptor Antagonists. Clinical and Experimental Hypertension 32:6, 341-346
CrossRef525
Diederik F. van Wijk, Erik S.G. Stroes, G.M. Dallinga-Thie. (2010) Novel insights into anti-inflammatory actions of HDL. Atherosclerosis 212:2, 388-389
CrossRef526
Manfredi Rizzo, Giatgen A. Spinas, Giovam Battista Rini, Kaspar Berneis. (2010) Is diabetes the cost to pay for a greater cardiovascular prevention?. International Journal of Cardiology 144:2, 309-310
CrossRef527
Antonio J Vallejo Vaz, María L Miranda Guisado, Pablo Stiefel García-Junco, Encarnación Pamies Andreu, Salvador García Morillo, José Villar Ortiz. (2010) Differences in the prevalence of metabolic syndrome and levels of C-reactive protein after puerperium in women with hypertensive disorders during pregnancy. Hypertension Research 33:10, 1012-1017
CrossRef528
Fumitaka Tanaka, Shinji Makita, Toshiyuki Onoda, Kozo Tanno, Masaki Ohsawa, Kazuyoshi Itai, Kiyomi Sakata, Masayuki Onodera, Yorihiko Koeda, Kazuko Kawarura, Yasuo Terayama, Yuki Yoshida, Akira Ogawa, Akira Okayama, Motoyuki Nakamura. (2010) Prehypertension Subtype With Elevated C-Reactive Protein: Risk of Ischemic Stroke in a General Japanese Population. American Journal of Hypertension 23:10, 1108-1113
CrossRef529
Willibald Hochholzer, David A. Morrow, Robert P. Giugliano. (2010) Novel biomarkers in cardiovascular disease: Update 2010. American Heart Journal 160:4, 583-594
CrossRef530
Peter T.W. Cheng, Ellen Kick, Ranjan Mukherjee. 2010. Nuclear Hormone Receptor Medicinal Chemistry. .
CrossRef531
Duane A. Burnett, Harry R. Davis. 2010. Atherosclerosis I: LDL Cholesterol Lowering. .
CrossRef532
Chris J Packard. (2010) Optimizing lipid-lowering therapy in the prevention of coronary heart disease. Expert Review of Clinical Pharmacology 3:5, 649-661
CrossRef533
Nathan D. Wong. (2010) Should We Focus on Novel Risk Markers and Screening Tests to Better Predict and Prevent Cardiovascular Disease? Or Are We Putting the Cart Before the Horse?. Preventive Cardiology 13:4, 149-151
CrossRef534
Eduardo Nicolas Pollono, Maria A. Lopez-Olivo, Juan Antonio Martinez Lopez, Maria E. Suarez-Almazor. (2010) A systematic review of the effect of TNF-α antagonists on lipid profiles in patients with rheumatoid arthritis. Clinical Rheumatology 29:9, 947-955
CrossRef535
S. S. Anand, S. Yusuf. (2010) C-reactive protein is a bystander of cardiovascular disease. European Heart Journal 31:17, 2092-2096
CrossRef536
Peter P. Toth, Michael H. Davidson. (2010) High-density lipoproteins: Marker of cardiovascular risk and therapeutic target. Journal of Clinical Lipidology 4:5, 359-364
CrossRef537
David E. Winchester, Xuerong Wen, Lola Xie, Anthony A. Bavry. (2010) Evidence of Pre-Procedural Statin Therapy. Journal of the American College of Cardiology 56:14, 1099-1109
CrossRef538
Dimitris Tousoulis, Katerina Koniari, Charalambos Antoniades, Antigoni Miliou, Marina Noutsou, Aggeliki Nikolopoulou, Nikolaos Papageorgiou, Kyriakoula Marinou, Elli Stefanadi, Christodoulos Stefanadis. (2010) Impact of 6 weeks of treatment with low-dose metformin and atorvastatin on glucose-induced changes of endothelial function in adults with newly diagnosed type 2 diabetes mellitus: A single-blind study. Clinical Therapeutics 32:10, 1720-1728
CrossRef539
Jasper J Brugts, Jaap W Deckers. (2010) Statin prescription in men and women at cardiovascular risk: to whom and when?. Current Opinion in Cardiology 22:5, 484-489
CrossRef540
G. Corso, E. Bottacchi, A. Brusa, M. Di Benedetto, G. Giardini, C. Lia, M. Reggiani, M. Veronese Morosini. (2010) Is there a prognostic role for C-reactive protein in ischemic stroke?. Acta Neurologica Scandinavica 122:3, 209-216
CrossRef541
Sara Tehrani, Fariborz Mobarrez, Aleksandra Antovic, Pia Santesson, Per-Eric Lins, Ulf Adamson, Peter Henriksson, N. Håkan Wallén, Gun Jörneskog. (2010) Atorvastatin has antithrombotic effects in patients with type 1 diabetes and dyslipidemia. Thrombosis Research 126:3, e225-e231
CrossRef542
Deeptankar DeMazumder, Rani K. Hasan, Roger S. Blumenthal, Erin D. Michos, Steven Jones. (2010) Should Statin Therapy Be Allocated on the Basis of Global Risk or on the Basis of Randomized Trial Evidence?. The American Journal of Cardiology 106:6, 905-909
CrossRef543
Pradeep K Nair, Suresh R Mulukutla, Oscar C Marroquin. (2010) Stents and statins: history, clinical outcomes and mechanisms. Expert Review of Cardiovascular Therapy 8:9, 1283-1295
CrossRef544
J. Eugen-Olsen, O. Andersen, A. Linneberg, S. Ladelund, T. W. Hansen, A. Langkilde, J. Petersen, T. Pielak, L. N. Møller, J. Jeppesen, S. Lyngbaek, M. Fenger, M. H. Olsen, P. R. Hildebrandt, K. Borch-Johnsen, T. Jørgensen, S. B. Haugaard. (2010) Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. Journal of Internal Medicine 268:3, 296-308
CrossRef545
Gerard Pasterkamp, Guus W van Lammeren. (2010) Pleiotropic effects of statins in atherosclerotic disease. Expert Review of Cardiovascular Therapy 8:9, 1235-1237
CrossRef546
Jill M. Cholette, Lara Mamikonian, George M. Alfieris, Neil Blumberg, Norma B. Lerner. (2010) Aspirin resistance following pediatric cardiac surgery. Thrombosis Research 126:3, 200-206
CrossRef547
Milan Gupta, Paul E Szmitko, Michelle Tsigoulis, Manoela F B Braga, Mahesh Kajil, Sheriar Herjikaka, Adrian Quan, Hwee Teoh, Subodh Verma. (2010) Effects of Ezetimibe Add-on to Statin Therapy on Adipokine Production in Patients With Metabolic Syndrome and Stable Vascular Disease. Journal of Cardiovascular Pharmacology 56:3, 241-245
CrossRef548
R. J. Bisoendial, S. M. Boekholdt, M. Vergeer, E. S. G. Stroes, J. J. P. Kastelein. (2010) C-reactive protein is a mediator of cardiovascular disease. European Heart Journal 31:17, 2087-2091
CrossRef549
D. M. FLEMING, N. Q. VERLANDER, A. J. ELLIOT, H. ZHAO, D. GELB, D. JEHRING, J. S. NGUYEN-VAN-TAM. (2010) An assessment of the effect of statin use on the incidence of acute respiratory infections in England during winters 1998–1999 to 2005–2006. Epidemiology and Infection 138:09, 1281-1288
CrossRef550
V. Agarwal, O. J. Phung, V. Tongbram, A. Bhardwaj, C. I. Coleman. (2010) Statin use and the prevention of venous thromboembolism: a meta-analysis. International Journal of Clinical Practice 64:10, 1375-1383
CrossRef551
Ivana Lukacova-Zib, Geetha Gopalakrishnan. (2010) Therapeutic Options for the Prevention of Type 2 Diabetes Mellitus in the Metabolic Syndrome. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 77:5, 524-532
CrossRef552
G.B. John Mancini, Jiri Frohlich. (2010) Carotid Ultrasound, Coronary Calcium, and Dyslipidemia Patterns in the MESA (Multi-Ethnic Study of Atherosclerosis) Cohort. Journal of the American College of Cardiology 56:13, 1042-1044
CrossRef553
Haniyyah Ahmad, Angela Cheng-Lai. (2010) Pitavastatin. Cardiology in Review 18:5, 264-267
CrossRef554
Farouk Mookadam, Sherif E. Moustafa, Steven J. Lester, Tahlil Warsame. (2010) Subclinical Atherosclerosis: Evolving Role of Carotid Intima-Media Thickness. Preventive Cardiology 13:4, 186-197
CrossRef555
Rajesh Tota-Maharaj, Andrew P Defilippis, Roger S Blumenthal, Michael J Blaha. (2010) A practical approach to the metabolic syndrome: review of current concepts and management. Current Opinion in Cardiology 22:5, 502-512
CrossRef556
Markku Qvarnstrom, Sok-Ja Janket, Judith A. Jones, Kamal Jethwani, Pekka Nuutinen, Raul I. Garcia, Alison E. Baird, Thomas E. Van Dyke, Jukka H. Meurman. (2010) Association of salivary lysozyme and C-reactive protein with metabolic syndrome. Journal of Clinical Periodontology 37:9, 805-811
CrossRef557
Pathmaja Paramsothy, Robert H. Knopp, Alain G. Bertoni, Roger S. Blumenthal, Bruce A. Wasserman, Michael Y. Tsai, Tessa Rue, Nathan D. Wong, Susan R. Heckbert. (2010) Association of Combinations of Lipid Parameters With Carotid Intima-Media Thickness and Coronary Artery Calcium in the MESA (Multi-Ethnic Study of Atherosclerosis). Journal of the American College of Cardiology 56:13, 1034-1041
CrossRef558
L. B. Travis, C. Beard, J. M. Allan, A. A. Dahl, D. R. Feldman, J. Oldenburg, G. Daugaard, J. L. Kelly, M. E. Dolan, R. Hannigan, L. S. Constine, K. C. Oeffinger, P. Okunieff, G. Armstrong, D. Wiljer, R. C. Miller, J. A. Gietema, F. E. van Leeuwen, J. P. Williams, C. R. Nichols, L. H. Einhorn, S. D. Fossa. (2010) Testicular Cancer Survivorship: Research Strategies and Recommendations. JNCI Journal of the National Cancer Institute 102:15, 1114-1130
CrossRef559
John R Guyton. (2010) Combination regimens with statin, niacin, and intestinally active LDL-lowering drugs: alternatives to high-dose statin therapy?. Current Opinion in Lipidology 21:4, 372-377
CrossRef560
Mackram F. Eleid, Steven J. Lester, Troy L. Wiedenbeck, Sharad D. Patel, Christopher P. Appleton, Matthew R. Nelson, Julie Humphries, R. Todd Hurst. (2010) Carotid Ultrasound Identifies High Risk Subclinical Atherosclerosis in Adults with Low Framingham Risk Scores. Journal of the American Society of Echocardiography 23:8, 802-808
CrossRef561
Ching-Chih Chang, Sun-Sang Wang, Hui-Chun Huang, Jing-Yi Lee, Fa-Yauh Lee, Han-Chieh Lin, Shou-Dong Lee. (2010) Pravastatin administration does not induce detrimental effects on hemodynamics and collaterals of portal hypertensive rats. Journal of Gastroenterology and Hepatology 25:8, 1394-1400
CrossRef562
James S. Forrester. (2010) Redefining Normal Low-Density Lipoprotein Cholesterol. Journal of the American College of Cardiology 56:8, 630-636
CrossRef563
Diederik F van Wijk, S Matthijs Boekholdt. (2010) Improving risk stratification for cardiovascular disease. Expert Review of Cardiovascular Therapy 8:8, 1091-1093
CrossRef564
Philippe Garot, Nabil Bendaoud, Thierry Lefèvre, Marie-Claude Morice. (2010) Favourable effect of statin therapy on early survival benefit at the time of percutaneous coronary intervention for ST-elevation myocardial infarction and shock. EuroIntervention 6:3, 350-355
CrossRef565
F. Malekzadeh, T. Marshall, A. Pourshams, M. Gharravi, A. Aslani, A. Nateghi, M. Rastegarpanah, M. Khoshnia, S. Semnani, R. Salahi, G. N. Thomas, B. Larijani, K. K. Cheng, R. Malekzadeh. (2010) A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy (‘polypill’) on cardiovascular risk factors. International Journal of Clinical Practice 64:9, 1220-1227
CrossRef566
Antonio M Gotto Jr, Jennifer Moon. (2010) Pitavastatin for the treatment of primary hyperlipidemia and mixed dyslipidemia. Expert Review of Cardiovascular Therapy 8:8, 1079-1090
CrossRef567
W David Strain, Salim Elyas, Phillip E Gates, Angela C Shore. (2010) Age-related change in endothelial and microvessel function and therapeutic consequences. Reviews in Clinical Gerontology 20:03, 161-170
CrossRef568
Lorenzo Arnaboldi, Alberto Corsini. (2010) Do structural differences in statins correlate with clinical efficacy?. Current Opinion in Lipidology 21:4, 298-304
CrossRef569
Vincent E. Friedewald, Peter Ganz, Joel M. Kremer, Philip J. Mease, James R. O'Dell, Thomas A. Pearson, C. Venkata S. Ram, Paul M. Ridker, Jane E. Salmon, William C. Roberts. (2010) AJC Editor's Consensus: Rheumatoid Arthritis and Atherosclerotic Cardiovascular Disease. The American Journal of Cardiology 106:3, 442-447
CrossRef570
Peter Henke. (2010) Incidence and Risk Factors of Peripheral Arterial Occlusive Disease in a Prospective Cohort of 700 Adult Men Followed for 5 Years. World Journal of Surgery 34:8, 1980-1981
CrossRef571
Emily A. Ferenczi, Perviz Asaria, Alun D. Hughes, Nishi Chaturvedi, Darrel P. Francis. (2010) Can a Statin Neutralize the Cardiovascular Risk of Unhealthy Dietary Choices?. The American Journal of Cardiology 106:4, 587-592
CrossRef572
Tatjána Ábel, János Fehér†. (2010) A rosuvastatin klinikai jelentősége napjaink lipidológiai gyógyszerelésében. Orvosi Hetilap 151:35, 1424-1428
CrossRef573
R Datar, WH Kaesemeyer, S Chandra, DJ Fulton, RW Caldwell. (2010) Acute activation of eNOS by statins involves scavenger receptor-B1, G protein subunit Gi, phospholipase C and calcium influx. British Journal of Pharmacology 160:7, 1765-1772
CrossRef574
S. A. E. Peters, M. K. Palmer, D. E. Grobbee, J. R. Crouse, D. H. O’Leary, J. S. Raichlen, M. L. Bots. (2010) C-reactive protein lowering with rosuvastatin in the METEOR study. Journal of Internal Medicine 268:2, 155-161
CrossRef575
Nesan Shanmugam, Ana Román-Rego, Peter Ong, Juan Carlos Kaski. (2010) Atherosclerotic Plaque Regression: Fact or Fiction?. Cardiovascular Drugs and Therapy 24:4, 311-317
CrossRef576
Tsuyoshi Chiba, Osamu Ezaki. (2010) Dietary restriction suppresses inflammation and delays the onset of stroke in stroke-prone spontaneously hypertensive rats. Biochemical and Biophysical Research Communications 399:1, 98-103
CrossRef577
John S. Millar, Bonnie Ky, Megan L. Wolfe, Leticia Pruscino, Amanda Baer, Daniel J. Rader. (2010) Short-Term Treatment with High-Dose Atorvastatin Reduces LDL Cholesterol but Shows no Anti-Inflammatory Effects in Normolipidemic Subjects with Normal CRP Levels. Clinical and Translational Science 3:4, 140-146
CrossRef578
L. Yan-Yan. (2010) Relationship of serum homocysteine and high sensitivity C-reactive protein in elderly people with essential hypertension. International Journal of Clinical Practice 64:9, 1318-1319
CrossRef579
Alexandre B. Rosendo, Luciana O. Lima, Felipe Dal-Pizzol, Silvana Almeida. (2010) Lipid and C-Reactive Protein Levels, Cardiovascular Disease Risk Factors and Simvastatin Treatment in Brazilian Individuals. Inflammation 33:4, 244-250
CrossRef580
M. Stramba-Badiale. (2010) Women and research on cardiovascular diseases in Europe: a report from the European Heart Health Strategy (EuroHeart) project. European Heart Journal 31:14, 1677-1681
CrossRef581
Petter Quist-Paulsen. (2010) Statins and inflammation: an update. Current Opinion in Cardiology 25:4, 399-405
CrossRef582
J. Zacho, A. Tybjaerg-Hansen, B. G. Nordestgaard. (2010) C-reactive protein and all-cause mortality--the Copenhagen City Heart Study. European Heart Journal 31:13, 1624-1632
CrossRef583
J. Hsia. (2010) Managing cardiovascular risk factors: Trial evidence in women. Nutrition, Metabolism and Cardiovascular Diseases 20:6, 445-450
CrossRef584
W. Virgil Brown. (2010) From the Editor-in-Chief. Journal of Clinical Lipidology 4:4, 237
CrossRef585
A. Denes, P. Thornton, N.J. Rothwell, S.M. Allan. (2010) Inflammation and brain injury: Acute cerebral ischaemia, peripheral and central inflammation. Brain, Behavior, and Immunity 24:5, 708-723
CrossRef586
Jeffrey W. Olin, Brett A. Sealove. (2010) Peripheral Artery Disease: Current Insight Into the Disease and Its Diagnosis and Management. Mayo Clinic Proceedings 85:7, 678-692
CrossRef587
Gian Paolo Fadini, Mattia Albiero, Elisa Boscaro, Lisa Menegazzo, Anna Cabrelle, Teodoro Piliego, Massimo Federici, Carlo Agostini, Angelo Avogaro. (2010) Rosuvastatin stimulates clonogenic potential and anti-inflammatory properties of endothelial progenitor cells. Cell Biology International 34:7, 709-715
CrossRef588
Kristine A. Scordo. (2010) Treating antiretroviral-induced dyslipidemia in HIV-infected adults. The Nurse Practitioner 35:7, 32-37
CrossRef589
Sander I. van Leuven, Diederik F. van Wijk, Oscar L. Volger, Jean-Paul P.M. de Vries, Chris M. van der Loos, Dominique V.P. de Kleijn, Anton J.G. Horrevoets, Paul P. Tak, Allard C. van der Wal, Onno J. de Boer, Gerard Pasterkamp, Michael R. Hayden, John J.P. Kastelein, Erik S. Stroes. (2010) Mycophenolate mofetil attenuates plaque inflammation in patients with symptomatic carotid artery stenosis. Atherosclerosis 211:1, 231-236
CrossRef590
Batya B Davidovici, Naveed Sattar, Prinz C Jörg, Luis Puig, Paul Emery, Jonathan N Barker, Peter van de Kerkhof, Mona Ståhle, Frank O Nestle, Giampiero Girolomoni, James G Krueger. (2010) Psoriasis and Systemic Inflammatory Diseases: Potential Mechanistic Links between Skin Disease and Co-Morbid Conditions. Journal of Investigative Dermatology 130:7, 1785-1796
CrossRef591
Marcelo L de Gusmão Correia. (2010) Adiposity and hypertension: the inflammatory link. Journal of Hypertension 28:7, 1377-1379
CrossRef592
Michael S. Lauer. (2010) Screening Asymptomatic Subjects for Subclinical Atherosclerosis. Journal of the American College of Cardiology 56:2, 106-108
CrossRef593
Kaori Inoue, Sadako Motoyama, Masayoshi Sarai, Takahisa Sato, Hiroto Harigaya, Tomonori Hara, Yoshihiro Sanda, Hirofumi Anno, Takeshi Kondo, Nathan D. Wong, Jagat Narula, Yukio Ozaki. (2010) Serial Coronary CT Angiography–Verified Changes in Plaque Characteristics as an End Point. JACC: Cardiovascular Imaging 3:7, 691-698
CrossRef594
Gerard Devlin. (2010) Women and elderly: subgroups under-represented in clinical trials. Current Opinion in Cardiology 25:4, 335-339
CrossRef595
Peter P. Toth. (2010) Drug Treatment of Hyperlipidaemia. Drugs 70:11, 1363-1379
CrossRef596
A. S. Wierzbicki. (2010) Practice makes perfect: reflections on a primary care treatment-to-target study. International Journal of Clinical Practice 64:8, 1006-1008
CrossRef597
Paul M. Ridker, Jean MacFadyen, Peter Libby, Robert J. Glynn. (2010) Relation of Baseline High-Sensitivity C-Reactive Protein Level to Cardiovascular Outcomes With Rosuvastatin in the Justification for Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER). The American Journal of Cardiology 106:2, 204-209
CrossRef598
Anders Hovland, Inger Aagnes, Ole-Lars Brekke, John Helge Flage, Knut Tore Lappegård. (2010) No evidence of impaired endothelial function or altered inflammatory state in patients with familial hypercholesterolemia treated with statins. Journal of Clinical Lipidology 4:4, 288-292
CrossRef599
Jennifer G. Robinson. (2010) How Low to Go for Primary Prevention?. Current Cardiovascular Risk Reports 4:4, 245-247
CrossRef600
Mary N. Haan. (2010) Can Statins Prevent Dementia in Older Adults?. Journal of the American Geriatrics Society 58:7, 1393-1394
CrossRef601
Shigeho Takarada, Toshio Imanishi, Kohei Ishibashi, Takashi Tanimoto, Kenichi Komukai, Yasushi Ino, Hironori Kitabata, Takashi Kubo, Atsushi Tanaka, Keizo Kimura, Masato Mizukoshi, Takashi Akasaka. (2010) The Effect of Lipid and Inflammatory Profiles on the Morphological Changes of Lipid-Rich Plaques in Patients With Non–ST-Segment Elevated Acute Coronary Syndrome. JACC: Cardiovascular Interventions 3:7, 766-772
CrossRef602
Derek J Hausenloy, Lionel Opie, Derek M Yellon. (2010) Dissociating HDL cholesterol from cardiovascular risk. The Lancet 376:9738, 305-306
CrossRef603
Paul M Ridker, Jacques Genest, S Matthijs Boekholdt, Peter Libby, Antonio M Gotto, Børge G Nordestgaard, Samia Mora, Jean G MacFadyen, Robert J Glynn, John JP Kastelein. (2010) HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. The Lancet 376:9738, 333-339
CrossRef604
Gabriel C. Brooks, Michael J. Blaha, Roger S. Blumenthal. (2010) Relation of C-Reactive Protein to Abdominal Adiposity. The American Journal of Cardiology 106:1, 56-61
CrossRef605
, T. K. Hansen, C. Forsblom, M. Saraheimo, L. Thorn, J. Wadén, P. Høyem, J. Østergaard, A. Flyvbjerg, P.-H. Groop. (2010) Association between mannose-binding lectin, high-sensitivity C-reactive protein and the progression of diabetic nephropathy in type 1 diabetes. Diabetologia 53:7, 1517-1524
CrossRef606
Aly Lakhani. (2010) Imperfect Pharmacovigilance. Southern Medical Journal 103:7, 602-603
CrossRef607
Martin Steinmetz, Caroline Brouwers, Georg Nickenig, Sven Wassmann. (2010) Synergistic effects of telmisartan and simvastatin on endothelial progenitor cells. Journal of Cellular and Molecular Medicine 14:6b, 1645-1656
CrossRef608
C. Noel Bairey Merz, Saralyn Mark, Barbara D. Boyan, Alice K. Jacobs, Prediman K. Shah, Leslee J. Shaw, Doris Taylor, Eduardo Marbán. (2010) Proceedings from the Scientific Symposium: Sex Differences in Cardiovascular Disease and Implications for Therapies. Journal of Women's Health 19:6, 1059-1072
CrossRef609
M. John Chapman, Jan S. Redfern, Mark E. McGovern, Philippe Giral. (2010) Niacin and fibrates in atherogenic dyslipidemia: Pharmacotherapy to reduce cardiovascular risk. Pharmacology & Therapeutics 126:3, 314-345
CrossRef610
Vicente Correa Jr, Miguel Gus, Flávio Danni Fuchs. (2010) Does the blood pressure-lowering effect of statins contribute to their beneficial cardiovascular effects?. Expert Review of Cardiovascular Therapy 8:6, 775-779
CrossRef611
Gina Biasillo, Milena Leo, Roberta Della Bona, Luigi Marzio Biasucci. (2010) Inflammatory biomarkers and coronary heart disease: from bench to bedside and back. Internal and Emergency Medicine 5:3, 225-233
CrossRef612
Hakan Buyukhatipoglu, Yusuf Sezen, Unal Guntekin, Idris Kirhan, Omer Faruk Dag. (2010) Acute renal failure with the combined use of rosuvastatin and fenofibrate. Renal Failure 32:5, 633-635
CrossRef613
Basil S. Lewis, David A. Halon. (2010) More Progression Toward Regression?. Journal of the American College of Cardiology 55:24, 2743-2744
CrossRef614
John W McEvoy. (2010) Statins and risk of incident diabetes. The Lancet 375:9732, 2139
CrossRef615
Luca Mascitelli, Francesca Pezzetta, Mark R Goldstein. (2010) Statins and risk of incident diabetes. The Lancet 375:9732, 2140-2141
CrossRef616
Lluís Masana, Núria Plana. (2010) Actualización de las tablas de planificación terapéutica de la hipercolesterolemia. Medicina Clínica 135:3, 120-123
CrossRef617
Rima Kaddurah-Daouk, Rebecca A. Baillie, Hongjie Zhu, Zhao-Bang Zeng, Michelle M. Wiest, Uyen Thao Nguyen, Steven M. Watkins, Ronald M. Krauss. (2010) Lipidomic analysis of variation in response to simvastatin in the Cholesterol and Pharmacogenetics Study. Metabolomics 6:2, 191-201
CrossRef618
Apurva O. Badheka, Ankit Rathod, Mohammad A. Kizilbash, Neha Garg, Tamam Mohamad, Luis Afonso, Sony Jacob. (2010) Impact of Lipid-Lowering Therapy on Outcomes in Atrial Fibrillation. The American Journal of Cardiology 105:12, 1768-1772
CrossRef619
Finn Gustafsson, Dan Atar, Bertram Pitt, Faiez Zannad, Marc A. Pfeffer. (2010) Maximizing scientific knowledge from randomized clinical trials. American Heart Journal 159:6, 937-943
CrossRef620
N. Butte, B.W. Böttiger, O. Liakopoulos, P. Teschendorf. (2010) Neue Aspekte der perioperativen Statintherapie. Der Anaesthesist 59:6, 539-548
CrossRef621
Henry Buchwald, Kyle D. Rudser, Stanley E. Williams, Van N. Michalek, James Vagasky, John E. Connett. (2010) Overall Mortality, Incremental Life Expectancy, and Cause of Death at 25 Years in the Program on the Surgical Control of the Hyperlipidemias. Annals of Surgery 251:6, 1034-1040
CrossRef622
Abhimanyu Beri, Tahmeed Contractor, Atul Khasnis, Ranjan Thakur. (2010) Statins and the Reduction of Sudden Cardiac Death. American Journal Cardiovascular Drugs 10:3, 155-164
CrossRef623
Kjetil H. Løland, Øyvind Bleie, Are J. Blix, Elin Strand, Per M. Ueland, Helga Refsum, Marta Ebbing, Jan E. Nordrehaug, Ottar Nygård. (2010) Effect of Homocysteine-Lowering B Vitamin Treatment on Angiographic Progression of Coronary Artery Disease: A Western Norway B Vitamin Intervention Trial (WENBIT) Substudy. The American Journal of Cardiology 105:11, 1577-1584
CrossRef624
Paul N Hopkins. (2010) Encouraging appropriate treatment for familial hypercholesterolemia. Clinical Lipidology 5:3, 339-354
CrossRef625
Sameed Ahmed M. Khatana, Tracey H. Taveira, Andrea G. Dooley, Wen-Chih Wu. (2010) The Association Between C-Reactive Protein Levels and Insulin Therapy in Obese vs Nonobese Veterans With Type 2 Diabetes Mellitus. The Journal of Clinical Hypertension 12:6, 462-468
CrossRef626
Haseeb Jafri, Alawi A. Alsheikh-Ali, Richard H. Karas. (2010) Baseline and On-Treatment High-Density Lipoprotein Cholesterol and the Risk of Cancer in Randomized Controlled Trials of Lipid-Altering Therapy. Journal of the American College of Cardiology 55:25, 2846-2854
CrossRef627
Carolyn S. Calfee, B. Taylor Thompson, Polly E. Parsons, Lorraine B. Ware, Michael A. Matthay, Hector R. Wong. (2010) Plasma interleukin-8 is not an effective risk stratification tool for adults with vasopressor-dependent septic shock*. Critical Care Medicine 38:6, 1436-1441
CrossRef628
Abhaya Gupta, Veronique Guyomard, M. Justin S. Zaman, Habib U. Rehman, Phyo Kyaw Myint. (2010) Systematic review on evidence of the effectiveness of cholesterol-lowering drugs. Advances in Therapy 27:6, 348-364
CrossRef629
Eddie Vos. (2010) High-Dose Statin, Not So IDEAL?. Journal of the American College of Cardiology 55:22, 2516-2517
CrossRef630
Martin K Reriani, Lilach O Lerman, Amir Lerman. (2010) Endothelial function as a functional expression of cardiovascular risk factors. Biomarkers in Medicine 4:3, 351-360
CrossRef631
Enrico Orsini, Giovanni Battista Zito. (2010) Matching pathophysiology and evidence-based medicine for optimal management of ischemic heart disease. Journal of Cardiovascular Medicine 11:6, 469-476
CrossRef632
Ravi Varadhan, Carlos O. Weiss, Jodi B. Segal, Albert W. Wu, Daniel Scharfstein, Cynthia Boyd. (2010) Evaluating Health Outcomes in the Presence of Competing Risks. Medical Care 48, S96-S105
CrossRef633
Hironori Kitabata, Atsushi Tanaka, Takashi Kubo, Shigeho Takarada, Manabu Kashiwagi, Hiroto Tsujioka, Hideyuki Ikejima, Akio Kuroi, Hideaki Kataiwa, Kohei Ishibashi, Kenichi Komukai, Takashi Tanimoto, Yasushi Ino, Kumiko Hirata, Nobuo Nakamura, Masato Mizukoshi, Toshio Imanishi, Takashi Akasaka. (2010) Relation of Microchannel Structure Identified by Optical Coherence Tomography to Plaque Vulnerability in Patients With Coronary Artery Disease. The American Journal of Cardiology 105:12, 1673-1678
CrossRef634
Makoto Goto. (2010) A comparative study of anti-inflammatory and antidyslipidemic effects of fenofibrate and statins on rheumatoid arthritis. Modern Rheumatology 20:3, 238-243
CrossRef635
Kiyoko Uno, Stephen J Nicholls. (2010) Biomarkers of inflammation and oxidative stress in atherosclerosis. Biomarkers in Medicine 4:3, 361-373
CrossRef636
Stephen J. Nicholls, Pia Lundman, Jean-Claude Tardif. (2010) Diabetic dyslipidemia: extending the target beyond LDL cholesterol. European Journal of Cardiovascular Prevention & Rehabilitation 17, S20-S24
CrossRef637
Marc Y. Donath, Marianne Böni-Schnetzler, Helga Ellingsgaard, Philippe A. Halban, Jan A. Ehses. (2010) Cytokine production by islets in health and diabetes: cellular origin, regulation and function. Trends in Endocrinology & Metabolism 21:5, 261-267
CrossRef638
George S. Abela. (2010) Cholesterol crystals piercing the arterial plaque and intima trigger local and systemic inflammation. Journal of Clinical Lipidology 4:3, 156-164
CrossRef639
Venkata M. Alla, Manu Kaushik, Aryan Mooss. (2010) Targeting Residual Risk: The Rationale for the Use of Non-HDL Cholesterol. Southern Medical Journal 103:5, 434-439
CrossRef640
Juan F. Ascaso. (2010) Avances en el tratamiento de la hipercolesterolemia. Endocrinología y Nutrición 57:5, 210-219
CrossRef641
Himabindu Vidula, Lu Tian, Kiang Liu, Michael H. Criqui, Luigi Ferrucci, Jack M. Guralnik, David Green, Paul Ridker, Mary M. McDermott. (2010) Comparison of Effects of Statin Use on Mortality in Patients With Peripheral Arterial Disease With Versus Without Elevated C-Reactive Protein and D-Dimer Levels. The American Journal of Cardiology 105:9, 1348-1352
CrossRef642
J. Gustav Smith, Christopher Newton-Cheh. (2010) Genetic Loci Associated with C-Reactive Protein Levels and Risk Of Coronary Heart Disease. Current Cardiovascular Risk Reports 4:3, 178-180
CrossRef643
Thierry Passeron, Serge Boulinguez. (2010) Quel est l’apport des nouvelles données des essais cliniques ?: Quelles leçons pour la prise en charge des patients ?. Annales de Dermatologie et de Vénéréologie 137:5, H11-H15
CrossRef644
George D. Giannoglou, Konstantinos C. Koskinas, Yiannis S. Chatzizisis. (2010) The Authorsʼ Reply. Drug Safety 33:5, 436-437
CrossRef645
Irene M. Van Der Meer, Piero Ruggenenti, Giuseppe Remuzzi. (2010) THE DIABETIC CKD PATIENT-A MAJOR CARDIOVASCULAR CHALLENGE. Journal of Renal Care 36, 34-46
CrossRef646
Chan Seok Park, Sang-Hyun Ihm, Ki-Dong Yoo, Dong-Bin Kim, Jong-Min Lee, Hee-Yeol Kim, Wook-Sung Chung, Ki Bae Seung, Jae-Hyung Kim. (2010) Relation Between C-Reactive Protein, Homocysteine Levels, Fibrinogen, and Lipoprotein Levels and Leukocyte and Platelet Counts, and 10-Year Risk for Cardiovascular Disease Among Healthy Adults in the USA. The American Journal of Cardiology 105:9, 1284-1288
CrossRef647
Lewis H. Kuller. (2010) Does the Framingham Risk Score Predict Risk in Women as Well as It Does in Men?. Current Cardiovascular Risk Reports 4:3, 229-236
CrossRef648
Jorge R. Kizer, Christopher Madias, Brian Wilner, Carl J. Vaughan, Alvin I. Mushlin, Paula Trushin, Antonio M. Gotto, Richard C. Pasternak. (2010) Relation of Different Measures of Low-Density Lipoprotein Cholesterol to Risk of Coronary Artery Disease and Death in a Meta-Regression Analysis of Large-Scale Trials of Statin Therapy. The American Journal of Cardiology 105:9, 1289-1296
CrossRef649
Wilbert S. Aronow, William H. Frishman. (2010) Management of Hypercholesterolemia in Older Persons for the Prevention of Cardiovascular Disease. Cardiology in Review 18:3, 132-140
CrossRef650
Stacy Loeb, Donghui Kan, Brian T. Helfand, Robert B. Nadler, William J. Catalona. (2010) Is statin use associated with prostate cancer aggressiveness?. BJU International 105:9, 1222-1225
CrossRef651
Vinay Prasad. (2010) Perspective: Beyond Storytelling in Medicine: An Encounter-Based Curriculum. Academic Medicine 85:5, 794-798
CrossRef652
Elena Myasoedova, Sherine E Gabriel. (2010) Cardiovascular disease in rheumatoid arthritis: a step forward. Current Opinion in Rheumatology 22:3, 342-347
CrossRef653
Raquel Melchior Roman, Paulo Vicente Camargo, Flávia Kessler Borges, Ana Paula Rossini, Carisi Anne Polanczyk. (2010) Prognostic value of myeloperoxidase in coronary artery disease: comparison of unstable and stable angina patients. Coronary Artery Disease 21:3, 129-136
CrossRef654
A Planagumà, M A Pfeffer, G Rubin, R Croze, M Uddin, C N Serhan, B D Levy. (2010) Lovastatin decreases acute mucosal inflammation via 15-epi-lipoxin A4. Mucosal Immunology 3:3, 270-279
CrossRef655
Ruo-Li Chen, Joyce S. Balami, Margaret M. Esiri, Liang-Kung Chen, Alastair M. Buchan. (2010) Ischemic stroke in the elderly: an overview of evidence. Nature Reviews Neurology 6:5, 256-265
CrossRef656
Thomas J. Wang. (2010) Multiple Biomarkers for Predicting Cardiovascular Events. Journal of the American College of Cardiology 55:19, 2092-2095
CrossRef657
P. M. Ridker. (2010) Psoriasis, inflammation, and vascular risk: a problem more than skin deep?. European Heart Journal 31:8, 902-904
CrossRef658
U. Laufs, U.C. Hoppe, S. Rosenkranz, P. Kirchhof, M. Böhm, H.-C. Diener, M. Endres, M. Grond, W. Hacke, T. Meinertz, E.B. Ringelstein, J. Röther, M. Dichgans. (2010) Kardiologische Diagnostik nach zerebraler Ischämie. Der Nervenarzt 81:4, 444-462
CrossRef659
E. Erdmann, R. Wilcox. (2010) Pioglitazone and mechanisms of CV protection. QJM 103:4, 213-228
CrossRef660
S E Kjeldsen, J Stålhammar, P Hasvold, J Bodegard, U Olsson, D Russell. (2010) Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension. Journal of Human Hypertension 24:4, 263-273
CrossRef661
P. Libby, F. Crea. (2010) Clinical implications of inflammation for cardiovascular primary prevention. European Heart Journal 31:7, 777-783
CrossRef662
Yuri B Pride, C Michael Gibson. (2010) Intensive statin therapy: a goal worth targeting. Interventional Cardiology 2:2, 103-105
CrossRef663
Vivencio Barrios, Carlos Escobar. (2010) Rosuvastatin and Cardiovascular Continuum. Journal of the American College of Cardiology 55:15, 1645-1646
CrossRef664
&NA;. (2010) The Acute (Cerebro) Vascular Effects of Statins. Survey of Anesthesiology 54:2, 100-101
CrossRef665
Per Torger Skretteberg, Johan Bodegård, Sverre E. Kjeldsen, Gunnar Erikssen, Erik Thaulow, Leif Sandvik, Jan E. Erikssen. (2010) Interaction between inflammation and blood viscosity predicts cardiovascular mortality. Scandinavian Cardiovascular Journal 44:2, 107-112
CrossRef666
TIMOTHY S. CHURCH, CONRAD P. EARNEST, ANGELA M. THOMPSON, ELISA L. PRIEST, RUBEN Q. RODARTE, TRAVIS SAUNDERS, ROBERT ROSS, STEVEN N. BLAIR. (2010) Exercise without Weight Loss Does Not Reduce C-Reactive Protein. Medicine & Science in Sports & Exercise 42:4, 708-716
CrossRef667
Jodi R. Godfrey, Nanette K. Wenger. (2010) Toward Optimal Health: Advances in the Cardiovascular Care of Women. Journal of Women's Health 19:4, 659-664
CrossRef668
Ambareesh Bajpai, Abhinav Goyal, Laurence Sperling. (2010) Should We Measure C-reactive Protein on Earth or Just on JUPITER?. Clinical Cardiology 33:4, 190-198
CrossRef669
Stanley S. Levinson. (2010) Weak associations between prognostic biomarkers and disease in preliminary studies illustrates the breach between statistical significance and diagnostic discrimination. Clinica Chimica Acta 411:7-8, 467-473
CrossRef670
Michael Blazing. (2010) Statins-Is There Potential for Uncovering New Benefits (or Detriments)?. Cardiovascular Therapeutics 28:2, 67-69
CrossRef671
Barry Lewis, Gerald F. Watts, David R. Sullivan. (2010) On Reducing Cardiovascular Disease to a Rarity: Clinical Strategies and their Cost-Effectiveness. Heart, Lung and Circulation 19:4, 225-227
CrossRef672
John R. Crouse, Michiel L. Bots, Gregory W. Evans, Mike K. Palmer, Daniel H. OʼLeary, Diederick E. Grobbee, Joel S. Raichlen. (2010) Does baseline carotid intima–media thickness modify the effect of rosuvastatin when compared with placebo on carotid intima–media thickness progression? The METEOR study. European Journal of Cardiovascular Prevention & Rehabilitation 17:2, 223-229
CrossRef673
Nina E Tolonen, Per-Henrik Groop. (2010) Can lipid abnormalities predict renal disease in patients with diabetes?. Clinical Lipidology 5:2, 151-155
CrossRef674
Luis Rodriguez Padial. (2010) The ENHANCE trial: analysis and clinical significance. Clinical Lipidology 5:2, 161-166
CrossRef675
Benjamin M. Scirica. (2010) Acute Coronary Syndrome. Journal of the American College of Cardiology 55:14, 1403-1415
CrossRef676
Peter H. Jones, Kenneth Cusi, Michael H. Davidson, Maureen T. Kelly, Carolyn M. Setze, Kamlesh Thakker, Darryl J. Sleep, James C. Stolzenbach. (2010) Efficacy and Safety of Fenofibric Acid Co-Administered with Low- or Moderate-Dose Statin in Patients with Mixed Dyslipidemia and Type 2 Diabetes Mellitus. American Journal Cardiovascular Drugs 10:2, 73-84
CrossRef677
W. H. Wilson Tang, Gary S. Francis. (2010) Statin treatment for patients with heart failure. Nature Reviews Cardiology
CrossRef678
Peter P Toth, Peter A McCullough, Michael S Wegner, Kenneth J Colley. (2010) Lipoprotein-associated phospholipase A 2 : role in atherosclerosis and utility as a cardiovascular biomarker. Expert Review of Cardiovascular Therapy 8:3, 425-438
CrossRef679
Jonathan Hagedorn, Rohit Arora. (2010) Association of Statins and Diabetes Mellitus. American Journal of Therapeutics 17:2, e52-e55
CrossRef680
Sridevi Devaraj, Simona Valleggi, David Siegel, Ishwarlal Jialal. (2010) Role of C-Reactive Protein in Contributing to Increased Cardiovascular Risk in Metabolic Syndrome. Current Atherosclerosis Reports 12:2, 110-118
CrossRef681
Kwang Kon Koh, Michael J. Quon, Seung Hwan Han, Yonghee Lee, Soo Jin Kim, Eak Kyun Shin. (2010) Atorvastatin Causes Insulin Resistance and Increases Ambient Glycemia in Hypercholesterolemic Patients. Journal of the American College of Cardiology 55:12, 1209-1216
CrossRef682
David Goldsmith, Adrian C. Covic. (2010) Jupiter or Aurora? Micro-inflammation and dyslipidaemia: twin targets for statin therapy in CKD. International Urology and Nephrology 42:1, 133-136
CrossRef683
Yiannis S. Chatzizisis, Konstantinos C. Koskinas, Gesthimani Misirli, Christos Vaklavas, Apostolos Hatzitolios, George D. Giannoglou. (2010) Risk Factors and Drug Interactions Predisposing to Statin-Induced Myopathy. Drug Safety 33:3, 171-187
CrossRef684
Paolo Calabrò, Enrica Golia, Lucia Riegler, Giuseppe Limongelli, Paolo Golino, Maria Giovanna Russo, Raffaele Calabrò. (2010) Inflammation: The Link Between Obesity and Cardiovascular Risk. Current Cardiovascular Risk Reports 4:2, 101-111
CrossRef685
Philipp Eller, Kathrin Eller, Anna M Wolf, Sebastian J Reinstadler, Andrea Tagwerker, Josef R Patsch, Gert Mayer, Alexander R Rosenkranz. (2010) Atorvastatin attenuates murine anti-glomerular basement membrane glomerulonephritis. Kidney International 77:5, 428-435
CrossRef686
Peter Kolkhof, Andreas Geerts, Stefan Schäfer, Jan Torzewski. (2010) Cardiac glycosides potently inhibit C-reactive protein synthesis in human hepatocytes. Biochemical and Biophysical Research Communications 394:1, 233-239
CrossRef687
Allan D. Sniderman, Ken Williams, Matthew J. McQueen, Curt D. Furberg. (2010) When is equal not equal?. Journal of Clinical Lipidology 4:2, 83-88
CrossRef688
Robert B. Schonberger, Ala S. Haddadin. (2010) The Anesthesia Patient with Acute Coronary Syndrome. Anesthesiology Clinics 28:1, 55-66
CrossRef689
Tjörvi E. Perry, Jochen D. Muehlschlegel, Kuang-Yu Liu, Amanda A. Fox, Charles D. Collard, Simon C. Body, Stanton K. Shernan. (2010) Preoperative C-reactive Protein Predicts Long-term Mortality and Hospital Length of Stay after Primary, Nonemergent Coronary Artery Bypass Grafting. Anesthesiology 112:3, 607-613
CrossRef690
Herbert D Aronow, Gregory Hess, Jerrold Hill, Andreas Kuznik, Larry Z Liu. (2010) Switching From Atorvastatin to Simvastatin in Patients at High Cardiovascular Risk: Effects on Low-Density Lipoprotein Cholesterol. American Journal of Therapeutics 17:2, 167-175
CrossRef691
Maria Vistnes, Geir Christensen, Torbjørn Omland. (2010) Multiple cytokine biomarkers in heart failure. Expert Review of Molecular Diagnostics 10:2, 147-157
CrossRef692
Radjesh J. Bisoendial, Erik S. G. Stroes, John J. P. Kastelein, Paul Peter Tak. (2010) Targeting cardiovascular risk in rheumatoid arthritis: a dual role for statins. Nature Reviews Rheumatology 6:3, 157-164
CrossRef693
Joe Gray, Steven J. Edwards, Gregory Y.H. Lip. (2010) Comparison of sequential rosuvastatin doses in hypercholesterolaemia: a meta-analysis of randomised controlled trials. Current Medical Research and Opinion 26:3, 537-547
CrossRef694
Paul M. Ridker, Jean MacFadyen, Michael Cressman, Robert J. Glynn. (2010) Efficacy of Rosuvastatin Among Men and Women With Moderate Chronic Kidney Disease and Elevated High-Sensitivity C-Reactive Protein. Journal of the American College of Cardiology 55:12, 1266-1273
CrossRef695
Thomas J. Grahame, Richard B. Schlesinger. (2010) Cardiovascular health and particulate vehicular emissions: a critical evaluation of the evidence. Air Quality, Atmosphere & Health 3:1, 3-27
CrossRef696
Justin M. S. Lee, Robin P. Choudhury. (2010) Rheumatoid arthritis: RA—lowering cardiovascular risk with statins. Nature Reviews Rheumatology 6:3, 123-124
CrossRef697
Charles A. Dinarello. (2010) Anti-inflammatory Agents: Present and Future. Cell 140:6, 935-950
CrossRef698
S Matthijs Boekholdt, John J Kastelein. (2010) C-reactive protein measurement and cardiovascular disease – Authors' reply. The Lancet 375:9720, 1077-1078
CrossRef699
Christos V. Rizos, Haralampos J. Milionis, Michael S. Kostapanos, Matilda Florentin, Christina E. Kostara, Moses S. Elisaf, Evangelos N. Liberopoulos. (2010) Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: A 24-week, randomized, open-label, prospective study. Clinical Therapeutics 32:3, 492-505
CrossRef700
Jacques Genest. (2010) C-reactive protein: Risk factor, biomarker and/or therapeutic target?. Canadian Journal of Cardiology 26, 41A-44A
CrossRef701
Tené T. Lewis, Allison E. Aiello, Sue Leurgans, Jeremiah Kelly, Lisa L. Barnes. (2010) Self-reported experiences of everyday discrimination are associated with elevated C-reactive protein levels in older African-American adults. Brain, Behavior, and Immunity 24:3, 438-443
CrossRef702
Johan M. Lorenzen, Henrike Neunhöffer, Sascha David, Jan T. Kielstein, Hermann Haller, Danilo Fliser. (2010) Angiotensin II receptor blocker and statins lower elevated levels of osteopontin in essential hypertension—Results from the EUTOPIA trial. Atherosclerosis 209:1, 184-188
CrossRef703
Pablo Aschner. (2010) Metabolic syndrome as a risk factor for diabetes. Expert Review of Cardiovascular Therapy 8:3, 407-412
CrossRef704
Scott L. Charland, Daniel C. Malone. (2010) Prediction of cardiovascular event risk reduction from lipid changes associated with high potency dyslipidemia therapy. Current Medical Research and Opinion 26:2, 365-375
CrossRef705
Kevin S. Heffernan, Richard H. Karas, Eshan A. Patvardhan, Haseeb Jafri, Jeffrey T. Kuvin. (2010) Peripheral Arterial Tonometry for Risk Stratification in Men With Coronary Artery Disease. Clinical Cardiology 33:2, 94-98
CrossRef706
Carl J. Pepine. (2010) Residual risk for secondary ischemic events in patients with atherothrombotic disease: Opportunity for future improvements in patient care. Annals of Medicine 42:1, 19-35
CrossRef707
Joe J. Leyon, Saraswathy Jaiveer, Derek L. Connolly, Suresh Babu. (2010) Statin Prescription is Essential in Peripheral Vascular Disease. Journal of Vascular and Interventional Radiology 21:2, 175-177
CrossRef708
Sabin Shurraw, Marcello Tonelli. (2010) AURORA: Is There a Role for Statin Therapy in Dialysis Patients?. American Journal of Kidney Diseases 55:2, 237-240
CrossRef709
Amin Esfahani, David J. A. Jenkins, Cyril W. C. Kendall. (2010) Session 4: CVD, diabetes and cancer A dietary portfolio for management and prevention of heart disease. Proceedings of the Nutrition Society 69:01, 39
CrossRef710
Christopher P Cannon. (2010) Balancing the benefits of statins versus a new risk—diabetes. The Lancet 375:9716, 700-701
CrossRef711
Anna Toso, Mauro Maioli, Mario Leoncini, Michela Gallopin, Delio Tedeschi, Carlo Micheletti, Concetta Manzone, Marcello Amato, Francesco Bellandi. (2010) Usefulness of Atorvastatin (80 mg) in Prevention of Contrast-Induced Nephropathy in Patients With Chronic Renal Disease. The American Journal of Cardiology 105:3, 288-292
CrossRef712
Rory R. Koenen, Christian Weber. (2010) Therapeutic targeting of chemokine interactions in atherosclerosis. Nature Reviews Drug Discovery 9:2, 141-153
CrossRef713
Liam R. Brunham, Janine K. Kruit, Michael R. Hayden, C. Bruce Verchere. (2010) Cholesterol in β-cell Dysfunction: The Emerging Connection Between HDL Cholesterol and Type 2 Diabetes. Current Diabetes Reports 10:1, 55-60
CrossRef714
Lewis H Kuller. (2010) Cardiovascular disease is preventable among women. Expert Review of Cardiovascular Therapy 8:2, 175-187
CrossRef715
Hazem F Elewa, Azza B El-Remessy, Payaningal R Somanath, Susan C Fagan. (2010) Diverse Effects of Statins on Angiogenesis: New Therapeutic Avenues. Pharmacotherapy 30:2, 169-176
CrossRef716
S. L. Westlake, A. N. Colebatch, J. Baird, P. Kiely, M. Quinn, E. Choy, A. J. K. Ostor, C. J. Edwards. (2010) The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology 49:2, 295-307
CrossRef717
George S Abela. (2010) Role of cholesterol crystals in myocardial infarction and stroke. Clinical Lipidology 5:1, 57-69
CrossRef718
Craig D. Ferguson, Paula Clancy, Bernard Bourke, Philip J. Walker, Anthony Dear, Tim Buckenham, Paul Norman, Jonathan Golledge. (2010) Association of statin prescription with small abdominal aortic aneurysm progression. American Heart Journal 159:2, 307-313
CrossRef719
E. Aigner, C. Hinz, K. Steiner, B. Rossmann, J. Pfleger, F. Hohla, B. Steger, A. Stadlmayr, W. Patsch, C. Datz. (2010) Iron stores, liver transaminase levels and metabolic risk in healthy teenagers. European Journal of Clinical Investigation 40:2, 155-163
CrossRef720
Michael S. Kostapanos, Haralampos J. Milionis, Moses S. Elisaf. (2010) Rosuvastatin-Associated Adverse Effects and Drug-Drug Interactions in the Clinical Setting of Dyslipidemia. American Journal Cardiovascular Drugs 10:1, 11-28
CrossRef721
Naveed Sattar, David Preiss, Heather M Murray, Paul Welsh, Brendan M Buckley, Anton JM de Craen, Sreenivasa Rao Kondapally Seshasai, John J McMurray, Dilys J Freeman, J Wouter Jukema, Peter W Macfarlane, Chris J Packard, David J Stott, Rudi G Westendorp, James Shepherd, Barry R Davis, Sara L Pressel, Roberto Marchioli, Rosa Maria Marfisi, Aldo P Maggioni, Luigi Tavazzi, Gianni Tognoni, John Kjekshus, Terje R Pedersen, Thomas J Cook, Antonio M Gotto, Michael B Clearfield, John R Downs, Haruo Nakamura, Yasuo Ohashi, Kyoichi Mizuno, Kausik K Ray, Ian Ford. (2010) Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. The Lancet 375:9716, 735-742
CrossRef722
M. J. Chapman, W. Le Goff, M. Guerin, A. Kontush. (2010) Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. European Heart Journal 31:2, 149-164
CrossRef723
O. Hegland, M. W. Kurz, P. S. Munk, J. P. Larsen. (2010) The effect of statin therapy on the progression of carotid artery stenosis in relation to stenosis severity. Acta Neurologica Scandinavica 121:1, 11-15
CrossRef724
N. K. Wenger, S. J. Lewis. (2010) Use of Statin Therapy to Reduce Cardiovascular Risk in Older Patients. Current Gerontology and Geriatrics Research 2010, 1-9
CrossRef725
Byron F. Vandenberg, Jennifer Robinson. (2010) Management of the Patient with Statin Intolerance. Current Atherosclerosis Reports 12:1, 48-57
CrossRef726
Jean-Paul Bounhoure. 2010. Traitement des complications cardiovasculaires du stress. , 203-222.
CrossRef727
Lucas A. Dvoracek, Jeffrey I. Kreisberg, Jordan McKinney, Gabrielle Schmid, Amanda D. Francis, Katie L. Kacmarik, Huey Miin Lee, Melinda S. Detrick, Donald A. Primerano, Nalini Santanam, Robert Kreisberg. (2010) Lovastatin inhibits oxidized L-A-phosphatidylcholine B-arachidonoyl-gamma-palmitoyl (ox-PAPC)-stimulated interleukin-8 mRNA and protein synthesis in human aortic endothelial cells by depleting stores of geranylgeranyl pyrophosphate. Atherosclerosis 208:1, 50-55
CrossRef728
B.J. Gersh. (2010) C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Yearbook of Cardiology 2010, 295-297
CrossRef729
Yuki Horiuchi, Satoshi Hirayama, Satoshi Soda, Utako Seino, Mika Kon, Tsuyoshi Ueno, Mayumi Idei, Osamu Hanyu, Takashi Tsuda, Hirotoshi Ohmura, Takashi Miida. (2010) Statin therapy reduces inflammatory markers in hypercholesterolemic patients with high baseline levels. Journal of Atherosclerosis and Thrombosis 17:7, 722-729
CrossRef730
Madhan Shanmugasundaram, Steven J. Rough, Joseph S. Alpert. (2010) Dyslipidemia in the Elderly: Should it Be Treated?. Clinical Cardiology 33:1, 4-9
CrossRef731
Paul Anderson. (2010) Post-transcriptional regulons coordinate the initiation and resolution of inflammation. Nature Reviews Immunology 10:1, 24-35
CrossRef732
Paul D. Thompson, Beth A. Parker, Priscilla M. Clarkson, Linda S. Pescatello, C. Michael White, Adam S. Grimaldi, Benjamin D. Levine, Ronald G. Haller, Eric P. Hoffman. (2010) A Randomized Clinical Trial to Assess the Effect of Statins on Skeletal Muscle Function and Performance: Rationale and Study Design. Preventive Cardiology
CrossRef733
Anna M. Lundberg, Göran K. Hansson. (2010) Innate immune signals in atherosclerosis. Clinical Immunology 134:1, 5-24
CrossRef734
Parag H. Joshi, Terry A. Jacobson. (2010) Therapeutic Options to Further Lower C-Reactive Protein for Patients on Statin Treatment. Current Atherosclerosis Reports 12:1, 34-42
CrossRef735
Ross J. Simpson, Sidney C. Smith. 2010. Treatment of Lipid Abnormalities. , 619-625.
CrossRef736
Yali Zheng, Wenfei Ma, Yan Zeng, Jiani Liu, Shan Ye, Shaohua Chen, Ling Lan, Raimund Erbel, Qigong Liu. (2010) Comparative study of clinical characteristics between Chinese Han and German Caucasian patients with coronary heart disease. Clinical Research in Cardiology 99:1, 45-50
CrossRef737
Xinkang Wang, Thomas M. Connolly. 2010. Biomarkers of Vulnerable Atheromatous Plaques. , 1-22.
CrossRef738
Danai Khemasuwan, Matthew L. DiVietro, Kawin Tangdhanakanond, Sherry C. Pomerantz, Glenn Eiger. (2010) Statins Decrease the Occurrence of Venous Thromboembolism in Patients with Cancer. The American Journal of Medicine 123:1, 60-65
CrossRef739
Charles J. Everett, Dana E. King, Marty S. Player, Eric M. Matheson, Robert E. Post, Arch G. Mainous. (2010) Association of urinary polycyclic aromatic hydrocarbons and serum C-reactive protein. Environmental Research 110:1, 79-82
CrossRef740
Pauliina Tuomikoski, Tomi S. Mikkola, Esa Hämäläinen, Matti J. Tikkanen, Ursula Turpeinen, Olavi Ylikorkala. (2010) Biochemical markers for cardiovascular disease in recently postmenopausal women with or without hot flashes. Menopause 17:1, 145-151
CrossRef741
S Matthijs Boekholdt, John JP Kastelein. (2010) C-reactive protein and cardiovascular risk: more fuel to the fire. The Lancet 375:9709, 95-96
CrossRef742
N.R. Robles, J.F. Macias. (2010) Cardiovascular Risk in Uremic Patients: Darkness after AURORA. Renal Failure 32:2, 269-272
CrossRef743
Sung Sug (Sarah) Yoon, Charles F Dillon, Margaret Carroll, Kachi Illoh, Yechiam Ostchega. (2010) Effects of Statins on Serum Inflammatory Markers: The U.S. National Health and Nutrition Examination Survey 1999-2004. Journal of Atherosclerosis and Thrombosis 17:11, 1176-1182
CrossRef744
A. Rodríguez Terol, J. Cárdenas Gómez, D. Palma Morgado. (2010) El uso de rosuvastatina reduce la aparición de tromboembolismo venoso en personas sanas y frente a placebo. Farmacéuticos de Atención Primaria 8:1-3, 24-25
CrossRef745
Georgeta Vaidean. 2010. Cardiovascular Epidemiology. , 589-595.
CrossRef746
(2010) C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. The Lancet 375:9709, 132-140
CrossRef747
John A. Ambrose, Sundararajan Srikanth. (2010) Vulnerable Plaques and Patients: Improving Prediction of Future Coronary Events. The American Journal of Medicine 123:1, 10-16
CrossRef748
Masahiko Kurabayashi, Ichiro Sakuma, Ryuzo Kawamori, Hiroyuki Daida, Tsutomu Yamazaki, Masayuki Yoshida, Mitsumasa Hata, Izuru Masuda, Kohei Kaku, Hiroyoshi Yokoi, Junji Kishimoto, Ryuji Nohara. (2010) Can Intensive Lipid-Lowering Therapy with Statins Ameliorate Atherosclerosis in Japanese Patients?. Journal of Atherosclerosis and Thrombosis 17:4, 416-422
CrossRef749
Shepard D. Weiner, LeRoy E. Rabbani. (2010) Secondary prevention strategies for coronary heart disease. Journal of Thrombosis and Thrombolysis 29:1, 8-24
CrossRef750
G. Klose, W. März, T.B. Grammer, S. Nitschmann. (2010) Rosuvastatin zur Primärprävention vaskulärer Komplikationen. Der Internist 51:1, 103-106
CrossRef751
Ian A Menown, James A Shand. (2010) Recent advances in cardiology. Future Cardiology 6:1, 11-17
CrossRef752
Young Jin Lee, Joong Man Kim, Do-Sim Park. (2010) Evaluation of Analytical Measurement Ranges of Three Full Range C-Reactive Protein Tests Using Immunoturbidimetric Assay. The Korean Journal of Laboratory Medicine 30:1, 9
CrossRef753
Mary Cushman, Leslie A. McClure, Susan G. Lakoski, Nancy S. Jenny. (2010) Eligibility for Statin Therapy by the JUPITER Trial Criteria and Subsequent Mortality. The American Journal of Cardiology 105:1, 77-81
CrossRef754
Young Song, Young Lan Kwak, Yong Seon Choi, Jong Chan Kim, Sang Baek Heo, Jae Kwang Shim. (2010) Effect of preoperative statin therapy on myocardial protection and morbidity endpoints following off-pump coronary bypass surgery in patients with elevated C-reactive protein level. Korean Journal of Anesthesiology 58:2, 136
CrossRef755
Christoph H. Saely, Heinz Drexel. (2010) Bedeutung der Lipidtherapie bei Diabetes. Wiener Medizinische Wochenschrift 160:1-2, 25-29
CrossRef756
Christopher Schneeweis, Michael Gräfe, Anne Bungenstock, Chantel Spencer-Hänsch, Eckart Fleck, Stephan Goetze. (2010) Chronic CRP-Exposure Inhibits VEGF-Induced Endothelial Cell Migration. Journal of Atherosclerosis and Thrombosis 17:2, 203-212
CrossRef757
William L. Baker, Ripple Talati, C. Michael White, Craig I. Coleman. (2010) Differing effect of statins on insulin sensitivity in non-diabetics: A systematic review and meta-analysis. Diabetes Research and Clinical Practice 87:1, 98-107
CrossRef758
Amish A Patel, Matthew J Budoff. (2010) Screening for heart disease: C-reactive protein versus coronary artery calcium. Expert Review of Cardiovascular Therapy 8:1, 125-131
CrossRef759
Aimé Bonny, Nicolas Lellouche, Ivo Ditah, Françoise Hidden-Lucet, Martial T. Yitemben, Benjamin Granger, Fabrice Larrazet, Robert Frank, Guy Fontaine. (2010) C-Reactive Protein in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy and Relationship with Ventricular Tachycardia. Cardiology Research and Practice 2010, 1-7
CrossRef760
Vincent J. Willey, Michael F. Bullano, Nze N. Shoetan, Sanjay K. Gandhi. (2010) Therapy modifications and low-density lipoprotein cholesterol goal attainment rates associated with the initiation of generic simvastatin. Current Medical Research and Opinion 26:1, 121-128
CrossRef761
Carlos Iribarren. (2010) Lipoprotein-Associated Phospholipase A2 and C-Reactive Protein for Measurement of Inflammatory Risk: Independent or Complementary?. Current Cardiovascular Risk Reports 4:1, 57-67
CrossRef762
Alfredo Bardají, José A. Barrabés, Juan Sanchis, Pedro L. Sánchez. (2010) Actualización en cardiopatía isquémica. Revista Española de Cardiología 63, 49-60
CrossRef763
Kavita Sharma, Christian D. Nagy, Roger S. Blumenthal. 2010. Dyslipidemia Management in Women and MenExploring Potential Gender Differences. , 175-185.
CrossRef764
Petra Schnell-Inderst, Ruth Schwarzer, Alexander Göhler, Norma Grandi, Kristin Grabein, Björn Stollenwerk, Jennifer Manne, Volker Klauss, Uwe Siebert, Jürgen Wasem. (2010) Prognostic value, clinical effectiveness, and cost-effectiveness of high-sensitivity C-reactive protein as a marker for major cardiac events in asymptomatic individuals: A health technology assessment report. International Journal of Technology Assessment in Health Care 26:01, 30
CrossRef765
Beatrice A. Golomb. (2009) Doctoring the Evidence: The Case Against Lying to Patients about Placebos. The American Journal of Bioethics 9:12, 34-36
CrossRef766
S. Trompet, J. W. Jukema, M. B. Katan, G. J. Blauw, N. Sattar, B. Buckley, M. Caslake, I. Ford, J. Shepherd, R. G. J. Westendorp, A. J. M. de Craen. (2009) Apolipoprotein E Genotype, Plasma Cholesterol, and Cancer: A Mendelian Randomization Study. American Journal of Epidemiology 170:11, 1415-1421
CrossRef767
, H. M. Hertog, J. A. Rossum, H. B. Worp, H. M. A. Gemert, R. Jonge, P. J. Koudstaal, D. W. J. Dippel. (2009) C-reactive protein in the very early phase of acute ischemic stroke: association with poor outcome and death. Journal of Neurology 256:12, 2003-2008
CrossRef768
Karen L. Margolis, Kay Dunn, Lara M. Simpson, Charles E. Ford, Jeff D. Williamson, David J. Gordon, Paula T. Einhorn, Jeffrey L. Probstfield. (2009) Coronary heart disease in moderately hypercholesterolemic, hypertensive black and non-black patients randomized to pravastatin versus usual care: The Antihypertensive and Lipid Lowering to Prevent Heart Attack Trial (ALLHAT-LLT). American Heart Journal 158:6, 948-955
CrossRef769
Vicente Bertomeu Martínez, J. Ramón González-Juanatey. (2009) Markers of Inflammation and Cardiovascular Disease. American Journal Cardiovascular Drugs 9:Supplement 1, 3-7
CrossRef770
Kubilay Ukinc, Selcuk Eminagaoglu, Halil Onder Ersoz, Cihangir Erem, Caner Karahan, Arif Bayram Hacihasanoglu, Mustafa Kocak. (2009) A novel indicator of widespread endothelial damage and ischemia in diabetic patients: ischemia-modified albumin. Endocrine 36:3, 425-432
CrossRef771
Henry R. Black, Jacqueline Bailey, Dion Zappe, Rita Samuel. (2009) Valsartan. Drugs 69:17, 2393-2414
CrossRef772
R. Clarke, J. Armitage. (2009) Greater absolute reductions in LDL cholesterol should yield greater proportional reductions in risk of cardiovascular disease. Journal of Internal Medicine 266:6, 499-501
CrossRef773
M. S. Kostapanos, H. J. Milionis, M. S. Elisaf. (2009) Does intensive cholesterol lowering increase the risk of diabetes?. International Journal of Clinical Practice 63:12, 1809-1809
CrossRef774
Eric Y. Yang, Vijay Nambi, Zhengzheng Tang, Salim S. Virani, Eric Boerwinkle, Ron C. Hoogeveen, Brad C. Astor, Thomas H. Mosley, Josef Coresh, Lloyd Chambless, Christie M. Ballantyne. (2009) Clinical Implications of JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) in a U.S. Population. Journal of the American College of Cardiology 54:25, 2388-2395
CrossRef775
Giuseppe Mancia, Stéphane Laurent, Enrico Agabiti-Rosei, Ettore Ambrosioni, Michel Burnier, Mark J. Caulfield, Renata Cifkova, Denis Clément, Antonio Coca, Anna Dominiczak, Serap Erdine, Robert Fagard, Csaba Farsang, Guido Grassi, Hermann Haller, Antony Heagerty, Sverre E. Kjeldsen, Wolfgang Kiowski, Jean Michel Mallion, Athanasios Manolis, Krzysztof Narkiewicz, Peter Nilsson, Michael H. Olsen, Karl Heinz Rahn, Josep Redon, José Rodicio, Luis Ruilope, Roland E. Schmieder, Harry A.J. Struijker-Boudier, Pieter A. Van Zwieten, Margus Viigimaa, Alberto Zanchetti. (2009) Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Pressure 18:6, 308-347
CrossRef776
Ming-Yow Hung, Kuang-Hung Hsu, Ming-Jui Hung, Chi-Wen Cheng, Li-Tang Kuo, Wen-Jin Cherng. (2009) Interaction Between Cigarette Smoking and High-Sensitivity C-Reactive Protein in the Development of Coronary Vasospasm in Patients Without Hemodynamically Significant Coronary Artery Disease. The American Journal of the Medical Sciences 338:6, 440-446
CrossRef777
Thomas S. Monahan, Christopher D. Owens. (2009) Risk Factors for Lower-Extremity Vein Graft Failure. Seminars in Vascular Surgery 22:4, 216-226
CrossRef778
Sanjay K. Gandhi, Krister Järbrink, Kathleen M. Fox, Gunnar Brandrup-Wognsen. (2009) Effectiveness of rosuvastatin in reducing LDL-C and target LDL-C goal attainment in real-world clinical practice. Current Medical Research and Opinion 25:12, 2817-2828
CrossRef779
Peter Libby, Paul M. Ridker, Göran K. Hansson. (2009) Inflammation in Atherosclerosis. Journal of the American College of Cardiology 54:23, 2129-2138
CrossRef780
D. S. H. Bell, James H. OâKeefe. (2009) Rediscovering bile acid sequestrants. Diabetes, Obesity and Metabolism 11:12, 1114-1121
CrossRef781
Mark A. Hlatky, Paul Heidenreich. (2009) The Year in Epidemiology, Health Services Research, and Outcomes Research. Journal of the American College of Cardiology 54:25, 2343-2351
CrossRef782
L. Mascitelli, F. Pezzetta, M. R. Goldstein. (2009) Does intensive cholesterol lowering increase the risk of diabetes?. International Journal of Clinical Practice 63:12, 1808-1808
CrossRef783
T. Hugh Jones, Farid Saad. (2009) The effects of testosterone on risk factors for, and the mediators of, the atherosclerotic process. Atherosclerosis 207:2, 318-327
CrossRef784
Catherine Fiévet, Bart Staels. (2009) Combination therapy of statins and fibrates in the management of cardiovascular risk. Current Opinion in Lipidology 20:6, 505-511
CrossRef785
C. Tissa Kappagoda, Ezra A. Amsterdam. (2009) Another Look at the Results of the JUPITER Trial. The American Journal of Cardiology 104:11, 1603-1605
CrossRef786
T. Tsutamoto, M. Yamaji, C. Kawahara, K. Nishiyama, M. Fujii, T. Yamamoto, M. Horie. (2009) Effect of simvastatin vs. rosuvastatin on adiponectin and haemoglobin A1c levels in patients with non-ischaemic chronic heart failure. European Journal of Heart Failure 11:12, 1195-1201
CrossRef787
R. Klingenberg, G. K. Hansson. (2009) Treating inflammation in atherosclerotic cardiovascular disease: emerging therapies. European Heart Journal 30:23, 2838-2844
CrossRef788
Yutaka Mori, Genshin Kuriyama, Takaaki Tanaka, Naoko Tajima. (2009) Usefulness of aggressive lipid-lowering therapy with rosuvastatin in hypercholesterolemic patients with concomitant type 2 diabetes. Endocrine 36:3, 412-418
CrossRef789
Carl J. Lavie, Richard V. Milani, Anil Verma, James H. OʼKeefe. (2009) C-Reactive Protein and Cardiovascular Diseases—Is it Ready for Primetime?. The American Journal of the Medical Sciences 338:6, 486-492
CrossRef790
Michael J. Lipinski, Clay A. Cauthen, Giuseppe G.L. Biondi-Zoccai, Antonio Abbate, Bojan Vrtovec, Bobby V. Khan, George W. Vetrovec. (2009) Meta-Analysis of Randomized Controlled Trials of Statins Versus Placebo in Patients With Heart Failure. The American Journal of Cardiology 104:12, 1708-1716
CrossRef791
Sabina A. Murphy, Christopher P. Cannon, Stephen D. Wiviott, Carolyn H. McCabe, Eugene Braunwald. (2009) Reduction in Recurrent Cardiovascular Events With Intensive Lipid-Lowering Statin Therapy Compared With Moderate Lipid-Lowering Statin Therapy After Acute Coronary Syndromes. Journal of the American College of Cardiology 54:25, 2358-2362
CrossRef792
Mahir Karakas, Wolfgang Koenig. (2009) CRP in Cardiovascular Disease. Herz 34:8, 607-613
CrossRef793
Alanna Morris, Keith C Ferdinand. (2009) Hyperlipidemia in racial/ethnic minorities: differences in lipid profiles and the impact of statin therapy. Clinical Lipidology 4:6, 741-754
CrossRef794
Jonathan M. Meyer, Joseph P. McEvoy, Vicki G. Davis, Donald C. Goff, Henry A. Nasrallah, Sonia M. Davis, John K. Hsiao, Marvin S. Swartz, T. Scott Stroup, Jeffrey A. Lieberman. (2009) Inflammatory Markers in Schizophrenia: Comparing Antipsychotic Effects in Phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness Study. Biological Psychiatry 66:11, 1013-1022
CrossRef795
Alistair S. Hall, Beryl M. Jackson, Amanda J. Farrin, Maria Efthymiou, Julian H. Barth, Joanne Copeland, Kristian M. Bailey, Simon P. R. Romaine, Anthony J. Balmforth, Terry McCormack, Andrew Whitehead, Marcus D. Flather, Jane Nixon. (2009) A randomized, controlled trial of simvastatin versus rosuvastatin in patients with acute myocardial infarction: the Secondary Prevention of Acute Coronary Events – Reduction of Cholesterol to Key European Targets Trial. European Journal of Cardiovascular Prevention & Rehabilitation 16:6, 712-721
CrossRef796
G R Shroff, Y-Y Cen, D A Duprez, B A Bart. (2009) Relationship between carotid artery stiffness index, BNP and high-sensitivity CRP. Journal of Human Hypertension 23:12, 783-787
CrossRef797
Harminder Singh, Salaheddin M Mahmud, Donna Turner, Lin Xue, Alain A Demers, Charles N Bernstein. (2009) Long-Term Use of Statins and Risk of Colorectal Cancer: A Population-Based Study. The American Journal of Gastroenterology 104:12, 3015-3023
CrossRef798
James McKenney, Sanjay K. Gandhi, Kathleen M. Fox, Robert L. Ohsfeldt. (2009) Atherosclerosis in a managed care plan: hypercholesterolemia treatment patterns and low-density lipoprotein cholesterol monitoring. Journal of Clinical Lipidology 3:6, 385-392
CrossRef799
T. Pusl, C. Rust, K.G. Parhofer. (2009) Diabetes und Fettleber. Der Diabetologe 5:8, 653-665
CrossRef800
Blumenthal, Roger S., Michos, Erin D., . (2009) The HALTS Trial — Halting Atherosclerosis or Halted Too Early?. New England Journal of Medicine 361:22, 2178-2180
Full Text801
Jacobus Lubsen. (2009) Commentary on ‘Measurement in clinical trials: A neglected issue for statisticians?’. Statistics in Medicine 28:26, 3215-3217
CrossRef802
Jennifer G. Robinson. (2009) Lipid-Lowering Therapy for the Primary Prevention of Cardiovascular Disease in the Elderly. Drugs & Aging 26:11, 917-931
CrossRef803
Joanne D. Schuijf, Stephan Achenbach, William A. Zoghbi, Eric Boersma, Paolo Raggi, Michael Weber, Eike Nagel, Jagat Narula, Frans J. Th. Wackers, Don Poldermans, Jeroen J. Bax. (2009) How to Identify the Asymptomatic High-Risk Patient?. Current Problems in Cardiology 34:11, 539-577
CrossRef804
Giuseppe Mancia, Stéphane Laurent, Enrico Agabiti-Rosei, Ettore Ambrosioni, Michel Burnier, Mark J Caulfield, Renata Cifkova, Denis Clément, Antonio Coca, Anna Dominiczak, Serap Erdine, Robert Fagard, Csaba Farsang, Guido Grassi, Hermann Haller, Anthony Heagerty, Sverre E Kjeldsen, Wolfgang Kiowski, Jean Michel Mallion, Athanasios Manolis, Krzysztof Narkiewicz, Peter Nilsson, Michael H Olsen, Karl Heinz Rahn, Josep Redon, José Rodicio, Luis Ruilope, Roland E Schmieder, Harry AJ Struijker-Boudier, Pieter A van Zwieten, Margus Viigimaa, Alberto Zanchetti. (2009) Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Journal of Hypertension 27:11, 2121-2158
CrossRef805
Vivencio Barrios, Carlos Escobar. (2009) Rosuvastatin along the cardiovascular continuum: from JUPITER to AURORA. Expert Review of Cardiovascular Therapy 7:11, 1317-1327
CrossRef806
Eric P Cohen, Jean-Marie Krzesinski. (2009) C-reactive protein and dialysis access. Kidney International 76:10, 1025-1026
CrossRef807
Alanna Morris, Keith C. Ferdinand. (2009) Patients With Hypertension and the Cardiometabolic Syndrome: The Potential Impact of Inflammatory Biomarkers. The Journal of Clinical Hypertension 11:11, 690-693
CrossRef808
László Márk, András Katona. (2009) A lipidcélértékektől a JUPITER vizsgálatig. Az irányelvekben előírt lipidszintek elérésének jelentősége és a gyakorlat hiányosságai. Orvosi Hetilap 150:44, 2012-2018
CrossRef809
A. S. Wierzbicki. (2009) Hot and bothered: C-reactive protein, inflammation and atherosclerosis. International Journal of Clinical Practice 63:11, 1550-1553
CrossRef810
William J. Kostis, John B. Kostis. (2009) Age-Neutral Guidelines for the Primary Prevention of Cardiovascular Disease. The Journal of Clinical Hypertension 11:11, 644-645
CrossRef811
Peter Kriekard, S. Michael Gharacholou, Eric D. Peterson. (2009) Primary and Secondary Prevention of Cardiovascular Disease in Older Adults: A Status Report. Clinics in Geriatric Medicine 25:4, 745-755
CrossRef812
Hiroyasu Iso, Renzhe Cui, Chigusa Date, Shogo Kikuchi, Akiko Tamakoshi. (2009) C-reactive protein levels and risk of mortality from cardiovascular disease in Japanese: The JACC Study. Atherosclerosis 207:1, 291-297
CrossRef813
Marshall A. Corson. (2009) Emerging inflammatory markers for assessing coronary heart disease risk. Current Cardiology Reports 11:6, 452-459
CrossRef814
Helen M. Colhoun, D. John Betteridge, Paul N. Durrington, Graham A. Hitman, H. Andrew W. Neil, Shona J. Livingstone, Valentine Charlton-Menys, David A. DeMicco, John H. Fuller. (2009) Effects of Atorvastatin on Kidney Outcomes and Cardiovascular Disease in Patients With Diabetes: An Analysis From the Collaborative Atorvastatin Diabetes Study (CARDS). American Journal of Kidney Diseases 54:5, 810-819
CrossRef815
Su Min Chang, Faisal Nabi, Jiaqiong Xu, Leif E. Peterson, Arup Achari, Craig M. Pratt, John J. Mahmarian. (2009) The Coronary Artery Calcium Score and Stress Myocardial Perfusion Imaging Provide Independent and Complementary Prediction of Cardiac Risk. Journal of the American College of Cardiology 54:20, 1872-1882
CrossRef816
Andrew D Calvin, Virend K Somers. (2009) Obstructive sleep apnea and cardiovascular disease. Current Opinion in Cardiology 24:6, 516-520
CrossRef817
Dan Lindholm, Beat C. Bornhauser, Laura Korhonen. (2009) Mylip makes an Idol turn into regulation of LDL receptor. Cellular and Molecular Life Sciences 66:21, 3399-3402
CrossRef818
J.C. Oldroyd, A. Heald, N. Bansal, A. Vyas, K. Siddals, M. Gibson, P. Clayton, J.K. Cruickshank. (2009) Inflammatory markers and growth in South Asian and European origin infants in Britain: The Manchester Children's Growth and Vascular Health Study. Atherosclerosis 207:1, 227-231
CrossRef819
Angel Vila-Córcoles. (2009) Vaccinate your child and save its grandparents from a heart attack? Current perspectives in antipneumococcal vaccination. Journal of Internal Medicine 266:5, 432-444
CrossRef820
George R. Saade. (2009) Pregnancy as a Window to Future Health. Obstetrics & Gynecology 114:5, 958-960
CrossRef821
Ali Abid, Ola Taha, William Nseir, Raymond Farah, Maria Grosovski, Nimer Assy. (2009) Soft drink consumption is associated with fatty liver disease independent of metabolic syndrome. Journal of Hepatology 51:5, 918-924
CrossRef822
S. H. Schirmer, A. M. Laan, M. Böhm, F. Mahfoud. (2009) Hotlines and clinical trial updates presented at the European Society of Cardiology Meeting 2009: data from RE-LY, PLATO, MADIT-CRT, PROTECT, SYNTAX, TRITON and more. Clinical Research in Cardiology 98:11, 691-699
CrossRef823
Joanna J. Wykrzykowska, Ascan Warnholtz, Peter Jaeger, Nick Curzen, Keith G. Oldroyd, Jean Philippe Collet, Jurrien M. Ten Berg, Tessa Rademaker, Dick Goedhart, Jurgen Lissens, Peter-Paul Kint, Patrick W. Serruys. (2009) Effect of clopidogrel discontinuation at 1 year after drug eluting stent placement on soluble CD40L, P-selectin and C-reactive protein levels: DECADES (Discontinuation Effect of Clopidogrel After Drug Eluting Stent): a multicenter, open-label study. Journal of Thrombosis and Thrombolysis 28:4, 410-417
CrossRef824
C. Morck, L. Olsen, C. Kurth, A. Persson, N. J. Storm, E. Svensson, J.-O. Jansson, M. Hellqvist, A. Enejder, N. J. Faergeman, M. Pilon. (2009) Statins inhibit protein lipidation and induce the unfolded protein response in the non-sterol producing nematode Caenorhabditis elegans. Proceedings of the National Academy of Sciences 106:43, 18285-18290
CrossRef825
Maryfran Sowers, Carrie A. Karvonen-Gutierrez, Riann Palmieri-Smith, Jon A. Jacobson, Yebin Jiang, James A. Ashton-Miller. (2009) Knee osteoarthritis in obese women with cardiometabolic clustering. Arthritis & Rheumatism 61:10, 1328-1336
CrossRef826
Inmaculada del Rincón. (2009) Atherothrombotic comorbidity in the rheumatic diseases. The evidence becomes clearer. What should clinicians do?. Arthritis & Rheumatism 61:10, 1284-1286
CrossRef827
Alan M Seif, Yong Hwang, Silvia S Pierangeli. (2009) Management of the antiphospholipid syndrome: new approaches. International Journal of Clinical Rheumatology 4:5, 533-549
CrossRef828
Ulla Petersson, Carl Johan Östgren, Lars Brudin, Peter M. Nilsson. (2009) A consultation-based method is equal to SCORE and an extensive laboratory-based method in predicting risk of future cardiovascular disease. European Journal of Cardiovascular Prevention & Rehabilitation 16:5, 536-540
CrossRef829
Jose Carlos Arévalo Lorido, Juana Carretero Gómez. (2009) Proteína C reactiva y grosor íntima-media carotídeo en pacientes con ictus isquémico aterotrombótico. Medicina Clínica 133:13, 496-500
CrossRef830
C. Constance. (2009) The good and the bad: what researchers have learned about dietary cholesterol, lipid management and cardiovascular disease risk since the Harvard Egg Study. International Journal of Clinical Practice 63, 9-14
CrossRef831
B.G. Nordestgaard, J. Zacho. (2009) Lipids, atherosclerosis and CVD risk: Is CRP an innocent bystander?. Nutrition, Metabolism and Cardiovascular Diseases 19:8, 521-524
CrossRef832
Ali A. Rizvi. (2009) Cytokine Biomarkers, Endothelial Inflammation, and Atherosclerosis in the Metabolic Syndrome: Emerging Concepts. The American Journal of the Medical Sciences 338:4, 310-318
CrossRef833
Mark Hamer, Yoichi Chida. (2009) Associations of very high C-reactive protein concentration with psychosocial and cardiovascular risk factors in an ageing population. Atherosclerosis 206:2, 599-603
CrossRef834
Abdulmaged M. Traish, Robert J. Feeley, Andre Guay. (2009) Mechanisms of obesity and related pathologies: Androgen deficiency and endothelial dysfunction may be the link between obesity and erectile dysfunction. FEBS Journal 276:20, 5755-5767
CrossRef835
Ishwarlal Jialal, Sridevi Devaraj. (2009) Statin Therapy for the Metabolic Syndrome: The Evidence Base. Metabolic Syndrome and Related Disorders 7:5, 393-396
CrossRef836
Jesse C. Stewart, Kevin L. Rand, Matthew F. Muldoon, Thomas W. Kamarck. (2009) A prospective evaluation of the directionality of the depression–inflammation relationship. Brain, Behavior, and Immunity 23:7, 936-944
CrossRef837
N. Nacasch, Z. Korzets. (2009) Worsening of hyperglycemia due to atorvastatin in a renal transplant patient. NDT Plus 2:5, 392-394
CrossRef838
Maria Drakopoulou, Konstantinos Toutouzas, Elli Stefanadi, Eleftherios Tsiamis, Dimitris Tousoulis, Christodoulos Stefanadis. (2009) Association of inflammatory markers with angiographic severity and extent of coronary artery disease. Atherosclerosis 206:2, 335-339
CrossRef839
D Kaur-Knudsen, S E Bojesen, B G Nordestgaard. (2009) Common polymorphisms in CYP2C9, subclinical atherosclerosis and risk of ischemic vascular disease in 52 000 individuals. The Pharmacogenomics Journal 9:5, 327-332
CrossRef840
J.A. Costa, E. Rodilla, F. Pérez-Lahiguera, A. Miralles, C. González, J.M. Pascual. (2009) Objetivos terapéuticos del colesterol LDL y cambios de la proteína C reactiva en pacientes de alto riesgo coronario. Revista Clínica Española 209:9, 415-423
CrossRef841
Maurizio Paciaroni, Julien Bogousslavsky. (2009) Statins and stroke prevention. Expert Review of Cardiovascular Therapy 7:10, 1231-1243
CrossRef842
Jacques Genest, Ruth McPherson, Jiri Frohlich, Todd Anderson, Norm Campbell, André Carpentier, Patrick Couture, Robert Dufour, George Fodor, Gordon A. Francis, Steven Grover, Milan Gupta, Robert A. Hegele, David C. Lau, Lawrence Leiter, Gary F. Lewis, Eva Lonn, G.B. John Mancini, Dominic Ng, Glen J. Pearson, Allan Sniderman, James A. Stone, Ehud Ur. (2009) 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendations. Canadian Journal of Cardiology 25:10, 567-579
CrossRef843
Wilbert S. Aronow. (2009) Statins Reduce Cardiovascular Events in Primary and Secondary Prevention Trials without Causing an Increase in Carcinoma. Journal of the American Geriatrics Society 57:10, 1942-1943
CrossRef844
Steffen U. Eisenhardt, Jonathon Habersberger, Karlheinz Peter. (2009) Monomeric C-Reactive Protein Generation on Activated Platelets: The Missing Link Between Inflammation and Atherothrombotic Risk. Trends in Cardiovascular Medicine 19:7, 232-237
CrossRef845
C. Constance. (2009) Le bon et le mauvais: nouvelles connaissances sur le cholestérol alimentaire, la maîtrise des lipides et le risque de maladies cardiovasculaires depuis la Harvard Egg Study. International Journal of Clinical Practice 63, 37-43
CrossRef846
Dipak Kotecha, Marcus Flather, Michele McGrady, John Pepper, Gishel New, Henry Krum, David Eccleston. (2009) Contemporary predictors of coronary artery disease in patients referred for angiography. European Journal of Cardiovascular Prevention & Rehabilitation1
CrossRef847
Børge G Nordestgaard. (2009) Does elevated C-reactive protein cause human atherothrombosis? Novel insights from genetics, intervention trials, and elsewhere. Current Opinion in Lipidology 20:5, 393-401
CrossRef848
B. Giannakopoulos, S. A. Krilis. (2009) How I treat the antiphospholipid syndrome. Blood 114:10, 2020-2030
CrossRef849
Madhuri M. Vasudevan, Christie M. Ballantyne. (2009) Advances in Lipid Testing and Management in Patients with Diabetes Mellitus. Endocrine Practice 15:6, 641-652
CrossRef850
Raphael See, Robert N. Piana. (2009) Achieving optimum lipid-lowering goals in patients with vascular disease. Current Cardiovascular Risk Reports 3:5, 323-330
CrossRef851
A. S. Wierzbicki. (2009) Storms, tea cups and the adverse effects of statins. International Journal of Clinical Practice 63:9, 1268-1270
CrossRef852
Heli Halava, Arja Helin-Salmivaara, Jouni Junnila, Risto Huupponen. (2009) Selective prescribing of simvastatin and atorvastatin by patient characteristics at treatment initiation over a 7-year period in Finland. European Journal of Clinical Pharmacology 65:9, 927-933
CrossRef853
Frederic S. Resnic, Akshay Desai. (2009) Highlights from the 58th Annual Scientific Sessions of the American College of Cardiology, March 28 to 31, 2009, Orlando, Florida. The Journal of Thoracic and Cardiovascular Surgery 138:3, 795-797
CrossRef854
John A Ambrose, Sundararajan Srikanth. (2009) Preventing future acute coronary events: is the target the so-called vulnerable plaque or the high-risk or vulnerable patient?. Current Opinion in Cardiology 24:5, 483-489
CrossRef855
Allan Sniderman, Ken Williams, Christa Cobbaert. (2009) ApoB versus non-HDL-C: What to do when they disagree. Current Atherosclerosis Reports 11:5, 358-363
CrossRef856
Seung Hwan Han, Ichiro Sakuma, Eak Kyun Shin, Kwang Kon Koh. (2009) Antiatherosclerotic and Anti-Insulin Resistance Effects of Adiponectin: Basic and Clinical Studies. Progress in Cardiovascular Diseases 52:2, 126-140
CrossRef857
Terje R. Pedersen. (2009) Lipid-lowering drugs and risk for cancer. Current Atherosclerosis Reports 11:5, 350-357
CrossRef858
Francisco AH Fonseca, Maria Cristina O Izar. (2009) Primary prevention of vascular events in patients with high levels of C-reactive protein: the JUPITER study. Expert Review of Cardiovascular Therapy 7:9, 1041-1056
CrossRef859
Robert P. Hebbel*. (2009) The systems biology-based argument for taking a bold step in chemoprophylaxis of sickle vasculopathy. American Journal of Hematology 84:9, 543-545
CrossRef860
Stella S Daskalopoulou. (2009) When statin therapy stops: implications for the patient. Current Opinion in Cardiology 24:5, 454-460
CrossRef861
Diane George, Doruk Erkan. (2009) Antiphospholipid Syndrome. Progress in Cardiovascular Diseases 52:2, 115-125
CrossRef862
Oliver Zimmermann, Magdalena Bienek-Ziolkowski, Bettina Wolf, Martin Vetter, Regine Baur, Volker Mailänder, Vinzenz Hombach, Jan Torzewski. (2009) Myocardial inflammation and non-ischaemic heart failure: is there a role for C-reactive protein?. Basic Research in Cardiology 104:5, 591-599
CrossRef863
David Preiss, Naveed Sattar. (2009) Authors’ reply to: Statin therapy as the fundamental therapy for cardiovascular prevention: be careful. Clinical Endocrinology 71:3, 456-457
CrossRef864
Mary M. McDermott, Donald M. Lloyd-Jones. (2009) The Role of Biomarkers and Genetics in Peripheral Arterial Disease. Journal of the American College of Cardiology 54:14, 1228-1237
CrossRef865
M. S. Kostapanos, H. J. Milionis, A.-D. Agouridis, C. V. Rizos, M. S. Elisaf. (2009) Rosuvastatin treatment is associated with an increase in insulin resistance in hyperlipidaemic patients with impaired fasting glucose. International Journal of Clinical Practice 63:9, 1308-1313
CrossRef866
Jens Metrikat, Marlies Albrecht, Peter Maya-Pelzer, Jan R. Ortlepp. (2009) Physical fitness is associated with lower inflammation, even in individuals with high cholesterol – An alternative to statin therapy?. CVD Prevention and Control 4:3, 149-156
CrossRef867
Leslee J. Shaw, James K. Min, Matthew Budoff, Heidi Gransar, Alan Rozanski, Sean W. Hayes, John D. Friedman, Romalisa Miranda, Nathan D. Wong, Daniel S. Berman. (2009) Induced Cardiovascular Procedural Costs and Resource Consumption Patterns After Coronary Artery Calcium Screening. Journal of the American College of Cardiology 54:14, 1258-1267
CrossRef868
Paul Muntner, Devin Mann, Louai Razzouk, Scott Klarenbach, Braden Manns, Marcello Tonelli, Michael E. Farkouh. (2009) Is Measuring C-Reactive Protein Useful for Guiding Treatment in Women ≥60 Years and Men ≥50 Years of Age?. The American Journal of Cardiology 104:3, 354-358
CrossRef869
Anju Nohria, Adnan Prsic, Ping-Yen Liu, Ryuji Okamoto, Mark A. Creager, Andrew Selwyn, James K. Liao, Peter Ganz. (2009) Statins inhibit Rho kinase activity in patients with atherosclerosis. Atherosclerosis 205:2, 517-521
CrossRef870
Brandon T. Larsen, David D. Gutterman. (2009) C-reactive protein: A multipronged assailant onendothelium-dependent vasodilation. Journal of Molecular and Cellular Cardiology 47:2, 177-179
CrossRef871
Amit V. Khera, Daniel J. Rader. (2009) Discovery and Validation of New Molecular Targets in Treating Dyslipidemia: The Role of Human Genetics. Trends in Cardiovascular Medicine 19:6, 195-201
CrossRef872
Fred A. Kummerow. (2009) The negative effects of hydrogenated trans fats and what to do about them. Atherosclerosis 205:2, 458-465
CrossRef873
Louai Razzouk, Michael E. Farkouh. (2009) Imaging outcomes in cardiovascular clinical trials. Nature Reviews Cardiology 6:8, 524-531
CrossRef874
Toshimitsu Nozaki, Seigo Sugiyama, Hidenobu Koga, Koichi Sugamura, Keisuke Ohba, Yasushi Matsuzawa, Hitoshi Sumida, Kunihiko Matsui, Hideaki Jinnouchi, Hisao Ogawa. (2009) Significance of a Multiple Biomarkers Strategy Including Endothelial Dysfunction to Improve Risk Stratification for Cardiovascular Events in Patients at High Risk for Coronary Heart Disease. Journal of the American College of Cardiology 54:7, 601-608
CrossRef875
J. H. O'Keefe, M. D. Carter, C. J. Lavie. (2009) Primary and Secondary Prevention of Cardiovascular Diseases: A Practical Evidence-Based Approach. Mayo Clinic Proceedings 84:8, 741-757
CrossRef876
Mandana Nikpour, Murray B. Urowitz, Dafna D. Gladman. (2009) Epidemiology of atherosclerosis in systemic lupus erythematosus. Current Rheumatology Reports 11:4, 248-254
CrossRef877
Andrew D. Calvin, Felipe N. Albuquerque, Francisco Lopez-Jimenez, Virend K. Somers. (2009) Obstructive Sleep Apnea, Inflammation, and the Metabolic Syndrome. Metabolic Syndrome and Related Disorders 7:4, 271-277
CrossRef878
C. Farrelly. (2009) Towards a more inclusive vision of the medical sciences. QJM 102:8, 579-582
CrossRef879
Germano Di Sciascio, Giuseppe Patti, Vincenzo Pasceri, Achille Gaspardone, Giuseppe Colonna, Antonio Montinaro. (2009) Efficacy of Atorvastatin Reload in Patients on Chronic Statin Therapy Undergoing Percutaneous Coronary Intervention. Journal of the American College of Cardiology 54:6, 558-565
CrossRef880
Vincent Prinz, Matthias Endres. (2009) The Acute (Cerebro)Vascular Effects of Statins. Anesthesia & Analgesia 109:2, 572-584
CrossRef881
Erin D. Michos, Roger S. Blumenthal. (2009) Reply. Journal of the American College of Cardiology 54:8, 744-745
CrossRef882
Stephan Gielen, Marcus Sandri, Gerhard Schuler, Daniel Teupser. (2009) Risk factor management: antiatherogenic therapies. European Journal of Cardiovascular Prevention & Rehabilitation 16:Supplement 1, S29-S36
CrossRef883
Bernhard R Winkelmann, Klaus von Holt, Martin Unverdorben. (2009) Smoking and atherosclerotic cardiovascular disease: Part I: Atherosclerotic disease process. Biomarkers in Medicine 3:4, 411-428
CrossRef884
E. GRAD, M. GOLOMB, N. KOROUKHOV, J. A. LAWSON, C. LOTAN, G. A. FITZGERALD, H. D. DANENBERG. (2009) Aspirin reduces the prothrombotic activity of C-reactive protein. Journal of Thrombosis and Haemostasis 7:8, 1393-1400
CrossRef885
Andreza O. Santos, Francisco A.H. Fonseca, Simone M. Fischer, Carlos M.C. Monteiro, Sergio A.B. Brandão, Rui M.S. Póvoa, Maria T.N. Bombig, Antonio C. Carvalho, Andréa M. Monteiro, Eduardo Ramos, Magnus Gidlund, Antonio M. Figueiredo Neto, Maria C.O. Izar. (2009) High circulating autoantibodies against human oxidized low-density lipoprotein are related to stable and lower titers to unstable clinical situation. Clinica Chimica Acta 406:1-2, 113-118
CrossRef886
Travis W. Hein, Erion Qamirani, Yi Ren, Lih Kuo. (2009) C-reactive protein impairs coronary arteriolar dilation to prostacyclin synthase activation: Role of peroxynitrite. Journal of Molecular and Cellular Cardiology 47:2, 196-202
CrossRef887
Allan Sniderman. (2009) Targets for LDL-lowering therapy. Current Opinion in Lipidology 20:4, 282-287
CrossRef888
Kwang Kon Koh, Michael J. Quon. (2009) The importance of considering alternative or combination strategies for lowering LDL-C. International Journal of Cardiology 136:2, 115-119
CrossRef889
(2009) Rosuvastatin in Patients Undergoing Hemodialysis. New England Journal of Medicine 361:1, 93-95
Full Text890
Stephen D. Wiviott, Satishkumar Mohanavelu, Joel S. Raichlen, Valerie A. Cain, Steven E. Nissen, Peter Libby. (2009) Safety and Efficacy of Achieving Very Low Low-Density Lipoprotein Cholesterol Levels With Rosuvastatin 40 mg Daily (from the ASTEROID Study). The American Journal of Cardiology 104:1, 29-35
CrossRef891
Carl J. Lavie, Mandeep R. Mehra. (2009) Statins and Advanced Heart Failure-Alive But Barely Breathing After CORONA and GISSI-HF. Congestive Heart Failure 15:4, 157-158
CrossRef892
Z. L. S. Brookes, C. C. McGown, C. S. Reilly. (2009) Statins for all: the new premed?. British Journal of Anaesthesia 103:1, 99-107
CrossRef893
A. S. Wierzbicki, T. M. Reynolds. (2009) Vascular risk screening: possible or too much, too soon?. International Journal of Clinical Practice 63:7, 989-996
CrossRef894
Yannick Le Manach, Pierre Coriat, Charles D. Collard, Bernhard Riedel. (2009) Perioperative Statin Therapy May Be Implicated in a Wide Array of Drug-Drug Interactions. Anesthesiology 111:1, 205-206
CrossRef895
Paul M. Ridker. (2009) Moving toward new statin guidelines in a post-JUPITER world: Principles to consider. Current Atherosclerosis Reports 11:4, 249-256
CrossRef896
PAUL M. RIDKER. (2009) Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT). Journal of Thrombosis and Haemostasis 7, 332-339
CrossRef897
Robert Rosenstein, David Parra. (2009) Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial. The Lancet 374:9683, 25
CrossRef898
Masayuki Shimano, Rei Shibata, Yasuya Inden, Naoki Yoshida, Tomohiro Uchikawa, Yukiomi Tsuji, Toyoaki Murohara. (2009) Reactive oxidative metabolites are associated with atrial conduction disturbance in patients with atrial fibrillation. Heart Rhythm 6:7, 935-940
CrossRef899
Johan Sundström. (2009) Troponin and heart failure: an early warning system worth listening to?. Future Cardiology 5:4, 321-324
CrossRef900
Vincent E. Friedewald, Kenneth S. Kornman, James D. Beck, Robert Genco, Allison Goldfine, Peter Libby, Steven Offenbacher, Paul M. Ridker, Thomas E. Van Dyke, William C. Roberts. (2009) The American Journal of Cardiology and Journal of Periodontology Editors' Consensus: Periodontitis and Atherosclerotic Cardiovascular Disease ♦. Journal of Periodontology 80:7, 1021-1032
CrossRef901
Vincent E. Friedewald, Kenneth S. Kornman, James D. Beck, Robert Genco, Allison Goldfine, Peter Libby, Steven Offenbacher, Paul M. Ridker, Thomas E. Van Dyke, William C. Roberts. (2009) The American Journal of Cardiology and Journal of Periodontology Editors' Consensus: Periodontitis and Atherosclerotic Cardiovascular Disease. The American Journal of Cardiology 104:1, 59-68
CrossRef902
Juliana Caballero Güeto, Miguel Ángel Ulecia Martínez, Emilio González Cocina, Manuel Lagares Carballo. (2009) Estrategias adecuadas en la enfermedad cardiovascular. Los pacientes de alto riesgo. Medicina Clínica 133:7, 261-271
CrossRef903
Anna-Maria Kampoli, Dimitris Tousoulis, Charalambos Antoniades, Gerasimos Siasos, Christodoulos Stefanadis. (2009) Biomarkers of premature atherosclerosis. Trends in Molecular Medicine 15:7, 323-332
CrossRef904
J Segura, LM Ruilope. (2009) Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial. The Lancet 374:9683, 26
CrossRef905
Michael Ward, Matthew H. Liang, Thomas Burns, Gurkirpal Singh. (2009) RA treatment study group: Improvement in RA management. Joint Bone Spine 76:4, 435-437
CrossRef906
Bill Lands. (2009) Planning primary prevention of coronary disease. Current Atherosclerosis Reports 11:4, 272-280
CrossRef907
Marc E. Weksler, Graham Pawelec, Claudio Franceschi. (2009) Immune therapy for age-related diseases. Trends in Immunology 30:7, 344-350
CrossRef908
Stephen S. Hecht, Fekadu Kassie, Dorothy K. Hatsukami. (2009) Chemoprevention of lung carcinogenesis in addicted smokers and ex-smokers. Nature Reviews Cancer 9:7, 476-488
CrossRef909
D. Steinberg, J. L. Witztum. (2009) Inhibition of PCSK9: A powerful weapon for achieving ideal LDL cholesterol levels. Proceedings of the National Academy of Sciences 106:24, 9546-9547
CrossRef910
Beatrice A. Golomb. (2009) Metabolic Syndrome. Journal of the American College of Cardiology 53:24, 2280-2282
CrossRef911
Sridevi Devaraj, Uma Singh, Ishwarlal Jialal. (2009) Human C-reactive protein and the metabolic syndrome. Current Opinion in Lipidology 20:3, 182-189
CrossRef912
Edward J. Mills, Philip J. Devereaux. (2009) Reply. Journal of the American College of Cardiology 53:24, 2312-2313
CrossRef913
Hooman Hennessey, Nadia Afara, Sasha Omanovic, Ante L. Padjen. (2009) Electrochemical investigations of the interaction of C-reactive protein (CRP) with a CRP antibody chemically immobilized on a gold surface. Analytica Chimica Acta 643:1-2, 45-53
CrossRef914
J. R. Ward, H. L. Wilson, S. E. Francis, D. C. Crossman, I. Sabroe. (2009) Translational Mini-Review Series on Immunology of Vascular Disease: Inflammation, infections and Toll-like receptors in cardiovascular disease. Clinical & Experimental Immunology 156:3, 386-394
CrossRef915
Amgad N. Makaryus, Philippe Akhrass, Samy I. McFarlane. (2009) Treatment of hypertension in metabolic syndrome: Implications of recent clinical trials. Current Diabetes Reports 9:3, 229-237
CrossRef916
Ishwarlal Jialal, Stacey L. Abby, Soamnauth Misir, Sukumar Nagendran. (2009) Concomitant Reduction in Low-Density Lipoprotein Cholesterol and Glycated Hemoglobin With Colesevelam Hydrochloride in Patients With Type 2 Diabetes: A Pooled Analysis. Metabolic Syndrome and Related Disorders 7:3, 255-258
CrossRef917
José L. Martín-Ventura, Luis M. Blanco-Colio, José Tuñón, Begoña Muñoz-García, Julio Madrigal-Matute, Juan A. Moreno, Melina Vega de Céniga, Jesús Egido. (2009) Biomarcadores en la medicina cardiovascular. Revista Española de Cardiología 62:6, 677-688
CrossRef918
M. L. Bots, M. K. Palmer, S. Dogan, Y. Plantinga, J. S. Raichlen, G. W. Evans, D. H. O’Leary, D. E. Grobbee, J. R. Crouse III, . (2009) Intensive lipid lowering may reduce progression of carotid atherosclerosis within 12 months of treatment: the METEOR study. Journal of Internal Medicine 265:6, 698-707
CrossRef919
Sarah Rosner Preis, Shih-Jen Hwang, Caroline S. Fox, Joseph M. Massaro, Daniel Levy, Udo Hoffmann, Christopher J. O'Donnell. (2009) Eligibility of Individuals With Subclinical Coronary Artery Calcium and Intermediate Coronary Heart Disease Risk for Reclassification (from the Framingham Heart Study). The American Journal of Cardiology 103:12, 1710-1715
CrossRef920
Fabrizio Montecucco, François Mach. (2009) Update on statin-mediated anti-inflammatory activities in atherosclerosis. Seminars in Immunopathology 31:1, 127-142
CrossRef921
Jeremiah P Depta, Richard A Krasuski. (2009) Therapy and clinical trials. Current Opinion in Lipidology 20:3, 262-263
CrossRef922
(2009) Plenary Lecture Abstracts. Clinical Chemistry and Laboratory Medicine 47:S1, S5-S6
CrossRef923
Patrick M Moriarty. (2009) Association of ApoE and HDL-C with cardiovascular and cerebrovascular disease: potential benefits of LDL-apheresis therapy. Clinical Lipidology 4:3, 311-329
CrossRef924
Zahi A. Fayad, Louai Razzouk, Karen C. Briley-Saebo, Venkatesh Mani. (2009) Iron Oxide Magnetic Resonance Imaging for Atherosclerosis Therapeutic Evaluation. Journal of the American College of Cardiology 53:22, 2051-2052
CrossRef925
Michael Aviram. (2009) Hyperlipidaemia and cardiovascular disease: inflammation and oxidative stress in diabetic patients. Current Opinion in Lipidology 20:3, 258-259
CrossRef926
Shan Jiang, Yuqian Bao, Xuhong Hou, Qichen Fang, Chen Wang, Jiemin Pan, Yuhua Zuo, Wenhong Zhong, Kunsan Xiang, Weiping Jia. (2009) Serum C-Reactive Protein and Risk of Cardiovascular Events in Middle-Aged and Older Chinese Population. The American Journal of Cardiology 103:12, 1727-1731
CrossRef927
Richard I. Levin. (2009) Arginine and Old MACE. Journal of the American College of Cardiology 53:22, 2068-2069
CrossRef928
Viviane Z. Rocha, Peter Libby. (2009) Obesity, inflammation, and atherosclerosis. Nature Reviews Cardiology 6:6, 399-409
CrossRef929
Billie-Jean Martin, Todd J. Anderson. (2009) Risk prediction in cardiovascular disease: The prognostic significance of endothelial dysfunction. Canadian Journal of Cardiology 25, 15A-20A
CrossRef930
Fabrizio Montecucco, François Mach. (2009) Atherosclerosis is an inflammatory disease. Seminars in Immunopathology 31:1, 1-3
CrossRef931
Paolo Calabrò, Enrica Golia, Edward T. H. Yeh. (2009) CRP and the risk of atherosclerotic events. Seminars in Immunopathology 31:1, 79-94
CrossRef932
David Preiss, Naveed Sattar. (2009) Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence. Clinical Endocrinology 70:6, 815-828
CrossRef933
Paul M. Ridker, Vincent E. Friedewald, Michael H. Davidson, James T. Willerson, William C. Roberts. (2009) The Editor's Roundtable: The JUPITER Trial—Initial Results and Clinical Implications. The American Journal of Cardiology 103:10, 1417-1425
CrossRef934
Alexandra Calmy, Angèle Gayet-Ageron, Fabrizio Montecucco, Alain Nguyen, Francois Mach, Fabienne Burger, Sasiwimol Ubolyam, Andrew Carr, Kiat Ruxungtham, Bernard Hirschel, Jintanat Ananworanich. (2009) HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial. AIDS 23:8, 929-939
CrossRef935
Guy W. Ll Lloyd. (2009) Preventive cardiology and cardiac rehabilitation programmes in women. Maturitas 63:1, 28-33
CrossRef936
Gianna Fabbri, Aldo Pietro Maggioni. (2009) Cardiovascular risk reduction: What do recent trials with rosuvastatin tell us?. Advances in Therapy 26:5, 469-487
CrossRef937
Paul M Ridker, Daniel H. Solomon. (2009) Should patients with rheumatoid arthritis receive statin therapy?. Arthritis & Rheumatism 60:5, 1205-1209
CrossRef938
Joseph S. Alpert. (2009) Should Physicians Measure High-sensitivity C-reactive Protein Levels to Assess Coronary Heart Disease Risk?. The American Journal of Medicine 122:5, 405-406
CrossRef939
Adam M. Rogers, Michael G. Shlipak. (2009) C-Reactive Protein, Statins, and Cardiovascular Risk: What Can JUPITER Teach Us?. American Journal of Kidney Diseases 53:5, 737-740
CrossRef940
A. S. Wierzbicki. (2009) SEARCHing for JUPITER: starry-eyed optimism is not warranted. International Journal of Clinical Practice 63:5, 685-688
CrossRef941
William Clifford Roberts. (2009) Evaluating Lipid-Lowering Trials in the Twenty-First Century. The American Journal of Cardiology 103:9, 1325-1328
CrossRef942
Suguru Yamamoto, Valentina Kon. (2009) Mechanisms for increased cardiovascular disease in chronic kidney dysfunction. Current Opinion in Nephrology and Hypertension 18:3, 181-188
CrossRef943
Larry A. Allen, Christopher B. Granger. (2009) Risk assessment in the genomic era: Are we missing the low-hanging fruit?. American Heart Journal 157:5, 799-801
CrossRef944
Kavita Sharma, Michael J. Blaha, Roger S. Blumenthal, Kiran Musunuru. (2009) Clinical and Research Applications of Carotid Intima-Media Thickness. The American Journal of Cardiology 103:9, 1316-1320
CrossRef945
Ralph AH Stewart. (2009) Predicting benefit from statins by C-reactive protein, LDL-cholesterol or absolute cardiovascular risk. Future Cardiology 5:3, 231-236
CrossRef946
P. Kar, D. Laight, H. K. Rooprai, K. M. Shaw, M. Cummings. (2009) Effects of grape seed extract in Type 2 diabetic subjects at high cardiovascular risk: a double blind randomized placebo controlled trial examining metabolic markers, vascular tone, inflammation, oxidative stress and insulin sensitivity. Diabetic Medicine 26:5, 526-531
CrossRef947
Pierre Amarenco, Julien Labreuche. (2009) Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. The Lancet Neurology 8:5, 453-463
CrossRef948
Glynn, Robert J., Danielson, Eleanor, Fonseca, Francisco A.H., Genest, Jacques, Gotto, Antonio M. Jr., Kastelein, John J.P., Koenig, Wolfgang, Libby, Peter, Lorenzatti, Alberto J., MacFadyen, Jean G., Nordestgaard, Børge G., Shepherd, James, Willerson, James T., Ridker, Paul M, . (2009) A Randomized Trial of Rosuvastatin in the Prevention of Venous Thromboembolism. New England Journal of Medicine 360:18, 1851-1861
Full Text949
Fellström, Bengt C., Jardine, Alan G., Schmieder, Roland E., Holdaas, Hallvard, Bannister, Kym, Beutler, Jaap, Chae, Dong-Wan, Chevaile, Alejandro, Cobbe, Stuart M., Grönhagen-Riska, Carola, De Lima, José J., Lins, Robert, Mayer, Gert, McMahon, Alan W., Parving, Hans-Henrik, Remuzzi, Giuseppe, Samuelsson, Ola, Sonkodi, Sandor, Sci., D.Süleymanlar, Gultekin, Tsakiris, Dimitrios, Tesar, Vladimir, Todorov, Vasil, Wiecek, Andrzej, Wüthrich, Rudolf P., Gottlow, Mattis, Johnsson, Eva, Zannad, Faiez, . (2009) Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis. New England Journal of Medicine 360:14, 1395-1407
Full Text950
Hicham Berrougui, Abdelouahed Khalil. (2009) Age-Associated Decrease of High-Density Lipoprotein-Mediated Reverse Cholesterol Transport Activity. Rejuvenation Research 12:2, 117-126
CrossRef951
Paul M Ridker, Eleanor Danielson, Francisco AH Fonseca, Jacques Genest, Antonio M Gotto, John JP Kastelein, Wolfgang Koenig, Peter Libby, Alberto J Lorenzatti, Jean G MacFadyen, Børge G Nordestgaard, James Shepherd, James T Willerson, Robert J Glynn. (2009) Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. The Lancet 373:9670, 1175-1182
CrossRef952
E. A. Stein. (2009) Low-Density Lipoprotein Cholesterol Reduction and Prevention of Cardiovascular Disease. Mayo Clinic Proceedings 84:4, 307-309
CrossRef953
John D. Baxter, Paul Webb. (2009) Thyroid hormone mimetics: potential applications in atherosclerosis, obesity and type 2 diabetes. Nature Reviews Drug Discovery 8:4, 308-320
CrossRef954
Javier Sanz, Pedro R. Moreno, Valentin Fuster. (2009) The Year in Atherothrombosis. Journal of the American College of Cardiology 53:15, 1326-1337
CrossRef955
M. CUSHMAN. (2009) A new indication for statins to prevent venous thromboembolism? Not yet. Journal of Thrombosis and Haemostasis 7:4, 511-513
CrossRef956
Angela D Armendariz, Ronald M Krauss. (2009) Hepatic nuclear factor 1-α: inflammation, genetics, and atherosclerosis. Current Opinion in Lipidology 20:2, 106-111
CrossRef957
Jean-Pierre Després. (2009) Bringing JUPITER down to earth. The Lancet 373:9670, 1147-1148
CrossRef958
Dena E. Rifkin, Mark J. Sarnak. (2009) Does Inflammation Fuel the Fire in CKD?. American Journal of Kidney Diseases 53:4, 572-575
CrossRef959
F. J. Al Badarin, I. J. Kullo, S. L. Kopecky, R. J. Thomas. (2009) Impact of Ezetimibe on Atherosclerosis: Is the Jury Still Out?. Mayo Clinic Proceedings 84:4, 353-361
CrossRef960
Kota J. Reddy, Manmeet Singh, Joey R. Bangit, Richard R. Batsell. (2009) The role of lipoprotein-associated phospholipase A2 on cardiovascular disease risk assessment and plaque rupture: a clinical review. Journal of Clinical Lipidology 3:2, 85-93
CrossRef961
Bijal M Shah, Robert Kemp, Michael Clearfield. (2009) Using statins to treat ‘healthy’ patients: are we there yet?. Expert Review of Pharmacoeconomics & Outcomes Research 9:2, 103-105
CrossRef962
Salim Yusuf, Eva Lonn, Jackie Bosch. (2009) Lipid lowering for primary prevention. The Lancet 373:9670, 1152-1155
CrossRef963
D. G. Karalis. (2009) Intensive Lowering of Low-Density Lipoprotein Cholesterol Levels for Primary Prevention of Coronary Artery Disease. Mayo Clinic Proceedings 84:4, 345-352
CrossRef964
John G.T. Augoustides, Harish Ramakrishna. (2009) Recent Advances in the Management of Coronary Artery Disease: Highlights From the Literature. Journal of Cardiothoracic and Vascular Anesthesia 23:2, 259-265
CrossRef965
Ewa Dembowski, Michael H Davidson. (2009) Statin and ezetimibe combination therapy in cardiovascular disease. Current Opinion in Endocrinology, Diabetes and Obesity 16:2, 183-188
CrossRef966
Khalid Alwaili, Khalid Alrasadi, Zuhier Awan, Jacques Genest. (2009) Approach to the diagnosis and management of lipoprotein disorders. Current Opinion in Endocrinology, Diabetes and Obesity 16:2, 132-140
CrossRef967
Sunita Dodani, Deanna G. Grice, Sunil Joshi. (2009) Is HDL function as important as HDL quantity in the coronary artery disease risk assessment?. Journal of Clinical Lipidology 3:2, 70-77
CrossRef968
Mariann Harangi, Peter Szodoray, György Paragh. (2009) Atherosclerosis: a complex interplay of inflammatory processes. Clinical Lipidology 4:2, 167-187
CrossRef969
Kritek, Patricia, Campion, Edward W., . (2009) JUPITER Clinical Directions — Polling Results. New England Journal of Medicine 360:10,
Full Text970
(2009) Rosuvastatin in Patients with Elevated C-Reactive Protein. New England Journal of Medicine 360:10, 1038-1042
Full Text971
Erin D. Michos, Roger S. Blumenthal. (2009) Prevalence of Low Low-Density Lipoprotein Cholesterol With Elevated High Sensitivity C-Reactive Protein in the U.S.. Journal of the American College of Cardiology 53:11, 931-935
CrossRef972
Steven E. Nissen. (2009) The Jupiter trial: Key findings, controversies, and implications. Current Cardiology Reports 11:2, 81-82
CrossRef973
Mouhannad M Sadek, Taleen Haddad, Haissam Haddad. (2009) The role of statins in chronic heart failure. Current Opinion in Cardiology 24:2, 167-171
CrossRef974
M. Rizzo, K. Berneis, G. A. Spinas, G. B. Rini, N. K. Kapur. (2009) Quantitative and qualitative effects of rosuvastatin on LDL-cholesterol: what is the clinical significance?. International Journal of Clinical Practice 63:3, 478-485
CrossRef975
Doruk Erkan, Michael D Lockshin. (2009) New approaches for managing antiphospholipid syndrome. Nature Clinical Practice Rheumatology 5:3, 160-170
CrossRef976
Shaista Malik, Nathan D Wong. (2009) Metabolic syndrome, cardiovascular risk and screening for subclinical atherosclerosis. Expert Review of Cardiovascular Therapy 7:3, 273-280
CrossRef977
Valentin Fuster, Sameer Bansilal. (2009) JUPITER strikes earth. Nature Clinical Practice Cardiovascular Medicine 6:3, 159-159
CrossRef978
S-A Price, M Evans. (2009) The JUPITER trial and its implications for patients with diabetes. Practical Diabetes International 26:2, 50-51
CrossRef979
G. Jackson, L. Citrome. (2009) JUPITER: wake up and smell the coffee - The absolute and relative merits of statin use. International Journal of Clinical Practice 63:3, 347-348
CrossRef980
Peter M. Kang, Marc Ruel, Frank W. Sellke. (2009) Highlights from the 2008 American Heart Association Scientific Session. The Journal of Thoracic and Cardiovascular Surgery 137:3, 791-794
CrossRef981
Philip R. Liebson. (2009) JUPITER and ACCOMPLISH. Preventive Cardiology 12:2, 114-119
CrossRef982
K. Graf. (2009) Die JUPITER-Studie: Primärprävention bei erhöhtem C-reaktivem Protein. Der Kardiologe 3:1, 35-36
CrossRef983
Philippa J. Delahoy, Dianna J. Magliano, Kate Webb, Mendel Grobler, Danny Liew. (2009) The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: An updated meta-analysis. Clinical Therapeutics 31:2, 236-244
CrossRef984
Elizabeth A Platz. (2009) Does statin use affect the risk of developing prostate cancer?. Nature Clinical Practice Urology 6:2, 70-71
CrossRef985
Javier Bermejo, Javier Segovia, Fernando Alfonso. (2009) Resumen de los ensayos clínicos presentados en las Sesiones Científicas Anuales de la American Heart Association (New Orleans, Estados Unidos, 8-12 de noviembre de 2008). Revista Española de Cardiología 62:2, 178-187
CrossRef986
(2009) Journal Club. Kidney International 75:3, 251-252
CrossRef987
M. M. Miner. (2009) Erectile Dysfunction and the "Window of Curability": A Harbinger of Cardiovascular Events. Mayo Clinic Proceedings 84:2, 102-104
CrossRef988
I. Jialal, S. Devaraj. (2009) Jupiter to Earth: CRP Promotes Atherothrombosis. Metabolic Syndrome and Related Disorders 7:1, 1-3
CrossRef989
Larry B Goldstein. (2009) JUPITER and the world of stroke medicine. The Lancet Neurology 8:2, 129-131
CrossRef990
Helmut Gohlke, Christian Albus, Detlef Bernd Gysan, Harry W. Hahmann, Peter Mathes. (2009) Cardiovascular Prevention in Clinical Practice (ESC and German Guidelines 2007). Herz 34:1, 4-14
CrossRef991
(2009) The Statins in Preventive Cardiology. New England Journal of Medicine 360:5, 541-542
Full Text992
A. Rabinstein. (2009) Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. Yearbook of Neurology and Neurosurgery 2009, 25-26
CrossRef993
P.R. Gajendragadkar, D.G. Cooper, S.R. Walsh, T.Y. Tang, J.R. Boyle, P.D. Hayes. (2009) Novel uses for statins in surgical patients. International Journal of Surgery 7:4, 285-290
CrossRef994
B.J. Gersh. (2009) Rosuvastation to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. Yearbook of Cardiology 2009, 282-284
CrossRef995
Hyo-Jin Lee, Sung-Ho Her, Yun-Sun Im, Kang-Yeon Won, Sun-Hong Yoo, Dong-Bin Kim, Dong-Il Shin, Pum-Joon Kim, Ki-Bae Seung, Jae-Hyung Kim, Keon-Yeop Kim. (2009) Significance of Inflammatory Markers in Diabetic Patients with Stable Coronary Artery Disease. The Korean Journal of Internal Medicine 24:3, 212
CrossRef996
Takahide Kohro, Tsutomu Yamazaki. (2009) Mechanism of Statin-Induced Myopathy Investigated Using Microarray Technology. Journal of Atherosclerosis and Thrombosis 16:1, 30-32
CrossRef997
B.J. Gersh. (2009) Genetically Elevated C-Reactive Protein and Ischemic Vascular Disease. Yearbook of Cardiology 2009, 328-330
CrossRef998
Helge Möllmann, Holger Nef, Michael Böhm, Ulrich Laufs. (2009) Highlights of the hotline sessions presented at the scientific sessions 2008 of the American Heart Association. Clinical Research in Cardiology 98:1, 1-7
CrossRef999
Ken-ichi Hirano. (2009) A Novel Clinical Entity: Triglyceride Deposit Cardiomyovasculopathy Implications and Perspectives from ''Obesity of the Heart''. Journal of Atherosclerosis and Thrombosis 16:5, 702-705
CrossRef1000
Jerry R. Colca, Rolf F. Kletzien. 2009. Current and Emerging Strategies for Treating Dyslipidemia and Macrovascular Disease. , 237-251.
CrossRef1001
Ezra A. Amsterdam, C. Tissa Kappagoda. (2009) Current Approaches to the Challenge of Coronary Heart Disease Risk Assessment: C-Reactive Protein Mania and Imaging-itis?. Preventive Cardiology 12:1, 1-2
CrossRef1002
Anders Hovland, Randolf Hardersen, Joe Sexton, Tom Eirik Mollnes, Knut Tore Lappegård. (2009) Different inflammatory responses induced by three LDL-lowering apheresis columns. Journal of Clinical Apheresis 24:6, 247-253
CrossRef1003
Konstantinos Tziomalos, Vasilios G. Athyros, Asterios Karagiannis, Dimitri P. Mikhailidis. (2009) JUPITER: major implications for vascular risk assessment. Current Medical Research and Opinion 25:1, 133-137
CrossRef1004
G.L. Moneta. (2009) Genetically Elevated C-Reactive Protein and Ischemic Vascular Disease. Yearbook of Vascular Surgery 2009, 3-4
CrossRef1005
Ki-Hoon Han. (2009) Control of Dyslipidemia. Journal of the Korean Medical Association 52:3, 299
CrossRef1006
Sandra J. Lewis. (2009) Prevention and Treatment of Atherosclerosis: A Practitioner's Guide for 2008. The American Journal of Medicine 122:1, S38-S50
CrossRef1007
Andrew D. Calvin, Jeffrey B. Geske, Malcolm R. Bell. (2008) 69-Year-Old Woman With Rapid Heartbeat. Mayo Clinic Proceedings 83:12, 1392-1395
CrossRef1008
Hlatky, Mark A., . (2008) Expanding the Orbit of Primary Prevention — Moving beyond JUPITER. New England Journal of Medicine 359:21, 2280-2282
Full Text1009
Katharine Sanderson. (2008) Should healthy people take statins too?. Nature
CrossRef1010
R. S Vasan. (2008) Commentary: C-reactive protein and risk prediction--moving beyond associations to assessing predictive utility and clinical usefulness. International Journal of Epidemiology 38:1, 231-234
CrossRef1011
Beatrice A Golomb, Marcella A Evans. (2008) Statin Adverse Effects. American Journal of Cardiovascular Drugs 8:6, 373-418
CrossRef
- Letters
